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GENERAL INTRODUCTION 

CHAPTER 1 
1.1 CLINICAL ASPECTS OF UVEAL MELANOMA 
1.1.1 Epidemiology 
MelanoCJtic tumours are believed to arise from the neural crest-derived melanocytes. 
Five to twelve percent of all melanomas are located in the eye, making it, after the skin, 
the second most common site of melanomas (Egan et al., 1988; Chang et al., 1998). 
Uveal melanoma is the most common form of primary eye cancer in adults, affecting 
approximately 7 per million people in the Western world each year (Egan et aI., 1988). 
In persons over 20 years of age, melanoma is the reported diagnosis in 80% of all 
primary intraocular cancers. Most uveal melanomas are located in the ciliary body 
and/or the choroid (23% and 72%, respectively), whereas iris melanomas account for 
only a small percentage of these tnmours (5%) (Yanoff and Fine, 1989). The majority of 
iris melanomas consist of non-metastasising lesions and 'Will not be discussed in this 
thesis. 
Although less than 2% of uveal melanoma patients have clinically detectable metastases 
at presentation, 50% of all patients ultimately die of metastases, predominantly located 
in the liver. The median survival time after discovery of the primary tumour is 6.5 years 
(McLean, 1993), and peaks between the second and the fourth year (Zimmerman et aI., 
1978). The 5, 10 and 15 year survival rates based on tumour related mortality are 72%, 
59% and 53% respectively (Gamel et aI., 1993; McLean and Gamel, 1998). As of yet, no 
effective treatment is available once metastatic disease has developed and the survival 
time after its diagnosis is limited to two to seven months (Seddon et aI., 1983; Kath et 
aI., 1993). 
1.1.2 Therapy 
Until recently, the standard therapy for uveal melanomas was enucleation of the 
tumour<ontaining eye. In the last three decades, a trend towards conservative 
treatment modalities has evolved. It has now become the first choice of treatment. The 
treatment the patient receives is based on specific findings with regard to tumour 
characteristics, visual acuity of the contralateral eye, the wishes and general health of 
the patient and the professional opinion of the ophthalmologist. Melanomas, greater 
than 12 mm in thickness and 16 mm in diameter, are generally treated with 
enucleation. Small and medium sized uveal melanomas (less than 12 mm thick and a 
largest basal diameter under 16 mm) can be treated with radiation therapy (proton 
beam, brachytherapy 'With or 'Without transpupillary thermotherapy or stereotactic 
radiotherapy) and enucleation, or it can be decided to simply observe the tumour for 
further growth. The most effective treatment for these small and medium sized 
melanomas remains under discussion. 
Currently, metastatic uveal melanoma is considered to be an incurable disease. As is 
reviewed by Woll (Woll et aI., 1999), most clinical trials studying the impact of sy"Stemic 
therapy on metastatic uveal melanoma used only a limited number of patients and 
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therefore, a clear-cut statement of drug efficacy is difficult to make. However, patients 
with metastatic disease limited to the liver may benefit from chemo-embolisation vvith 
cisplatin, intra-arterial administration of carboplatin and fotemustine or hyperthermic 
perfusion with tumour necrosis factor (TNF) plus melphalan (Cantore et aI., 1994; 
Bedikian et aI., 1995; Leyvraz et aI., 1997; Alexander et aI., 1998). The ocular oncology 
groups of the European Organisation of Research and Treatment of Cancer (EORTC) 
are currently studying the effects of adjuvant therapies and new treatment protocols for 
metastatic uveal melanoma. In selected patients with solitary metastases, surgical 
excision has been reported to yield long-lasting control of local disease (Aoya.ma et aI., 
2000). 
1.1.3 Predisposing factors 
Certain conditions may predispose patients to uveal melanoma. Individuals Vlith light 
coloured eyes, for example, have been found to be at greater risk for uveal melanoma 
than those with brown eyes (Gallagher et al.. 1985: Tucker et aI., 1985). Ultraviolet light 
ceV) exposure has also been suggested to increase the risk of uveal melanoma (Tucker 
et aI., 1985; Holly et aI., 1990). However, some investigators have found no increase of 
the incidence of uveal melanoma in the last 40 years. This is in contrast to cutaneous 
melanoma whose occurrence increased and with which a clear association between UV 
has been demonstrated. Also, no higher incidence in the most light-exposed areas of the 
eye was observed (Dolin et aI., 1994; Dolin and Johnson, 1994; Schwartz et a!., 1997) 
although a recent publication of Li et al. suggests a correlation between patterns of 
tumour initiation and solar light on the retinal sphere (Li et aI., 2000). On a molecular 
level, no evidence has been found which supports the role of UV exposure in the 
development of uveal melanoma, i.e. no N-ras mutations have been discovered in uveal 
melanoma, in contrast to cutaneous melanoma (Mooy et aI., 1991). Therefore, the 
association of "GV and uveal melanoma remains controversial. Other predisposing 
factors may be ethnic background, as white individuals have an 8 times higher risk of 
developing uveal melanoma than individuals of African descent, and a three times 
higher risk than }\Sians (Woll et aI., 1999). However, since ethnic background is 
correlated to eye colour, it remains unclear if both parameters are independent 
markers. Furthermore, factors such as socio-economic status, smoking and occupation 
have been postulated as to having an effect, but a causative agent has yet to be 
recognised. 
A condition, which is known to increase the risk of uveal melanoma, is the oculodermal 
melanocytosis, also known as the nevus of Ota. Dysplastic nevus syndrome (DNS), 
neurofibromatosis, Li-Fraumeni syndrome and the BRCA2 linked breast and ovarian 
cancer syndrome have also been suggested to be associated Vlith uveal melanoma. 
Oculodermal melanocytosis is a congenital condition characterised by 
hyperpigmentation of the episclera, uvea and ipsilateral eyelid or the scalp. Although 
only 2% or less of all uveal melanomas are linked to oculodermal melanocytosis, the 
correlation between the two is well recognised (Gonder et aI., 1982). It is estimated that 
oculodermal melanocytosis occurs approximately 35 times more often in uveal 
melanoma patients than in the normal population. In our study population of 80 uveal 
melanoma patients we found one patient with concurrent oculodermal melanocytosis 
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and uveal melanoma. This individual had a chromosome 9p21 deletion, suggesting the 
involvement of the p16c\'K4a gene (see chapter 1.2.2 and 8). 
Individuals with DNS are known to be at increased risk of developing cutaneous 
melanoma and are frequendy observed in familial melanoma kindreds. Uveal and 
conjunctival nevi both occur more commonly in patients mth DNS and in patients 
with uveal melanoma more dysplastic nevi and cutaneous melanoma are observed than 
expected in the general population (Bataille et aI., 1995; van Hees et aI., 1998), 
Another condition possibly associated with uveal melanoma is neurofibromatosis type 1 
(Specht and Smith, 1988; Antle et aI., 1990). This autosomal dominant multisystem 
disorder affects neural crest derived cells and causes an excess of melanocytes. However, 
within in our database containing more than 700 uveal melanoma patients, no patient 
suffering from neurofibromatosis type 1 was observed. 
BRCA.2 (hereditary breast and ovarian cancer gene type 2) linked breast and ovarian 
cancer has been theorised to be associated with uveal melanoma (Easton et aI., 1997). 
Sinilnikova et al. investigated a series of 62 ocular melanoma patients with a family 
history of ocular melanoma or a family or personal history of breast and ovarian 
cancer. In 3 of their cases germline mutations in BRCA2 were detected to be likely 
associated with the cancer syndrome (Sinilnikova et aI., 1999): two of these patients had 
a personal history of breast cancer and one had multiple relatives affected with breast 
cancer and ocular melanoma. 
Furthermore, the autosomal dominant Li-Fraumeni syndrome predisposes patients to 
soft tissue sarcoma, brain tumours, leukemia, breast and other cancers. The presence of 
breast carcinoma in a family with uveal melanoma suggests the association between the 
Li-Fraumeni and uveal melanoma Gay and McCartney, 1993). However, it remains 
unestablished whether this family is a true Li-Fraumeni family since no mutation 
analyses were performed. 
1.1.4 Prognostic factors 
Research on uveal melanoma has mainly been concentrated on the identification of 
prognostic factors for development metastatic disease. These prognostic factors can be 
subdivided into clinical, histopathological and genetic parameters. 
Clinical markers predicting tumour growth and metastases in small uveal melanoma are 
described by Shields et al (Shields et aI., 1995; Shields et aI., 2000). A mnemonic, To 
Find Small Ocular Melanoma, was constructed to assist clinicians in detecting early 
choroidal melanoma. These factors for gro¥1th include: Thickness larger than 2 mm, 
subretinal Fluid, Symptoms, Orange pigment and Margin at the disc. Risk factors for 
metastases were analogous to those of tumour growth: thickness larger than 2 mm, 
location at the optic disc, s·ymptoms and demonstrated growth. Additional clinical 
prognostic parameters include tumour margins anterior to the equator of the eye 
(Seddon et aI., 1983), older age, the male gender (Folberg et aI., 1993; Luyten et aI., 
1995) and tumour-induced glaucoma (Coleman et aI., 1993). 
The most consistent of the histopathological markers is the largest tumour diameter, in 
particular, the diameter which is in contact with the sclera (reviewed by Mooy and De 
Jong, 1996). Furthermore, an association between scleral invasion (Seddon et aI., 1983), 
the standard deviation of the nuclear area (Coleman et aI., 1996) and the presence of 
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epithelioid cells (Seddon et aI., 1983; Coleman et aI., 1993) with the outcome of the 
patient has been described. In the early nineties, Folberg et al. (Folberg et aI., 1993) 
suggested that the presence of vascular networks, defined as at least three back to back 
closed vascular loops, is strongly associated with fatal metastatic melanoma. The 
relevance of this prognostic marker was also confirmed by others (McLean et aI., 1997; 
:Makitie et aI., 1999). Furthermore, it was demonstrated that patienrs had a better 
survival if their tumour did not express HLA class 1 (Blorn et aI., 1997). Other 
histopathological markers have also been suggested in isolated reports, such as the 
expression of epidermal growth factor receptors (Burks et aI., 2000), the expression of 
the cell adhesion factors ICf\..;.\f (intercellular cell adhesion molecule) (Anastassiou et aI." 
2000) and NCAM (neural cell adhesion molecule) (Mooy et aI., 1995) and cyclin Dl 
(Coupland et aI., 2000). However, the independent value of these parameters has yet to 
be confirmed and evaluated in larger studies. These factors all seem to correlate with 
the outcome of uveal melanoma patients. Nevertheless, predicting the outcome for an 
individual patient still remains difficult. 
In 1996, it was shown that loss of chromosome 3, in comparison to tumour location or 
tumour diameter, is a more reliable prognostic parameter for decreased relapse-free 
and overall survival (Prescher et al., 1996). The chromosomal abnormalities and the 
prognostic relevance will be further discussed in paragraph 1.2.1 and chapter 2. 
1.1.5 Fine needle aspiration biopsy 
Uveal melanoma is an exceptional tumour in which the type of treatment is based 
solely on clinical judgement, without requiring a histopathological diagnosis. In most 
cases, this diagnosis can be reliably made based on the clinical findings, but more 
atypical cases challenge an accurate diagnosis. In these cases confirmation of the 
diagnosis using cytology is advised. 
The first needle biopsies on solid ophthalmic tumours were performed in the late 19th 
and early 20th century. In the late 1950s, occasional reports of uveal melanoma 
diagnosed with 20 to 24 gauge needle biopsies were published (Veasey, 1951; 
Kauffman, 1952; Long et aI., 1953; Makley Jr" 1967). However, the use of these large 
needles resulted in unacceptable morbidity and local tumour seeding, leading the 
technique to be abandoned in most centres by the end of the decade (Jensen and 
Andersen, 1959). Jakobiec et al. reintroduced the use of needle biopsies for solid 
intraocular tumours in 1979, by reporting on six cases examined by fine needle 
aspiration biopsies (FNABs) (Jakobiec et al.. 1979), The FNAB method using 25 gauge 
needles and, in particular, the transvitreal biopsies have now proven to be safe and 
useful in diagnosing uveal melanoma. No severe ocular morbidity or tumour spread 
has been demonstrated using this technique (Glasgow et al., 1988; Shields et aI., 1993; 
Char et aI., 1996). 
In cases of irradiation, no tumour tissue is available for histopathological evaluation. 
'Most clinical prognostic markers can, in these cases, still be used to select patients with a 
high risk of metastases. The tumour diameter can also be measured in vivo using 
ultrasound methods. However, prognostic markers such as genetic changes, vascular 
patterns and cell type cannot be assessed when irradiation takes place. vVe used 
fluorescent in situ hybridisation (FISH) analysis on FNPilis of enucleated eyes to 
investigate whether it could detect chromosomal changes in radiotherapy cases. This 
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method proved itself to be very reliable in ex vivo biopsies (chapter 4). Since these 
biopsies were taken under ideal conditions, a larger prospective study on in vivo 
biopsies has to be performed to confirm these data and to enable a translation of these 
data for clinical situations. 
1.2 GENETIC BACKGROUND OF UVEAL AND CUTANEOUS MELANOMA 
1.2.1 Cytogenetic findings 
Cytogenetic and molecular genetic studies of leukemias provide important prognostic 
information and are thereby becoming the rna jor tool in determining the appropriate 
treatment protocol. Furthermore, they have made a significant contribution to our 
understanding of the different haematological malignancies (Sandberg and Chen, 
1994; McKenna, 2000). In contrast, data from the cytogenetic analysis on solid tumours 
are severely restricted due to the technical difficulties associated 'With obtaining good 
quality metaphase spreads for the analysis and due to the complexity of the tumour. 
However, uveal melanomas were found to be more amenable to cytogenetic analysis 
than other solid neoplasms. From the late eighties on, several reports on the cy"togenetic 
analysis of uveal melanoma have been published. It was found that in these tumours, 
monosomy 3, abnormalities of chromosome 6 and gain of chromosome 8q were non-
random (Table 1.1, Figure 1.1). 
TABLE 1.1 OVERVIEW OF CHROMOSOMAL ABERRATIONS (%) 
No. METHOD LOSS OF Ip36 LOSsOF3 GAIN OF 6p GAIN OF 8(Q) 
Own data (chapter 2) 80 cytogenetic; /FISH 34 45 30 56 
Sisley et aI., 1997 42 cytogenetics 29 50 19 54 
Prescher et aI., 1996 54 cytogenetics/CGH nc 57 m m 
" ..... "hite et aI., 1998 54 cytogenetics m 50 46' 48 
Parella et ai" 1996 50 microsatellite 33 59 28 60 
Mc :-Jamara, 1997 17 FISH nc 12 m m 
*abnormalities of chromosome 6 
abbreviations: nr, not reported; TISH, fluorescent in situ hybridisation; CGH, comparative genomic 
hybridisation 
Furthermore, changes in chromosome 11 and the loss of chromosome 2, 21 and the sex 
chromosomes were reported (Mukai and Dryja, 1986: Griffin et aI., 1988: Horsman et 
aI., 1990; Prescher et aI., 1990; Sisley et aI., 1990; Horsthemke et aI., 1992; Prescher et 
aI., 1992; Sisley et aI., 1992; Dahlenfors et aI., 1993; Horsman and White, 1993; 
Wiltshire et aI., 1993; Prescher et aI., 1994; Singh et aI., 1994; Prescher et aI., 1995; 
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Prescher et aI., 1996, White et aI., 1996, Sisley et aI., 1997; Sisley et aI., 1998; White et 
aI., 1998; Parrella et aI., 1999; Sisley et aI., 2000). The large amount of publications 
suggests that extensive evaluation on this subject has been done. However, excluding 
our 80 cases, only 166 cases in total have been studied with cytogenetics or FISH 
analysis and another 40 cases -with CGH, since most of the studies referred to repeatedly 
used cohorts of patients. 
Chromosome 3 loss was found to occur most commonly in those tumours -with gain of 
chromosome 8. These genetic changes were found to occur in particular in tumours 
arising from the ciliary body (Prescher et aI., 1992: Sisley et aI., 1992; Dahlenfors et aI., 
1993; Horsman and White, 1993: Sisley et aI., 2000). :Moreover, Parrella et al. proposed 
a bifurcated tumour pathway with mutual exclusivity of the loss of chromosome 3 and 
gain of chromosome 6p (Parrella et aI., 1999). However, in our own series, we observed 
several cases where both the gain of chromosome 6p and loss of 3 took place, arguing 
against this proposed pathway. 
The changes of chromosomes 1, 3, 6 and 8 are thought to be correlated with patient 
survival, as is described in paragraph 1.1.4 and chapter 2 of this thesis. Prescher et al. 
found a strong correlation between loss of chromosome 3 and a poor prognosis of the 
patient (Prescher, 1996). It was found that no patient with tumours with normal copies 
of chromosome 3 (n=24) died within 3 years after diagnosis, whereas only 57% of the 
patients with tumours with loss of a chromosome 3 (n=30) survived the same interval. 
Sisley et aI. confirmed the prognostic value of monosomy 3 and demonstrated a strong 
inverse correlation between the presence of extra copies of Sq and survival (Sisley et aI., 
1997). They showed a dosage effect relationship of additional copies of chromosome Sq 
and the survival of the patient. However, our own data of 80 uveal melanomas suggest 
that gain of chromosome Sq is not an independent prognostic marker, since it is also 
correlated with the largest tumour diameter, which may influence the correlation with 
survival. Furthermore, the tumours with gain of chromosome Sq copies appear to have 
a gro"Wth advantage in cell culture, since after culture an accumulation of chromosomes 
8q copies can be found. A link between chromosomal changes was also studied by 
VVhite et al. (White et aI., 1995). They demonstrated a correlation between chromosome 
3 loss and chromosome 8q gain but moreover, they also found a protective effect from 
chromosome 6 abnormalities over abnormalities of chromosome 3 and S. However, the 
abnormalities of chromosome 6 were not further specified as gain or loss of 
chromosome 6p or 6q and it remains unclear which biological mechanisms could 
explain this finding. 
A.s is shown in chapter 2 of this thesis, we confirmed the significance of monosomy 3 as 
a prognostic marker, but found no independent correlation between chromosome 6 
abnormalities and gain of chromosome Sq and survival. Additionally, we found that 
the effect of chromosome 3 loss was determined by chromosome 1 p loss: only those 
patients with concurrent chromosomes 1 p36 and 3 losses showed a decreased disease-
free survival when compared to patients with only loss of chromosome 3 or with no loss 
of 1 p36 and 3. 
In most cases, whole chromosomes or chromosome-arms are affected, hampering the 
identification of loci specific for uveal melanoma development or progression. 
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However, some chromosome regions, such as 3p13 (Blasi et aI., 1999) and 8q23-24-qter, 
have been suggested as potential target regions (Speicher et aI., 1994). 'C"sing spectral 
karyotyping (SKy) and comparative genomic hybridisation (CGH) analysis on uveal 
melanoma with complex chromosomal abnormalities, we were able to discover a small 
deletion of chromosome 3ql3-21. Furthermore, we found two regions on chromosome 
Sq, i.e. 8q21.1-21.2 and 8q23--24 which could be the target sites of amplification (Kaus 
et a!., 2001). 
Fig. 1.1 Karyogram of tumour E0M207. This tumour showed a -3, i(6)(p) and +8, typical for uveal 
melanoma. Furthermore, there is a loss of the Y chromosome, a common fearure in solid tumours. 
In cutaneous melanoma, chromosomal abnormalities involving chromosomes 1 and 6 
are also present . .As is reviewed by Fountain et al. (Fountain et aI., 1990), the most 
frequent abnormality consists of rearrangements of the distal part of the short arm of 
chromosome 1, occurring in about 80% of all cases. Chromosome 6 also appears to be 
altered frequently (66% of the cases) and the 6qIl-q26 region shows the highest 
frequency of rearrangements as a result of deletion, translocation or due to the 
formation of an isochromosome of its short arm. :Moreover, changes in chromosomes 7 
and 9 were found to occur in 61 % and 44% respectively of the cutaneous melanoma. 
Chromosomes 2, 3, 10 and 11 also show significant involvement, with alterations of 
these chromosomes being present in approximately 30% of all melanomas. In literature, 
only few cases of abnormal karyotypes in nevi or dysplastic nevi have been described. 
Changes of chromosomes 4, 8, 9 and 10 were, however, consistently found. 
Chromosome 9 was involved in three out of nine nevi, whereas chromosome 4, 8 and 
10 changes were found in only two cases. The overall infrequent involvement of 
chromosome 4 and 8 in cutaneous melanoma suggests that these changes happened by 
chance or were actually in-vitro artefacts (Becher et aI., 1983). Using microsatellite 
17 
CHAPTER I 
analysis, no LOB for regions 9p21-22, 5q22, l1q23 and 17q21 could be demonstrated 
in 26 common nevi LOR (Birindelli et aI., 2000). Based on the results of the karyotype 
and molecular genetic analyses of nevi and melanomas, a tumour progression model, 
from melanocyte to metastatic melanoma has been proposed (Figure 1.2). 
normal 
melanocyte 
sun-damaged --. 
melanocyte 
! 
chromosome 9p 
chromosome 109 
at)pical 
naevus 
primary 
melanoma 
metastatic 
melanoma 
t t t t 
chromosome 6q 
chromosome II 
chromosome Ip 
chromosome 2 
chromosome 3 
Fig 1.2 Twnour progression model for cutaneous melanoma. (Adapted from Fountain et aI., 
1990) 
Although chromosome 1 and 6 changes are common in both cutaneous and uveal 
melanoma, their genetic tumour progression pathway seems to be different. Loss of 
chromosome 2, 9p, 10q and 11, frequently seen in cutaneous melanoma, are rarely 
found in uveal melanoma. On the other hand, monosomy 3 is rather specific for uveal 
melanoma. Furthermore, we were able to show that mutual loss of chromosomes 1 p and 
3 was associated with a more aggressive phenotype (chapter 2). Recent data also suggest 
that loss of chromosome 1 p is only present in primary uveal melanoma that had 
metastasised and in its metastases (Aaho et aI., 2001). These data point to putative 
tumour suppressor genes on chromosomes 1 p and 3 involved in tumour progression. A 
tumour progression pathway is. however, difficult to propose, based on the genetic 
abnormalities found since no or few genetic information is available from normal 
uveal melanocytes, uveal nevi or suspected uveal melanoma. In three cases of suspected 
uveal melanoma we performed FISH analysis on FKABs (chapter 5). In one case gain of 
chromosome 8 was found, suggesting malignant transformation. In the other cases, no 
chromosomal abnormalities could be detected. Since this study was performed on only 
three tumours, no general conclusions can be dravvn. 
1.2.2 Genes 
In 1971, Knudson proposed the two-hit hypothesis to explain cancer predisposition. 
This model still holds for most tumour suppressor genes: two successive mutations (hits), 
which inactivate both copies of the tumour suppressor gene, are needed for tumour 
formation (Knudson, 1971; Knudson, 1993). 
Germline mutations of one allele of a tumour suppressor gene, such as the 
retinoblastoma (RE) gene, predispose one to tumour formation. A somatic mutation of 
the second allele subsequently results in the tumour initiation and/or progression 
(Figure 1.3). 
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Our knowledge about tumour suppressor genes has expanded rapidly since that time 
and it became clear the first hit often consists of a small alteration such as a deletion or 
a point mutation, whereas the second hit mainly consists of gross chromosomal 
rearrangements. The latter can be seen as recurrent losses of chromosomal loci 
associated with specific human cancers. 
A B 
m1 auGc RB RB 
m2 b c 
c 
I 
First hit 
+ 
R~[}:' 
o E F 
Fig. 1.3 Knudson's two hit model. RE, wildtype retinoblastoma allele; rb*, mutated allele; ml/m2, 
polymorphic markers at both sides of the gene; alb/c, genot}pe at ml or m2. In inherited cancers, the 
first hit is brought about by germline transmission of a mutated allele. The second allele can be 
inactivated by: A. mitotic recombination; B. loss of a chromosome; C. chromosome loss and consequent 
duplication; D, partial deletion; E, interstitial deletion or F, gene conversion. (adapted from (Pronk et 
aI., 1994)) 
For several years now, these specific chromosomal abnormalities have been recognised 
in uveal melanoma (see paragraph 2.1: cytogenetic findings). However, the first hit, i.e. 
mutations or alterations within uveal melanoma specific genes are yet to be identified. 
In contrast to this, cutaneous melanomas display aberrations in specific tumour 
suppressor genes, such as p16INK.fa (inhibitor of the cyclin dependent kinase 4a) and 
PTEN (phosphatase and tensin homologue). The role of p53 and its homologues, p63 
and p73, remain to be established in both melanoma types. These genes and their 
biological functions will be discussed in the following paragraphs. 
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pI6lNK4" and pI4ARF genes 
The first report on the linkage of familial cutaneous melanoma to chromosome 9p21 
was described in 1992 (Cannon-Albright et aI., 1992). Subsequently, several studies have 
confirmed this result. It has been demonstrated that approximately 50% of all familial 
atypical multiple malignant mole (FAl\fMJ\1) syndrome cases show linkage to this 
particular region (Goldstein et aI., 1994; Gruis et aI., 1995). Furthermore, cytogenetic 
and LOB studies revealed frequent heterozygous and homozygous losses in sporadic 
melanoma and melanoma cell lines (Fountain et aI., 1992). This locus was found to 
harbour the p16"'K'" gene (Kamb et aI., 1994), also known as MTSI (multiple tumour 
suppressor gene 1) or CDKN2A (cyclin dependent kinase inhibitor 2A). 
The pI6~K4<l gene is composed of three exons and encodes a 156 aminoacid protein of 
16kD. Its protein is a cell-cycle inhibitor, which can bind to complexes of cyclin-
dependent kinases (CDK) 4 and 6 and cyclin Dl. This binding inhibits the kinase 
activity and thus results in an arrest of the cell cycle in the G I phase, thereby 
preventing abnormal cell growth and proliferation (Figure 1.4). 
Homozygous loss, mutation or methylation of the p16J1\K4a promotor region, results in 
an inefficient or absent binding to the CDKs. This enables damaged cells to progress 
throughout the cell cycle. The importance of the cell cycle regulatory function of the 
p16ll\K4a protein is illustrated by a wide variety of tumours in which this gene is altered, 
such as gliomas, bile duct, oesophageal, pancreas and bladder carcinomas and some 
subtypes of leukemia (Ruas and Peters, 1998), 
The 9p21 locus also harbours a p16LvK4a_related gene: the pl¢RF (alternative reading 
frame of p16ll\'K4a) gene. This gene uses an alternative exon I (exon 113), located 10-20 
kb upstream of exon lex and different open reading frames for exons 2 and 3, 
resulting in a structurally different protein (132 amino acids). The gene has been 
designated the p14ARF in human cells because of its predicted mass and plgARF in mouse 
cells. 
The .ARF protein binds to J\.IDM2 (mouse double minute 2 gene), whose function is to 
bind p53 (see below) and target it for degradation via the ubiquitin pathway. The 
binding of ARF to MDM2, prevents p53 degradation (Figure 1.4) thereby can p53 exert 
its functions, such as initiation of apoptosis. Furthermore, p53 is also known to playa 
I ' b'l" d ' 21WAF1 P9 1WAF1 , I ro e In genome sta 1 Ity mamtenance an It can target p . _ IS ab e to 
inhibit CDKs thereby interacting with the RB pathway and resulting in a GI/S arrest. 
P53 is considered to be the guardian of the genome and will be discussed below. 
In contrast to the p16JJ.lK4a gene, no mutations which selectively target exon 1/3 of p14ARF 
are found in familial or sporadic cutaneous melanoma (FitzGerald et aI., 1996; Fargnoli 
et aI., 1998; Peris et aI., 1999), although such mutations have been described in 
melanoma cell lines (Kumar et aI., 1998). Recently, however, evidence was found that 
specific loss of the exon 1/3 was involved in familial cases of melanoma-neural system 
tumour syndrome (Randerson-Moor et aI., 2001). 
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53 athwa~ RB athwav 
p16"""'j ... 
Protrin 
Fig. 1.4 Functions of p16INK4a. and p14ARF. Upper diagram: alternative transcripts are generated 
from the 9p21 locus. E.xons are displayed as boxes and identified as exons l~, la. 2 and 3. White 
boxes represent the untranslated region. E.'(on 1 is represented in light grey, exon 2 in dark grey and 
exon 3 in black. :Middle diagram (grey): the p53 and RB pathways. Important key players are depicted 
in circles. Both pathways are linked via p21IVAF1, which inhibits cyclin dependent kinases. Lower 
diagram: cell cycle. S (synthesis), DNA replication: Gl and G2 (gap). cell gro'Wth and preparation for 
entering next phase; M (mitosis), cell division. Gl/S and G2/M transition checkpoints are represented 
by grey circle. 
We (chapter 7) and others (Ohta et aI., 1994; Singh et aI., 1996b) have shown that, in 
contrast to cutaneous melanoma, homozygous deletions and mutations of the p16INK4a 
gene rarely occur in uveal melanoma. However, whereas methylation of the promotor is 
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rare in cutaneous melanoma, we found methylation in four out of nine uveal 
melanoma cell lines. Normal expression of p14ARF was found in all cell lines tested. 
PTEVgene 
PTEN, also known as MMAC (mutated in multiple advanced cancers) or TEP-I, (TGF~ 
regulated and epithelial celI-enriched phosphatase 1) is located on chromosome IOq23. 
It is a tumour suppressor gene which is often mutated or lost in several different 
tumour types, such as glioblastomas (Wang et aI., 1997), prostate carcinomas (Cairns et 
aI., 1997) breast carcinomas (Li et aI., 1997) and endometrial carcinomas (Risinger et 
aI., 1997). Furthermore, in 40% of the sporadic cutaneous malignant melanoma cell 
lines it is also mutated (Guldberg et aI., 1997), but reports on the incidence of 
mutations in primary sporadic cutaneous melanoma seem to be conflicting (Boni et aI., 
1998; Tsao et aI., 1998; Birck et aI., 2000). As described in chapter 8, we found no 
abnormalities of the PTEK gene in uveal melanoma cell lines (Naus et aI., 2000). 
Germline mutations of the PTEN gene were identified in the Cowden and Bannayan-
Zonana or Ruvalcaba-Riley-Smith syndrome (Nelen et aI., 1997; Marsh et aI., 1998). The 
phenotypes of these syndromes include hamartomas in many organ systems, such as the 
breast, thyroid, skin. central nervous system and gastrointestinal tract. Unlike Cowden 
syndrome no increased risk of malignancies is documented in the Bannayan-Zonana 
syndrome. This difference in phenotype remains puzzling, since identical mutations 
have been associated with both Cowden and Bannayan-Zonana syndromes. It might be 
that differences in other, as of yet unidentified, disease-modifying genes cause this 
variance in phenotype. 
The PTEN protein is a dual-specific phosphatase which is able to dephosphorylate 
proteins (serine/threonine and thyrosine) and phospholipids such as 
phosphatidylinositol 3.4.S triphosphate (PtdIns(3,4,S)P3) and phosphatidylinositol 3,4 
biphosphate (Ptdlns(3,4)P2) residues (Figure 1.S). PTEN counteracts 
phosphatidylinositol 3-0H kinases (PI3-kinases) functions, which are associated with cell 
gro'Wth and survival. PI3-kinases are activated by stimulation by several growth factors 
and phosphorylate Ptdlns(4,S)P and PtdIns(4)p residues. Upon phosphorylation of these 
residues, other proteins, which associate with the phospholipids, such as ART, are 
recruited. ART, in turn, is phosphorylated by phosphonositide-dependent kinase 1 
(PDK1) and is able to stimulate cell growth. By dephosphorylating Ptdlns(3,4,S)P3 and 
Ptdlns(3,4)P2, PTEN works in opposition to the PI3-kinase/AKT pathway, and thus 
functions as a gro'Wth suppressor (Di Cristofano and Pandolfi, 2000; Vazquez and 
Sellers, 2000). Additionally, PTEN plays a major role in inhibiting cell spreading and 
the formation of focal adhesions, by dephosphorylation of focal adhesion kinase 
(FAK)(Tamura et aI., 1998). 
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Fig. 1.5 PTEN signalling pathway. This diagram summarises the intracellular effects of PI3K 
activation by growth factors. which can be antagonised by PTEN. Phosphorylation of phosphatidyl 
inositol phosphates stimulates PDKl, resulting in phosphorylation of ART and promoting cell growth. 
PTEN can also dephosphorylate FAR. hereby inhibiting cell spreading. 
P531p631P73 genes 
One of the most srudied tumor-related genes is the p53 gene, located on chromosome 
17q13.1. This gene is mutated in over 50% of all human cancers. However, in cutaneous 
melanoma, the mutation rate seems to be low, although a recent report suggested that 
p53 mutation may be more common in certain types of melanomas, particularly those 
v.rith a poorer prognosis (Akslen et aI., 1998). In uveal melanoma, p53 mutations do not 
appear to be the major cause of gene inactivation (Chana et aI., 1999: ::vIouriau..x et aI., 
2000), but it is possible that the p53 pathway is functionally inactivated (Brantley Jr and 
Harbour, 2000), 
P53 plays an important role in regulating the GI/S and G2/.M transition of the cell 
cycle, in inducing apoptosis if the D).JA damage is too severe to be repaired and in 
maintaining genome stability. These properties cause p53 to be called the guardian of 
the genome (reviewed by Ko and Prives, 1996; Lohrum and Vousden, 2000). Normally, 
p53 is not active, but it can be stimulated by different triggers: 
23 
CHAPTER 1 
Firstly, by DNA damage, such as that caused by ionising radiation. Double strand 
breaks activate ATM (ataxia telangiectasia mutated), which in turn activates Chk2 
(checkpoint kinase 2). 
Secondly, p53 can be triggered by aberrant gromh signals, such as those resulting from 
expression of RA.S or :MYC. In this case p53 depends on the activation via the pl4ARF 
pathway. 
Thirdly, by a -wide range of stimuli, such as drugs and UV light. This pathway, which is 
independent from intact ATM or p14ARF, may involve ATR (ataxia telangiectasia 
related), an ATIi-related cell cycle checkpoint gene. 
All pathways inhibit degradation of p53, thereby creating excess of p53. :\1utations in 
p53 or binding of viral proteins to p53 (in cervix carcinoma and lymphomas) can cause 
malfunction of p53. Alterations in genes whose products directly or indirectly interact 
with p53 (such as MDM2 and p14ARF) or mislocalisation of p53 in the cytoplasm 
(Vogelstein et aI., 2000) can also prevent a proper p53 response. 
:Much less is known about the p53 homologues, p63 and p73, whose structure is similar, 
but not identical, to that of p53. Each contains a transactivation domain (TAD), a DNA 
binding domain (DBD) and an oligomerisation domain. Both homologues also contain 
a steric alpha motif (SAJ.\f). SAM domains are known to be present in proteins involving 
regulation of development (Levrero et a1.. 2000). unlike p53. both p73 and p63 give 
rise to differentially spliced mRN.As. At least 6 isoforms of p73 and of p63 have been 
identified. The isoforms of p63 lacking exons I and 2 (.6..N forms) do not activate 
transcription. but can act as a dominant negative regulator of full length (TA)p63 and 
p53 proteins. P73 can be stabilised by phosphorylation via c-Abl after treatment of cells 
with DKA damaging agents, such as cisplatin and taxoI. This results in p73 mediated 
apoptosis. 
P73 is located on chromosome 1 p36, a region which is frequently deleted in uveal 
melanoma (Chapter 2) and other tumour types such as neuroblastoma, colorectal and 
breast carcinoma. In neuroblastoma, it was suggested that p73 is an imprinted gene, 
expressing only the maternal allele (Kaghad et aI., 1997). However, recent studies seem 
to indicate that monoallelic expression of this gene is rare (Komoto et aI., 1998). 
Mutations in p73 are rarely found in human tumours. In the almost 900 tumours 
studied for mutations, including cutaneous melanoma, only three missense mutations 
have been found (Levrero et aI., 2000). 
P63 is the second p53 related gene (also known as KET. p51 p40 and p73L) and is 
located on chromosome 3q27 (Yang et aI., 1998). P63 is predominantly expressed in the 
epidermis, cervix, urothelium and prostate and no mutations have been detected in 
human malignancies. However, p63 mutations have been found in patients with 
ectodactyly, ectodermal dysplasia and facial clefts (EEC) syndrome. Knockout mice for 
p63 also demonstrate major defects in limb, craniofacial and epithelial development 
(M:ills et a1.. 1999; Yang et a1.. 1999). suggesting that p63 predominantly plays a role in 
development. 
Nthough it is assumed that the role of p63 in tumorigenesis is limited, other data 
suggest that, in cancers, the balance between the TA and .6..N isoforms is disrupted. The 
.6..N isoforms of p63 are known to have a dominant negative effect on both the TA-
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isoforms of p63 and on p53. As stated above, p53 plays an important role as a 
controller of the G2/M and G liS transitions and in genome stability. 
No data on the involvement of the p63 and p73 gene in uveal melanoma are available 
yet. However, since these genes are both located on chromosomes frequently involved in 
uveal melanoma, i.e. chromosome 1 p36 and 3, it will be interesting to investigate the 
role of these genes in uveal melanoma tumorigenesis. 
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1.3 AIMs AND OUTLINE OF THE THESIS 
Research on uveal melanoma has largely been concentrated on the identification of 
prognostic markers, since it allows clinicians to select patients with a high risk of 
metastatic disease and to adjust the treatment protocols depending on the prognosis. I 
started the research on the effects of genetic abnormalities in uveal melanoma in 1996. 
At that time it was already known that recurrent chromosomal abnormalities, such as 
loss of chromosome 1 p and 3 and gain of chromosome 6p and Sq, could be detected in 
these cancers. Furthermore, it was suggested that loss of chromosome 3 and gain of 
chromosome 8 were important prognostic markers for decreased survival in uveal 
melanoma patients. 
In the first part of this thesis, the cytogenetic aberrations found in these uveal 
melanomas will be discussed. In our laboratory, C}1:ogenetic analysis on uveal 
melanomas has been performed since 1992. Until 1995, most tumours were analysed by 
conventional cytogenetic analysis only. After that time, fluorescent in situ hybridisation 
and, when possible, cytogenetic analysis was performed on all tumours. We 
characterised a series of 80 uveal melanomas for chromosomal changes, with the aim to 
identify correlations between these changes and tumour characteristics, and to confirm 
the correlations between chromosomal changes and survival. These data might enable 
us to narrow down the regions of interest on chromosome 1, 3, 6 and 8. This study is 
described in chapter 2. 
In some cases, however, detailed cytogenetic analysis was not possible due to the 
presence of complex abnormalities. In chapter 3 we describe the application of 
comparative genomic hybridisation (CGH) and/or spectral karyotyping (SKY) on two 
uveal melanoma cell lines and five primary uveal melanomas, with partially defined 
and/or complex abnormalities to further characterise the chromosomal changes. 
The cytogenetic studies were performed on tumours available from enucleated eyes. 
However, more and more patients are now treated with radiotherapy and, as a result, 
the lack of tumour material compromises the evaluation of these chromosomal changes. 
In chapter 4, we describe the validation of using fine needle aspiration biopsies and 
fluorescent in situ hybridisation for the analysis of genetic prognostic markers. 
Therefore, we analysed 40 ex vivo uveal melanoma biopsies and the corresponding main 
tumour with FISH. To investigate whether chromosome analysis was also applicable on 
in vivo fine needle aspiration biopsies, we applied FISH analysis on biopsies of three 
patients suspected of uveal melanoma. These data are described in chapter 5. 
The second part of this thesis is dedicated to the detection of molecular genetic changes 
in uveal melanoma. As described above, non-random chromosomal changes have been 
described in uveal melanoma but the molecular pathogenesis remains largely unknown. 
In contrast to uveal melanoma, much more is known about cutaneous melanoma, 
JNK4a; ARf PT k . where genes such as p16- p14 and 'E.V are Tno'\-\TIl to play a role m 
tumorigenesis. Since both cutaneous and uveal melanomas originate from neural crest 
derived melanocytes, we decided to test these genes in uveal melanoma cell lines. To 
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allow experimental studies investigating the molecular changes in uveal melanoma, we 
established and characterised primary and metastatic uveal melanoma cell lines 
(chapter 6). We studied the involvement of the p16lNK4", p14ARF and the PTE.IV gene, 
which are known to be involved in cutaneous melanoma, in these cell lines. These 
studies are described in chapter 7 and 8 of this thesis. 
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ABSTRACT 
Background Melanoma of the eye is a highly malignant disease with a mortality of 
50%. It is suggested that chromosomal changes associate with a decreased survival of the 
patient. However, these studies had limited samples size, restricting statistical analysis. 
We aimed to assess the independent value of numerical changes of chromosomes 1,3, 6 
and 8 on the disease free survival in a large series of eye melanoma patients. 
Methods 80 eye melanomas were analysed for numerical changes of chromosomes 1, 3, 
6 and 8 with cytogenetic analysis and/or fluorescent in situ hybridisation. The genetic 
data were correlated with disease outcome in a univariate and multivariate model using 
Kaplan~Meyer and Cox regression analyses. 
Results After a mean follow-up time of 27 months, 17 patients had died or were 
suffering from metastatic disease. In the univariate analysis, loss of chromosome 3, gain 
of 8q and the presence of epithelioid cells were associated ¥lith a decreased disease free 
survival. In the multivariate analysis, we found that the effect of monosomy 3 on 
survival was largely modified by changes in chromosome 1 p. We found that, regarding 
all chromosomal changes, only concurrent loss of chromosome I p and 3 was an 
independent prognostic parameter for disease free survival (p=O.007) 
Conclusions Our findings suggest a synergistic effect of genes on chromosomes 1 p 
and 3 involved in melanoma progression. These chromosomal changes are an 
independent prognostic marker for disease free survival and may have implications for 
the treatment of eye melanoma patients. 
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INTRODUCTION 
Melanoma of the eye, the most common form of primary eye cancer in adults, is a 
highly malignant disease -with a mortality rate of fIfty percent (Egan et aI., 1988). 
Identification of patients at high risk of mortality may enable early detection of 
metastases in a stage in which adjuvant therapy may be justified. Chromosomal 
abnormalities are known to have prognostic importance in certain cancers, e.g. in 
leukemia patients (Dohner et aI., 2000). This helps clinicians to plan treatments and 
alerts them to patients with a high risk of relapse or (Sandberg and Chen, 1994; 
McKenna, 2000). Eye melanoma, also referred to as uveal melanoma, are highly 
amenable for cytogenetic analysis and show mostly simple karyotypes, in contrast to 
most other solid tumours. Specific chromosomal changes such as variation in 
chromosomes 1 p, 3, 6 and 8 are often found in these tumours (Sisley et al.. 1990: 
Prescher et aI., 1995). Loss of chromosome 3 and gain of chromosome 8 or Sq are 
associated with a high mortality rate, whereas abnormalities of chromosome 6 are 
suggested to correlate with a good prognosis. However, these data are from relatively 
small studies and the associations with other chromosome abnormalities and tumour 
parameters were not analysed. 
In the present study we investigated the associations between chromosomal changes and 
tumour parameters such as cell type, tumour diameter. We examined, in the largest 
series up until now, the independent effect of numerical changes of chromosomes 1, 3, 
6 and 8 on disease free survival in a series of 80 uveal melanoma patients. 
METHODS 
Patients and tumour samples 
From March 1992 to July 2000, we collected tumour material of 112 consecutive 
patients who underwent enucleation of the tumour-containing eye for ciliary body or 
choroidal melanoma. Informed consent was given prior to enucleation and the study 
was performed according to the tenets of the Declaration of Helsinki. Until the 
introduction of routine cytogenetic analysis for eye melanoma in May 1994, only very 
few cases were karyotyped (4 out of 31), From May 1994 nntilJanuary 1995 cytogenetic 
analyses were performed (n=15) which was successful in 11 cases. From January 1995 on 
all patients (n=66) were analysed with FISH and, if metaphases could be obtained, with 
cytogenetic analysis. Fresh tumour material was obtained within 1 hour after 
enucleation and processed for FISH and/or cytogenetic analysis as (Naus et aI., 2001). 
Conventional histopathological examination was performed on all tumours and 
confirmed the origin of the tumour. Cytogenetical studies were also carried out on 
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stimulated peripheral blood samples of each patient to exclude the presence of 
congenital chromosome abnormalities. Follow-up data from the time of diagnosis to 
the end of the study in September 2000 were obtained by reviewing each patient's 
charts and/or contacting their general practitioner. One patient was lost to follow-up. 
The remaining 80 patients consisted of 43 men and 37 women. The age at time of 
diagnosis ranged from 21 to 87 years (mean 60). The mean period from time of 
diagnosis to the presence of metastases or end of the study, was 27 months (range 1-87 
months). The mean tumour diameter and thickness were 12,0 mm (range 1.5-22) and 
7,0 mm (range 4.5-10), respectively. Thirteen tumours showed involvement of the ciliary 
body and 67 were located in the choroid. 
Cytogenetic and FISH analysis 
Chromosome preparations were made follo1\ring standard procedures and stained -with 
acridine orange or atebrine to obtain R or Q banding. Cytogenetic abnormalities were 
described in accordance with the ISCl\ (Basel, 1995). 
Dual colour FISH on uncultured tumour material using centromeric and locus specific 
cosmid, PI or YAC probes for chromosome I, 3, 6 and 8 was performed as described 
previously (Hagemeijer et aI., 1998). The concentration for centromeric probes was 5 
ng per slide; for cosmids, PI and YAC probes 50 to 75 ng per slide were used. Eight 
probes were used: pl-79 (mapped to chromosome band Ip36), Pa 3.5 (centromere 3), 
YAC 827D3 (3q24), cos85 (6p21) and cos52 (6q23) (Prof. Y Nakamura, Tokyo, Japan), 
cosl05HS (8pll) and D8Z2 (centromere 8) and ETO (8q22). After hybridisation and 
washing, slides were counterstained with 4,6-diamidino-2-phenylindole and mounted in 
anti-fade solution (Dabco-Vectashield 1:1). Signals were counted in 300 interphase 
nuclei according to the criteria of Hopman et al. (Hopman et aI., 1988). Cut-off limits 
for deletion (15% of the nuclei with one signal) or amplification (>10% of the nuclei 
-with 3 or more signals) were adapted from the available literature (van Dekken et aI., 
1990). 
Data classification 
We subdivided the variation in chromosomes Ip, 3, 6p, 6q and 8q using cytogenetic 
and FISH analysis into 5 categories: loss of one copy, normal copy numbers (two 
copies), gain of one copy, gain of two copies, and gain of more than two copies. Using 
FISH, monosomy 3 was defined when there was only one signal seen for the centromere 
3 and 3q24 probes. Gain of chromosome 8, when all three probes for chromosome 8 
(i.e. 8pII, centromere 8 and 8q22) showed more than 2 signals; gains of 6p and 8q 
were scored when more than 2 signals were found for each of the 6p2I and 8q22 
probes, and loss of Ip and 6q when the probes for Ip36 and 6q23 showed only one 
signal. 
When different subclones were identified, only the FISH findings of the largest clone 
were classified. Cytogenetic results were classified for the regions studied with FISH 
analysis . .All major chromosomal changes detected by cytogenetic analysis could also be 
detected by FISH analysis. Therefore, we classified only the uncultured direct FlSH data 
if both FlSH and cytogenetic analyses were available. 
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Statistical analysis 
Disease free survival was the time from enucleation to the development of metastatic 
disease. The influence of single prognostic factors on disease free survival was assessed 
using Kaplan-Meijer analysis and the log rank test (for categorical variables) or Cox 
proportional hazard analysis (for continuous variables) (Table 2.1), Comparisons of the 
distributions of clinical and chromosomal variables were performed with Fisher's exact 
test (for categorical variables) and the Mann-Whitney test (for continuous variables) 
(Table 2.2). The independent value of the prognostic factors on disease-free survival was 
assessed by multivariate Cox proportional hazard analysis and the likelihood ratio test. 
Included in the model were age at time of diagnosis, cell type (spindle cell vs. 
mixed/epithelioid cell), largest tumour diameter, mutual loss of chromosome Ip and 3, 
gain of 6p and gain of 8q. All tests were two-sided. An effect was considered significant 
when the p-value was 0.05 or less. The statistical analyses were performed vvith SPSS-9 
softw"are. 
RESULTS 
A total of 80 uveal melanoma cases was analysed for chromosomal changes using 
cytogenetic and/or E1SH analyses. Thirteen patients had died from metastatic disease 
and four were suffering from metastases at time of evaluation. Cytogenetic analysis was 
successful in 49 out of 80 tumours. For 37 tumours there were cytogenetic and 
fluorescent in situ hybridisation (FISH) data available, and in 31 tumours only FISH 
was performed. ='fot all probes could be tested on all patients because of lack of 
material. The mean number of probes successfully used for FISH was 6. Combining 
both cytogenetic and E1SH data, chromosomal abnormalities were found in 88 percent 
of all tumours. 
Univariate analysis of the single prognostic factors showed significantly lower disease 
free survival for patients with loss of chromosome 3 or gain of 8q in the tumour and 
for patients vvith a mixed or epithelioid tumour cell type (compared to patients vvithout 
these chromosomal changes or vvith a spindle cell type) (Table 1). Other potential 
prognostic factors, such as gender, age at time of diagnosis, tumour diameter, thickness, 
and tumour location (i.e. involvement of ciliary body) did not reach significance. 
Chromosomal changes such as loss of chromosome band 1 p, gain of chromosome 6p or 
8 and loss of chromosome 6q were not significantly associated vvith disease free survival. 
To examine the possibility that other chromosomal variations may affect the prognosis 
of the monosomy 3 patients, we constructed Kaplan Meijer curves of chromosome 3 
changes stratified for the other chromosomal changes and performed log rank tests to 
test for statistical significance. We found that the effect of monosomy 3 on disease free 
survival was largely modified by changes in number of copies of chromosome 1 p. In 
tumours with normal copy numbers of chromosome 1 p, no significant difference in 
disease free survival was observed betw"een those patients with and without loss of 
chromosome 3 (p=0.9841) (Fig.2.1a), whereas this difference was significant in patients 
with tumours with loss of chromosome Ip (lFO.0095) (Fig. 2.1b). 
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TABLE 2~1 RESULTS OF THE UNJVARIATE ANALYSIS OF PROGNOSTIC MARKERS ANO DISEASE FREE 
SURVIVAL IN 80 EYE MELANOMA 
VARIABLE 
Male gender 
Age at time of diagnosis (yrs) 
:Mixed/epithelioid cell type 
Tumour thickness (mm) 
Largest tumour diameter (mm) 
Involvement of ciliary body 
Genetic changes (%): 
loss of Ip 
loss of chromosome 3 
gain of chromosome 6p 
loss of chromosome 6q 
gain of chromosome 8 
gain of chromosome 89 
• Log-rank test: ~ Cox-regression analysis 
No. of patients (%)/Mean 
43 (54) 
60 
57 (71) 
7 
12 
13 (16) 
26/77 (34) 
32/71 (45) 
19/63 (30) 
21/65 (32) 
14/44 (32) 
39/70 (56) 
p-value 
0.754' 
0.50211 
O.015~ 
O.363~ 
O.330n 
0.414' 
0.178' 
0.004' 
0.696' 
0.896' 
0.090' 
0.050· 
Tumours with normal copies of 1 p36 Tumours with loss of 1 p36 
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Fig. 2.1 Kaplan Meijer survival curves of loss of chromosome 3 stratified. for chromosome 
Ip. Left Survival curves of tumours with normal copies of chromosome Ip36. with and without 
chromosome 3 loss. Right Survival curves of tumours with loss of chromosome 1 p36 with and without 
chromosome 3 loss. 
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TABLE 2.2 CORRELATION BETWEEN CHROMOSOMAL ABNORMALITIES AND CLINICAL DATA 
CLINICAL DATA CHROMOSOME Ip LOSS 1 CHROMOSOME 3 LOSS CHROMOSOME 6p GAIN CHROMOSOME 8q GAIN 
+ p + p + p + p 
, 
male 28 12 24 16 26 9 18 20 Gender 
0.330 0.348 OAIO 0.63'1 
female 19 J.l 15 16 17 10 13 19 
Mean age (yrs)3 62 60 0.557 56 68 0.001 61 55 0.079 58 61 OA67 
Cdl type 
, 
spindle 14 7 17 4 7 11 13 6 
1.000 0.005 0.002 0.013 
mixed/epithelioid 33 19 22 28 36 8 18 33 
Mean tumour thickness (UIIU)3 7.0 7.4 0.373 7.1 6.7 0.61,1 7.0 7.8 0.109 6.8 7.6 0.228 
Mean tumour diameter (mm)3 11.9 12.7 0.286 11. 12.2 0.647 11. 13.9 0.031 10.9 13.8 0.001 
9 8 
Involwment of dliiH)' bod/ no ·10 20 M 27 34 16 27 31 
0.524 0.746 0.740 0.529 
l('s 7 6 5 5 9 3 4 8 
1 Chromosome loclIs at which the abnormality is absent (-) or present (+). 
2 The p value is for the comparison among different suhgroups within a chromosome aberration group and was calculated by Fisher's exact lest. 
3 The p value is for the comparison of means among different subgroups ·within a chromosome aberration group and was calculated by the Mann-Whitne}' test. 
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In addition, the interaction term between loss of chromosome 1 p and chromosome 3 
was found to be significant (Cox proportional hazard analysis P=O.04). No interactions 
between chromosome 3 and the other chromosomes (6 and 8) were found. Moreover, 
we compared the disease free survival of patients Volith a concurrent loss of chromosome 
1 p and chromosome 3 with that of the other subgroups of patients (i.e. patients with 
tumours with normal copies of chromosome I p and 3 or with either 1 p or 3 loss). This 
difference in survival was fonnd to be highly significant (p=O.0003). 
Considering the strong interaction between chromosome 1 p and 3 loss, we validated 
whether this concurrent loss is an independent parameter for disease free survival in a 
multivariate model. Confounding variables were considered age at time of diagnosis, 
cell type, tumour diameter and chromosome 6p and 8q gains. After correcting for these 
variables, we found that patients with tumours having concurrent loss of chromosomes 
Ip and 3 had an almost 18 times higher chance of developing metastases compared to 
those without these losses or with either 1 p or 3 loss (p=O.0065) (Table 2.3). 
TABLE 2.3 MULTIVARIATE ANALYSIS OF PROGNOSTIC MARKERS AND DISEASE FREE SURvrv AL 
IN 80 EYE MELANOMA (FINAL MODEL)* 
VARIABLE 
Loss of chromosome 1 p with loss of 3 
Mixed/epithelioid cell type 
Largest tumour diameter 
Age at time of diagnosis 
Gain of chromosome 6p 
Gain of chromosome 89 
* Cox proportional hazard analysis 
Ii Likelihood ratio test 
DISCUSSION 
HAzARD RATIO P-VALUE# 
17.82 0.007 
16.53 0.098 
1.12 0.237 
0.98 0.465 
0.51 0.531 
0.27 0.274 
In uveal melanoma it is knoV\-'l1 that loss of chromosome 3 is a prognostic marker for 
decreased survival of the patient (Prescher et aI., 1996; Sisley et aI., 1997; White et aI., 
1998). using univariate analysis, we indeed found that loss of chromosome 3 was a good 
prognostic factor predicting the outcome of the patients. The present study is the 
largest series described up until now, and allows more extensive multivariate statistical 
analysis. We demonstrated that only those patients with a concurrent loss of 
chromosomes 3 and 1 p are at high risk for developing metastatic disease. 
The molecular genetic changes that underlie these chromosomal changes still have not 
been determined. However, the fact that both chromosomes 1 p and 3 must be lost to 
affect survival could suggest that an interaction between genes on these two 
chromosomes is necessary for the development of metastatic disease. Chromosome 1 p36 
is frequently deleted in many solid tumours like skin melanoma and neuroblastoma. In 
the latter tumour type, loss of chromosome 1 p is known to be a predictor of an 
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unfavourable outcome of the patient (Caron et aI., 1996). A putative tumour suppressor 
gene, p73, is located in this region (Levrero et aI., 2000). This gene is a homologue of 
p53, which is altered in approximately 50% of all human cancers. Another homologue 
of p53, p63, is located on chromosome 3q27, the other chromosome of interest (Yang et 
aI., 1998). Very few or no mutations in human malignancies have been described in 
p73 or p63, other molecular mechanisms, such as a dominant negative effect of 
isoforms of p73 and p63 on itself and on p53, might be responsible for the inactivation 
of these genes. Both genes are known to interact with each other and v.'ith p53 (Yang et 
aI., 1999) pointing to a possible role for these genes in eye melanoma tumorigenesis. 
Gain of chromosome 8q, which has been suggested to correlate with survival (Sisley et 
aI., 1997), was only significant in our univariate anal)'"Sis. In our multivariate analysis it 
was not found to be an independent prognostic marker and we demonstrated a strong 
correlation benveen the largest tumour diameter and the presence of chromosome 8q 
abnormalities. Also the abnormalities of chromosome 6 were not independently 
associated with survival, in contrast to what has been previously claimed (White et aI., 
1998). We found a strong correlation between the gain of chromosome 6p and a 
spindle cell type . .As far as we know, the chromosomal changes (i.e. loss of chromosome 
3, gain of chromosome Sq and abnormalities of chromosome 6) found by Sisley and 
White and co-workers and which they associated with prognosis, were not corrected for 
tumour diameter or cell type as in the present study. This could have influenced their 
findings. Another known prognostic marker for a poor outcome of uveal melanoma 
patients is the presence of epithelioid cells. Although in our series this cell type was 
significantly associated with decreased disease free survival in the univariate analysis, it 
was not in the multivariate analysis. Moreover, we found a strong correlation between 
chromosomal aberrations (chromosomes 3, 6 and 8) and cell type (Table 2.2). 
This present study on chromosomal abnormalities in eye melanoma is, to our 
knowledge, the largest reported in the literature. However, it is still a relatively small 
series with a short follow-up time. Furthermore, our study may be biased since we 
examined only tumours from patients treated by enucleation, as no tumour material is 
available from patients treated with radiotherapy protocols. These findings need to be 
assessed in a large unselected prospective trial, which can be carried out since we have 
already shown that chromosome analysis can be performed on fine needle aspiration 
biopsies of eye melanoma using simple FISH techniques (Kaus et aI., submitted). 
However, our results do demonstrate a prognostic role of concurrent loss of 
chromosomes Ip and 3, which may aid clinicians in identifying those patients at a high 
risk of metastatic disease, and could lead to the justification of the application of 
adjuvant therapies to these patients. 
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CHAPTER 3 
ABSTRACT 
Several non-random recurrent chromosomal changes are observed in uveal melanoma. 
Some of these abnormalities, e.g. loss of chromosome 3, gain of the q arm of 
chromosome 8 and chromosome 6 abnormalities, are of prognostic value. Cytogenetic 
analysis and/or fluorescent in situ hybridization (FISH) are used to detect these changes. 
In some cases, however, detailed cytogenetic analysis is not possible due to the presence 
of complex abnormalities. To more accurately define these cytogenetic changes, we 
have applied comparative genomic hybridization (CGH) and/or spectral karyotyping 
(SKY) to two uveal melanoma cell lines and five primary uveal melanomas, with 
partially defined and/or complex abnormalities. SKY provided additional information 
on 34/39 partially defined aberrant chromosomes and revealed a new abnormality, a 
der(17)t(7;17)(?;q?), that had not been recognized by conventional cytogenetics. 
Additionally, using SKY, abnormalities involving chromosome 6 or 8 were found to be 
twice as common as observed vvith cytogenetic analysis. CGH was especially useful in 
assigning the abnormalities identified by SKY to specific chromosomal regions, and in 
addition, resulted in the detection of a small deletion of chromosome region 3q 13-
3q21. We conclude that SKY and CGH, as complementary methods to cytogenetic and 
FISH analysis, provide more complete information on the chromosomal abnormalities 
occurring in uveal melanoma. 
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INTRODUCTION 
In human cancers non-random chromosomal abnormalities reflect tumor-specific 
events at the molecular level. These recurrent chromosomal abnormalities can provide 
starting points for positional cloning strategies. Furthermore, an accurate identification 
of the specific cytogenetic abnormalities can be of diagnostic and prognostic value. 
In uveal melanoma several recurrent chromosomal abnormalities have been described. 
Loss of chromosome band Ip36. monosomy 3, abnormalities of chromosome 6 and/or 
gain of the q arm of chromosome 8 is observed in most tumors (Horsman and VVhite, 
1993; Prescher et aI., 1995; Sisley et aI., 2000), Loss of chromosome 3 and gain of the q 
arm of chromosome 8 associate strongly with a decreased survival of the patient 
(prescher et aI., 1996; Sisley et aI., 1997). In contrast, chromosome 6 abnormalities are 
associated 'With a better prognosis (White et aI., 1998). Since most of these reported 
abnormalities involve the loss or gain of whole chromosomes or chromosome arms, it is 
difficult to determine which specific regions carry genes of particular importance to 
tumorigenesis. Karyotyping and/or FISH analyses are used to detect chromosomal 
changes in uveal melanoma. However, in some cases, detailed cytogenetic analysis can 
be complicated by the presence of complex abnormalities. 
We have applied comparative genomic hybridization (CGH) and/or spectral 
karyotyping (SKY) to two uveal melanoma cell lines and five primary uveal 
melanomas, alongside conventional karyotyping and FISH, in order to more accurately 
define the regions involved in the development of uveal melanoma. SKY is especially 
useful in recognizing the origin of structural abnormalities (Schrock et aI., 1996), 
whereas CGH provides information on net losses and gains of chromosomal regions 
(Kallioniemi et aL, 1992), 
MATERIALS AND METHODS 
Patients and cell lines 
Cytogenetic and FTSH studies are routinely carried out in our laboratory on fresh uveal 
melanoma and uveal melanoma cell lines. Five fresh tumors (EOM 159, 165, 178, 182 
and 191) from eyes enucleated at the Rotterdam Eye Hospital and two cell lines (Mel202 
and Mel270) were selected for the present study due to the presence of partially defined 
and/or complex cytogenetic abnormalities. Sterile tumor specimens were collected after 
enucleation at the department of pathology and processed as described previously 
(Luyten et aL, 1996). In only three instances (YleI202, Mel270 and EOM191) was there 
sufficient material to carry out CGH analysis. 
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TABLE 3.1 CUNlCAL, CYTOGENETIC AND SKY DATA OF TWO UVEAL MELANOMA CELL UNES AND 5 
PRIMARY UVEAL MELANOMAS 
CAsE# SEX" CF.:u.. TUMOR 
/ ACE" n'PE LOCATIO!'l 
Md202 F/ nr mb;ed choroid 
(cell Ene) 
Mel270 M/ nr mixed ciliary 
(cell line) body 
EOM159 F/SS ~pindle ehoroid 
EOM16Ci M!43 spindle choroid 
EOMl78 F/73 mi."ed choroid 
EOMl82 F/52 spindle choroid 
EOM191 F/45 ,pindle choroid 
KARyOTYPE [ISCN,19951 U:>JDEFINED 
CHROMOSOME C 
50-S3,X:X[3j,.XI13].add(X)Cq?).+<:lic(1 ;9)(P11 :p 11 ).+5[3]. add(X)(q?) 
add(6)(q?15),.,.add(6)(q?15) .... 7 ,t8,t8 ,del(S) add(6)(qf15)x2. 
(q2?l )[2J.del{9)(q3?2)[2].i(9)(p 1 O)[3],add(lJ )(q22).add dd(9)(q2?1) 
(16)(q II ),add(18)(q2J ),der(20)t(8;20)(q 12;'1 13).add(22) adci(1! )('122) 
(pll)[cpI6) 
43-48,XY ,<ldd(2)(P2?4)[ 4 j,?-.ldd(3)(q2)[5].dcr{6)(6; 17) 
(p2?5:q25)del(6)(q?),p~u i dic(6)(ql1).der(7) 
del(7)(q22q22)<ldci(i)(q32)[3J.+der(7)del(7)(q22q22) 
add(7)(q32)[3),?der(8)(p)[3j,-9[5].?add(9}(p)[4j, 
add(9)(p )[2],. .. dcr(9)add(9){p }del(9)(q)[2],.1 0[3J, 
add(l 0 )(q2t)[3],.add(12)(pll )[3],·13[Gj,add(13) 
(pll k 16[SJ,add(16)(q II ),.19,.add(21 )(pl )[2J,+mar 
[2J[ cpiJ!81-8i ,X-X'{y,da(6)t(6; li)(p2?5;q25)del(G) 
(q?),p.w i dic(6)(qll):.:2.der(i)del(i)(q22q22)add(i) 
(qS2)x2,:.dd(10)(q2?),+marx2[cp2J 
40-46,XX,add(2)(q3?4 )[6],add(5 )(q34 )[9J,del(6) 
add(l6)(qIl) 
add(l8)(q21} 
add(2)(p2?4) 
(-.ldd(3)(q2) 
p.w i dic(6)(qIl) 
dtl(7)del(7)(q22q22) 
add(7)(q32) 
?der(8)(p) 
r.ldd(9)(p) 
add(10){q2?) 
add(l2)(pll) 
add(lS)(pll) 
add(16)(ql11 
I7" 
add(21)(pJ) 
add(2)(q3?4) 
SKY 
der(X)t(X:19)(q?;?) 
der(6)t(6; 17 )(q?l(1:?),,~ 
der(9)t(9;17)(q2?1 :?) 
dtl(ll)t(lI·,12}(q22.',?) 
der(16)t(2;16)(i':qll) 
der(18)dup(18) 
der(2)dup(2) 
der(3)t(S:S)(q2;?) 
der(6)i(6) 
der(7)del(7)(q22q22) 
t(7:17)(q32;?) 
der(S}t(8:21 )(P21 ;?) 
der(9)dup(9) 
der(l O}tO 0: 13)(q2?:?) 
der(l2.)dup(12) 
der(13)t(10:13)(i':pl1) 
der(16)t(I6;19)(qll:?) 
der(17)t(7;J7}(?;?) 
der(21 )t(19;21 )(i':pl) 
der(2)t(2;6){q3?4:?) 
(q?)[3J,der(7)t(7;8)(p21 :q?),add{ 1 O)(p1?4 )!2j,add add(5){q34) der(5)t(5;6)(q34;?} 
(11 )(q 1?4 )[9j,dtl(16)t(8:16){q?:q24 )[7].add(18){q23)[IJ der(7)t(7:8)(p21 ;q?) der(7)t(7;1 J )(p21 ;?) 
[cp19]/46,x.X [1] 
40-J.6,XY,add(6)(q2I).der(7)t(1;7){qJ2:q36),+8[cp20] 
4.547,XX,deJ(1)(p21),add{5)(p)[4J,add{7}(q36) • ..s[2J, 
·14[5j.·15,add(17)(pJ 2) .+rin g[3J[ cpl OJ 
add(lO)(pl?4) 
add(1I)(ql?4) 
add(6)(q21) 
del(1)(p21) 
"dd{(1)(p} 
add(7}(q36) 
add(17}(pI2) 
46,X-X,dtl(6 )t(6:6)(q 16;p 12),add(22)(p 11 ),add(22}(q 13) "dd(22)(pll} 
[16J add(22)(q 13) 
46,x.X,.add(1 )(q42),add(4 }(qS?2).del(6)(q 11'4q2?5),der{8) add( 1 )(q42) 
t(6;8)(pI2;q24 ),.16,add(l6 )(q?2),add(17)(p 13).add(21) add(4 )(q3?2) 
(pI2), +1!'.arI.+mar2[l9J add(l6)(q?2) 
add(17)(pI3) 
add(2J)(pI2) 
m~l 
t(8;11)(q?;?) 
der(l 0)t(8;1 0)(?;pl?4) 
der(11)t(8:1 ])(?;ql?4) 
der(6 )t(6;6)(q I6;?) 
der(1)t(1;15)(pll;?) 
der(5 }t(5;] 4 IIp?;?) 
der(7)t(6;7)(?;qS6) 
der(l7)t(7~17}G".pI2) 
t(6:7)(?:?) 
der(22)t(S;22)(?~pl1) 
der(22)t(6;22}(i':Q IS) 
der(I )t(l ~6)(q42;?) 
der(4 )t(4;6)(q3?2;?) 
der(16)t(8;16)(?:q?2) 
der(17)t(IO;17)(?;p13) 
der(21 )t(21 ;21 )(p 12:q22) 
der(21 )t{8;2] )(?;p 12) 
t(6:21}(i':q?) 
"Abbreviations: F, female: M, male: nr, not reported: bAge at time of diagnosis (in years); C identified by 
conventional cytogenetic analysis: d cryptic aberration 
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Karyotyping and fluorescence in situ hybridization 
Chromosome analyses were carried out after short tefm tissue culture and the findings 
were described in accordance with the ISCN (1995). Results of the cytogenetic analysis 
are shown in Table 3.1. For direct FISH analysis, uncultured cells were fixed with 
methanol/acetic acid (3:1) and interphase FISH with locus/band specific probes was 
performed with a range of probes using standard procednres (Arnoldus et aI., 1990). 
The probes used were: p1.79 (band Ip36), Pas.5 (centromere 3), YAC 827D3 (band 
3q24) (Caltech Genome Research Laboratories, USA), cos52 (band 6q23) and cos85 
(band 6p21) (Prof. Y Nakamura, Tokyo, Japan), D8Z2 (centromere 8), ETO (band 
8q22), 105H8 (band 8pll). After hybridization and immunostaining, slides were 
counterstained vvith DAPI and mounted in anti-fade solution (Dabco- Vectashie1d 1:1). 
In each case, 300 nuclei per probe were scored according to the criteria of Hopman et 
al. (Hopman et al., 1988). The cut-off values used, were those described by van Dekken 
(van Dekken et aI., 1990). Polysomy was defined as more than 2 hybridization signals in 
more than 10% of nuclei, and monosomy as a single signal in more than 15% of the 
nuclei. The FISH results are shown in Table 3.2. In addition, the chromosomal 
abnormalities identified by SKY and CGH were confirmed "With additional FISH 
analyses on metaphases using subtelomeric probes (Collaboration, 1996), locus specific 
probes and whole chromosome paints. 
Fig 3.1 Example of SKY analysis of EOM159. 
Metaphase vvith DAPI staining (upper left panel), metaphase showing classification colors (upper right 
panel) and Karyotype showing display and classification colors (lower panel). The der(2)t(2;6)(q3?4;?) 
and der(lO)t(8;10)(?;pl?4) were not present this metaphase. Besides the described abnormalities. this 
metaphase showed also loss of chromosome 4 and 10. 
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Spectral karyotyping 
Cytogenetic preparations were pre-treated with RNAse for 60 minutes at 37°C and 
digested -with pepsin for 10 minutes. Mter washing, cells were fixed in 1 % 
formaldehyde/50 mM MgCI, in PBS for 10 minutes, washed and dehydrated. 
Hybridization for SKY analysis was performed according to the manufacturer's 
protocol with minor adjustments (Applied Spectral Imaging, Migdal Ha'Emek, Israel). 
In short, after two days of hybridization, slides were washed with 55% formamide/2x 
SSC (pH7.0) followed by lxSSC at 39°C and 4xSSC/0.05% Tween20 at RT. Cells were 
counterstained with Dl\PI and mounted in anti-fade solution (Dabco-Vectashield 1:1). 
"Gsing the Spectra Cube 200 system and the Skyview analysis software (ASI), 6 to 11 
metaphases from each tumor were examined. Sky results are summarized in Table 3.1 
and an example of SKY analysis in EOM 159 is shown in Figure 3.1. 
Comparative Genomic Hybridization 
DKA from formalin-fixed paraffin-embedded tumor material (£OM191) was isolated 
from 30 5J.Lm sections. The pigmented tumor was scrapedc;off from the glass slides using 
a fine scalpel. Excised material was deparaffinized in xylene and ethanol and air-dried. 
Isolation of the DNA was performed using the Puregene DNA isolation kit (Centra 
systems, Minneapolis, MN). DNA from cell lines (M:eJ202 and 270) was isolated using 
standard techniques. Concentration was determined using a fluorometer (DyNA Quant 
200™, Hoefer Biotech Inc., San Francisco, CA), whereas molecular weight of the DNA 
was estimated on ethidium bromide-stained agarose gels. 
Labeling of the DNA and hybridi7.ation were essentially performed as described (.A.lers 
et a!., 1999). Tumor DNA from EOM191 (<1kb) was labeled using the "GLS biotin 
labeling kit (Kreatech Diagnostics, Amsterdam, The Netherlands). DNA from cell lines 
Mel202 and Mel270 (>1 kb) and male reference DNA (Promega) were nick translated 
(Nick Translation System, Gibco BRL, Gaithersburg, MD) with biotin or digoxigenin 
respectively (Boehringer Mannheim, Indianapolis, IN). The probe mixture of tumor 
and reference DNA was denatured and hybridized to normal male metaphase 
chromosomes (Vysis ~nc. Downers Grove, IL) for three days at 37°C. After washing, 
detection of the biotin- and digoxigenin-Iabeled DNA probes was accomplished "With 
avidin-fluorescein isothiocyanate (green) and anti-digoxigenin rhodamine (red), 
respectively. Samples were counterstained with DAPI in anti-fade solution. 
Images were acquired with an epifluorescent microscope (Leica DM, Rijswijk, The 
Netherlands) equipped with a cooled CCD camera (Photometrics Inc., Tucson, AZ), 
three single excitation filters, a multi-band pass dichroic mirror and emission filters. 
For CGH analysis the Quips XL software from Vysis (version 3.1.1 Vysis Inc., Downers 
Grove, IL) was used. For each case 9 metaphases were analyzed. Loss of DNA sequences 
was defined as chromosomal regions where the mean green:red ratio was below 0.85, 
while gain was defined as chromosomal regions where the ratio was above 1.15. These 
threshold values were based on series of (paraffin embedded vs. fresh) normal controls. 
The CGH results are dipicted in Figure 3.2. 
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RESULTS 
Cytogenetic analysis of these 2 uveal melanoma cell lines and 5 primary uveal 
melanoma revealed a total of 39 partially defined chromosome aberrations which 
could be refined by SKY analysis. Of particular note is the high incidence of 
involvement of chromosomes 6 and 8. In 34/39 aberrations SKY identified the 
translocation partner. In the cell lines Mel202 no other chromosome material was 
shown to be involved in the add(18) and add(22) and, likewise, in the add(2), ?add(9) 
and add(12) of Me1270, suggesting duplication of regions on these chromosomes. 
However, only for the add(2), did CGH analysis confirm this duplication. It is possible 
that the regions duplicated on the other chromosomes consisted of amplicons too small 
to be detected by CGH or, in case of Mel202, that the abnormalities were not shown by 
CGH since they were not present in every metaphase analyzed. Furthermore, our 
studies revealed two cytogenetic changes not identified by conventional chromosome 
analysis. In Mel270 SKY showed a cryptic aberration where an apparently normal 
chromosome 17 was found to consist of a translocation der(17)t(7;17)(?;q?) (Fig. 3c). In 
addition, CGH unexpectedly revealed a deletion of chromosome region 3ql3--21 in this 
cell line (Fig. 3.2). Examples of the results obtained from combining cytogenetic, SKY 
and CGH analysis are sho¥ffi in Figure 3.3. 
i II ,I 0 Mel202 J i ~~ Mel270 " ... EOM191 t3 
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Fig. 3.2 Results from CGH analysis on two uveal melanoma cell lines and one primary tumor. 
Lines on the right side of the ideogram reflect copy number increases: lines on the left represent copy 
number decreases. 
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Variation of chromosomes 6 and 8 
In these seven uveal melanomas we observed frequent aberrations involving 
chromosome 6. Combining the SKY results "With interphase FISH, most of these 
abnormalities could be further refined. In EOM65, EOMl78 and EOM182, the extra 
copies of chromosome band 6p21 found by FISH, suggested the involvement of this 
region in the translocations of chromosome 6. However, in EOM159, a 
der(2)t(2;6)(q3?4;?) and der(5)t(5;6)(q34;?) were found by conventional C}~ogenetics and 
SKY (Fig. 3.2) but FISH anal}~is revealed gain of only one copy of 6p21. Additional 
FISH analysis on metaphases revealed involvement of band 6p21 only in the der(2). 
Consequently, other chromosome 6 regions have to be involved in the der(5). In 
EOM191, chromosome 6 material was translocated to marker 1 and chromosomes 1 
and 4. FISH analysis refined marker 1 as a der(21)t(8;21) (?;p12)t(6;21)(p?;q?) and the 
der(l) and der(4) as der(l)t(1;6)(q42;q?) and der(4)t(4;6)(q3?2;q?), respectively. 
TABLE 3.2 REsULTS OF ROUTINE FISH ANALYSES ON INTERPHASE CELLS" 
CELLUNE FISH ON INTERPHASE CELLSB 
IrCMOR 1~36 cenS 3924 6~21 6923 S~l1 cenS 8q22 
0' F!' 0 E 0 E 0 E 0 E 0 E 0 E 0 E 
Mel202 2 2 2 2 2 2 2.3.4 3 1.2 4.5 5 4,5 5 5 6 
Mel270 2 2.4' 2 2.4 2 1.2.4 3.4 4.8 1.2 1.2 2.3 2,4 2.3 2,4 2,3 2,4 
EOM159 2 2 2 2 2 2 3 2 1,2 1,2 2 2 2 2 2 2.4 
EOM165 2 2 2 2 ~D 2 2.3 2 3 3 3 3 S 3 
EOM178 1 2 2 ~D 2 4 2 2 2 2 2,3 2.3 2 2,3 2.3 
EOM182 2 2 2 2 2 2 3.4 3 1,2 2 2 2 2 2 2 
EOM191 2 2 2 2 2 2 4 3 1,2,3 2 2 2 2 3 2 
;l abbreviations: ND. not done: b Only significant cell populations (loss in >15% or gain in >10% of the 
cells) are indicated: C Observed copy number by FISH analysis: d E.xpected copy number based on 
cytogenetic data: "Tetraploid subclone is indicated in italics 
Chromosome 8 abnormalities were also found to be more common than expected from 
cytogenetic data. In Me1270, EOM159, EOM182 and EOM191 translocations involving 
chromosome 8 were detected with SKY. The FISH results for chromosome region 8q22 
showed, however, no unexpected copy numbers except for EOM191 (Table 2), In the 
other cases, FISH with the 8q22 probe was negative, indicating that other regions of 
chromosome 8 are the target of amplification. In one instance (EOM182) this was 
shown to involve the q arm of chromosome 8 since a subtelomeric probe for 
chromosome 8q hybridized to the der(22)t(8;22)(?;pll). 
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Fig. 3.3 Examples of cytogenetic, SKY and CGH results in two uveal melanoma cell lines (A-
C) and one primary uveal melanoma (D). In each panel the partial karyotype describes specific 
chromosomal abnormalities as found by conventional cytogenetics. In the SKY and CGH boxes the 
chromosomes found to be participating in the abnormalities are shown. 
DISCUSSION 
Our findings indicate that abnormalities involving subregions of chromosomes 6 and 8 
are far more common in uveal melanoma than previously assumed. Additional material 
from chromosome 6 was revealed by SKY to be more than twice as common as 
identified by cytogenetic analysis. Strikingly, in 11 out of 14 translocations involving 
chromosome 6, FISH analysis showed involvement of at least band 6p21. CGH results 
on two cell lines and one tumor showed gain of a whole short arm of chromosome 6, 
with loss of chromosome region 6ql6-24. Structural variation involving chromosome 8 
was identified by SKY in four tumors. This involved a total of seven different derivative 
chromosomes. In only one instance (EOMI9l) was this variation detected by the 8q22 
FISH probe. These findings indicate that band 8q22 is probably not the target region 
in uveal melanoma. The small CGH study would suggest that the chromosome regions 
8q21.1-21.2 and 8q23-24 may be involved, since these regions were lost in all samples 
analyzed. Overrepresentation of chromosome region 8q23-24--qter has also been found 
to be the smallest overlapping region in other studies using CGH or karyotyping 
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(Speicher et al., 1994; Prescher et al., 1995). All these results have narrowed down the 
regions of interest of chromosome 6 and 8 but the predictive value of these loci in 
prognostic terms needs to be evaluated in a larger study. 
In contrast to what is known from the literature (Horsman and White, 1993; Prescher et 
aI., 1995; Sisley et aI., 2000), we did not observe monosomy 3 in any of the cases. 
However, using CGH we did detect a deletion of chromosome region 3q13-q21 in one 
cell line. Other studies have not reported finding this deletion (Speicher et aI., 1994; 
Ghazvini et aI., 1996; Becher et aI., 1997) and it may be significant with respect to the 
demarcation of a region on chromosome 3 harboring a potential uveal melanoma 
tumor suppressor gene . .A.s of yet, no known tumor suppressor genes have been mapped 
to this region and more studies are required to determine the significance of these data. 
The lack of monosomy 3 cases could be the result of non-random sampling, since the 
tumors and cell lines were selected on the basis of partially defined and/or complex 
karyotypes, and on the availability of metaphases necessary for the SKY analyses. The 
data in the present study support the earlier observations of (Parrella et aI., 1999), of a 
mutual exclusivity of monosomy 3 and aberrations of the short arm of chromosome 6 
in uveal melanoma. However, in non~selected series, we (unpublished results) and others 
(White et aI., 1998), have observed combinations of concurrent aberrations of 
chromosomes 3, 6 and 8. 
We have successfully applied spectral karyotyping and comparative genomic 
hybridization alongside conventional cytogenetics and F1SH to unravel the genetic 
changes in seven cases of complex uveal melanoma. We have shovm that the great 
advantage of combining cytogenetics 'With BSH, SKY and CGH is that it provides 
complementary data that increase the level of resolution of the genetic studies. 
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ABSTRACT 
In uveal melanoma specific chromosomal abnormalities are kno'WTI to correlate with 
the risk of metastases. Usually, karyotyping and fluorescence in situ hybridization 
(FISH) analysis are used to detect these abnormalities and recent publications indicated 
that loss of chromosome 3 and gain of chromosome 8q correlate strongly with a 
decreased survival of the patient, whereas chromosome 6 abnormalities are associated 
with a better prognosis. However, the evaluation of these chromosomal changes can be 
compromised in patients treated with eye-retaining treatment protocols due to the lack 
of tumor material. 
In order to validate the use of fine needle aspiration biopsies (FNABs) and FISH for the 
analysis of genetic prognostic markers, we analyzed 40 of uveal melanoma biopsies and 
the corresponding main tumor with FISH. When possible cytogenetic analysis of the 
tumor was also performed. 
All biopsies were found to contain tumor cells and FISH analyses of the samples were 
successful in all cases. Statistical analysis showed a very good agreement between the 
FISH results from the biopsies and those from the main tumor. In only 2 out of 249 
hybridizations (0.8%) did we find a small variation that could have led to a 
misclassification. In one case, cytogenetic analysis pointed to relative losses of 
chromosome region 1 p36 and chromosome 3 in a triploid tumor. 
Our results indicate that the application of FISH to fine needle aspiration biopsies is a 
reliable method for assaying genetic prognostic parameters such as chromosome 3 loss 
and/or chromosome 8q gain. Implementation of this method in a diagnostic setting 
means that we are able to identify patients at risk of developing metastatic disease not 
only in enucleated patients but also in cases treated 'With conservative treatment 
modalities such as radiotherapy. 
CHA:PTER4 
INTRODUCTION 
Uveal melanoma is the most common primary intraocular tumor 'With an annual 
incidence of 0.7/100,000 in the Western popnlation (Egan et aI., 1988). Although less 
than 2% of the patients have clinically detectable metastases at presentation, 
approximately 50% of all patients ultimately die of metastatic disease. The median 
survival after the diagnosis of metastasis is extremely poor. No effective treatment exists 
for metastatic disease, but new approaches for the management of metastases, involving 
interferon, interleukin and a combined chemo- and immuno-therapy are under study 
(Albert et aI., 1992; Nathan et aI., 1997). 
The predictive value of classic histological prognostic parameters such as tumor size, 
vascular patterns and histologic cell type has been analyzed in several retrospective 
studies. Additional clinical parameters associated with a poorer prognosis are 
extrascleral growth, tumor location (ciliary body), older age and male gender (Mooy 
and De Jong, 1996). Prescher et al. (Prescher et aI., 1996) showed that loss of 
chromosome 3, in comparison to tumor location or tumor diameter, is a better 
prognostic parameter of relapse-free and overall survival. Sisley et al. (Sisley et aI., 
1997) confirmed the prognostic value of monosomy 3 and, in addition, demonstrated a 
strong inverse correlation between the presence of additional copies of 8q and survival. 
In contrast, patients with tumors having chromosome 6 abnormalities appear to have a 
better prognosis (White et aI., 1998). 
Although enucleation is still indicated in large uveal melanoma, radiotherapy (such as 
proton beam irradiation or plaque therapy, with or without transpupillary 
thermotherapy) has become the first choice of treatment for patients with smaller 
melanomas (Freire et aI., 1997). A clear advantage for the patient is saving the eye and 
vision, but the lack of histological specimens compromises the evaluation of the 
prognostic markers. Since fine needle aspiration biopsies (FNABs) have been used 
successfully for several years for intraocular tumor diagnosis (Char et aI., 1991; Shields 
et aI., 1993), the analysis of FN"ABs offers an attractive and safe alternative in these 
cases. 
In the present study we have investigated the possibility of applying fluorescence in situ 
hybridization (FISH) analysis to FNABs. FNABs were obtained ex vivo, i.e. after 
enucleation of the tumor-containing eye, and directly used for FISH analyses. To 
investigate whether these FNAB samples are a good representation of the main tumor, 
larger samples of the main tumor were processed for direct FISH analysis and 
conventional cy'"togenetics. The results of the FNAB were compared with those of the 
main tumor. 
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MATERIAL AND METHODS 
Patients and tumor samples 
From January 1997 to December 1999 we have collected FNABs and matched tumor 
material from forty uveal melanoma patients. These patients were referred for 
enucleation of the affected eye to the Department of Ophthalmology, University 
Hospital Rotterdam and the Rotterdam Eye Hospital. Informed consent was given prior 
to enucleation and the study was performed according to the tenets of the Declaration 
of Helsinki. The mean age was 60.0 years (range 34-85); 19 patients were male and 21 
female. The mean rumor diameter was 12.9 mm. Five rumors were derived from the 
ciliary body and 35 from the choroid. Immediately after enucleation transvitreal 
FNABs were taken and both the FNABs and fresh tumor material were processed for 
FISH and/or cytogenetic analysis according to standard procedures. Histopathological 
diagnosis and treatment of the patient were not compromised by biopsy collection. 
Cytogenetic studies were carried out on peripheral blood samples of each of the 
patients to exclude the presence of congenital balanced chromosome abnormalities. 
Fine needle aspirations biopsies 
After enucleation the bulbus was first transilluminated to define the location of the 
tumor. A 25-gauge needle attached to a 10 ml s)Tinge was inserted through the sclera 
into the tumor and suction was applied to the s)Tinge. After sampling, the pressure was 
equalized before removal of the needle in order to avoid seeding of tumor cells. Cells 
were collected in culture medium, fixed in methanol/acetic acid and FISH preparations 
were made as described (Hagemei jer et aI., 1998). 
Fresh tumor material 
Tumor specimens, collected after ex vivo FNABs, were processed as described (Luyten et 
aI., 1996). For direct FISH, one ml of the cell suspension was fixed and the remaining 
cell suspension of the tumor was cultured. For cytogenetic analysis, cells were incubated 
mth colcemid (0.15 J..lg/ml) for 6 hours at 37°C and fixed. The chromosome 
preparations were stained mth acridine orange or atebrine to obtain R or Q banding. 
Cytogenetic abnormalities were described in accordance with the ISC1\ (Basel, 1995). 
Remaining cultures were stored in 1\2 and in one instance (EOM-121) used for 
additional FISH studies. FISH analysis on metaphases using locus specific probes and 
whole chromosome paints was carried out to further characterize the abnormalities in 
cases where cytogenetic analyses revealed the presence of partially defined 
chromosomes. 
Fluorescence in situ hybridization 
Dual color FISH was performed using centromeric and locus specific cosmid, PI or YAC 
probes for chromosome 3 and 8. Probes for chromosome 1 and 6 were used if sufficient 
material was available. FISH was performed using standard procedures (Hagemei jer et 
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aI., 1998). The concentration for centromeric probes was 5 ng per slide; for cosmids, PI 
and YAC probes 50 to 75 ng per slide were used. The probes used were: pl-79 (lp36). 
pa 3.5 (centromere 3). YAC 827D3 (3q24). cos85 (6p21) and cos52 (6q23) (Prof. Y 
Nakamura. Tokyo. Japan). Cos105H8 (8pIl) and D8Z2 (centromere 8) and ETO (8q22). 
After hybridization and washing, slides were counterstained with 4',6-diamidino-2-
phenylindole and mounted in anti-fade solution (Dabco-Vectashie1d 1:1). Signals were 
counted in 300 interphase nuclei according to the criteria of Hopman et al (Hopman et 
aI., 1988). Cut-off limits for deletion (15% of the nuclei with one signal) or 
amplification (>10% of the nuclei with 3 or more signals) were adapted from the 
available literature (van Dekken et aI., 1990). Variation found by FlSH (in FNAB and 
the main tumor) were subdivided into 5 categories (Fig. 4.1): loss of one copy, normal 
copy numbers (twO copies), gain of one copy, gain of two copies, and gain of more 
than two copies. When different subclones were identified, only the FISH findings of 
the largest clone were used to classify the material. 
Statistical analysis 
To evaluate the agreement between the FISH results obtained from the FNAB and those 
obtained from the direct preparations of the tumor, we calculated the overall kappa 
(1<'), as well as the kappa of all probes separately. Kappa below 0.20 was considered as a 
poor strength of agreement, 0.21-0.40 as fair, 0.41-0.60 as moderate, 0.61-0.80 as good 
and 0.81-1.00 as very good. The Wilcoxon's matched pairs signed rank sum test was 
used to compare the number of FISH probes successfully used on the FKAB samples 
with the number of probes used on the direct preparation. 
RESULTS 
Figure 4.1 shows the results of the FISH analyses performed on forty FKAB specimens 
taken from enucleated eyes of uveal melanoma patients and the corresponding 
primary tumors. The findings of the conventional karyotype studies on the primary 
tumors are given in Table 4.1. Examples of karyotype analysis and FISH of patient 
EOM-121 are shown in Figure 4.2. In this case no direct preparations could be made 
because of shortage of material and a short-term culture (passage 1) was used for FISH 
and karyotype analysis of the main tumor. 
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TABLE 4.1 RESULTS OF THE CYTOGENETIC ANALYSIS OF THE MAIN TUMOR. 
TuMOR CYTOGENETIC A.'fALYSIS OF MAL .... 'I'UMOR eIseN, 1995) 
E0.M 121 46-47 ,XY ,delCl )(p31 pS6) .-S,clerC 4)t( 1 :4)( q 12:q 21).+8,+21 [cpS]/ 4S,X.-Y[3 J/46,Xy[S] 
EOM 123 46,XY(22) 
EOM 125 72-76,XXX,dic(1;7)(plO:p 14),+dic(1:7)(pl O:p14),-3,+4.+6.-7 ,+i(8)(q 10),+9.·11,-15.+ 16,+ 18,+20, 
+?21,+22[cpI2V49-54,idem [cp2J 
EOM 130 41-48.XX.der(l)t(l :6)(pll:p?2),add( 4)(ql?2),-5,..t).+7 .+8.+8.-9,add(11)(q 13-14),add(mCq 13-14),-13. 
-16,+22, +mar.ish der(6)(wcp6+),+mar.ish der(16)t(6;16)(wcp&,-,wcp16+) [cp6] 
EOM 131 46,x.,'[1l] 
EOM136 41-44,XX,der( 1 :8)( q 1 O:q 1 O).ish:der( 1 :8)(wcp8+ ,2053b3+, P 1.164+ .D8Z2+, puc 1. 77 +, wcp 1 + },-3, 
-Kier(8),ish:cler(S)ins (p?21q?23q?24.1)del(8)(q22q22)(wcp8+.114Cll+.l OSHS+,pl ,164+,20S3b3+ ),~ 
IS,dd( 16)( q l1q 1 (3).ish:del( 16) (wcp 16+, pHU"'R195-)[ cp IS] 
EOM141 
EOMI47 
EOM14S 
EOMlS0 
EOMISI 
EO:MlS2 
E0::-.11S7 
E0::-.11S8 
46.xy,+ 2,dic(6: 13)( q 12:p 1 0) ,dic(6: 14)( q 12:p 1 0)[ 16J 
44-47 .xy ,dele 1 )(p2?)[5 ],add(7)(p?2)[ 4],+9[2],· 15[ 4J ,add(I9)( q 1?3 )[3] ,+mar[2][ cp6]/ 46,XYI3] 
47 .xy, +?der(2)[2]146,XY ,add(S)( q 1 0) ,der(1S )t( 1: 15)( q 11 :p 11)[1 ]l4S,X,-YI3)/ 46,XYI 1 0 J 
47 ,XY, +9 ,der( 1 0 )t(6; 1 0 )(p 12:q26)[ 4]147.xy, +9[3 J/ 46,XYI 4] 
46 ,X.X,der(20 )t(6:20 )(p12: p12 )[5 ]/47 ,idem ,+S[ 4]/ 47 ,idem, +8, p~'Udic( I 7: IS )(p 13:p 11 )[3]/46,X,X[3] 
45-48,X.'X,-33(8)( q 1 O),+i(S)( q 1 0) ,+i(8)( q 1 0)[ cp5]14 7 -49,XX, +3[3], +6[2J, +6[2][ cp4JJ 46,X.'X[ 4) 
47,XX,+8[7]!46,XX[10] 
45,X,-YIl1]/46'xYI4] 
:£OM 159 ~ 40-46,XX,der(2)t(2:6)(q3?4:?),der(5)t(5;6)(q34:?),del(6)(q?)[3], der(7)t(7:II)(p21;?)t(8:11)(q?:?), 
der( 1 0 )t(8: 1 0) (?:p I?4) ,der(11 )t(8: 11 )(?:q 1?4 ),der(l6 )t(8: 16)( q?:q24)[7], 
der(18)t(l7: 18)(?:q23)[cpI9]/46,XX[1] 
EOM 160 40-42X'X,del( 1 )(p21 ) ,.3,..6,i(8)( q 1 0)[ I ],~ 12,~ IS[ cp5 J/ 4 7 ,X.X,del( 1)( q?) ,der( 1 )t( 1 :S )(p?;q?), + 7 ,-S,~ 
9,del(11 p)[lJ!46'xX[lOJ 
:£OM165 d 40-46,XY,der(6)t(6:6)(q 16:?),der(7)t(l:7)(q12;q36),+8[cp20] 
EOM166 4 7 'x,~X,-3,+7 ,i(S)(q 1 O)[I]/idem tetrap!oid[lJ/46,X.X[4) 
EOMl74 75,X.XY,add(1)(p),-3,+i(6)(p)3(8)(q),add(9)(p)[1] 
EOM177 45-47 ,XY ,·5[2J, +8[2J ,add(S)(p22), +add(8)(p22)[ 4J ,·9[2] ,dele 13)( q?14q?21) ,clerC 1 7)ins(17: 13) 
(q 12:?q 14q21)del(17)(q22q23),. 19[2],-22,+mar[cp7] 
EOM178 ~ 4547 ,X-X, der(l)t(1: IS)(p 11 :?),der(5)t(5: 14)(p?:?), der(7)t(6:7) (?:q36),+8[2J,-14[5],~ 
15,der(17)t(7: 17)(?:pI2)t(6;7)(?;?),+ reS) [epIO] 
EOM179 46,XYII5] 
EOMlS0 43-4S,X,·X,·3,i(8)( q I 0), +i(8)( q 1 0) ,+i(S)( q 1 0)[2],der(16:21)( q 1 O:q 1 0 ),der(22)[ 1 J[ cp5 ]/tetrap!oid,idem, 
inc[2] 
EOMI82" 46,X.X,der(6)t(6:6)(q16:pI2), der(22)t(S:22)(?:pll), der(22)t(6;22)(?;q 13)[16J 
EOM187 45,X,·Y,~3,-4,i(S)(q 1 O),+i(S)(q 1 O).+mar[lJ 
EOM189 44,XY,-1 ,-2,·3,dic( 1 :6)(91 0;91 0), +ring[S]/ 45.idem, +8,[l2]/90,XXYY.idem, +8,-t-8[1 J 
aIn these cases conventional cytogenetics were supplemented with spectral karyotyping (Kaus et at, 
2001) 
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FISH results on the FNABs versus direct preparations of the main tumor. 
All FKABs yielded sufficient tumor cells to allow FISH analysis. The number of probes 
used in the FISH analysis on the FKABs was not significantly different from the 
number of probes used on the direct tumor preparations (Wilcoxon's matched pairs 
signed rank sum test p=O.197). In 8 instances all 8 probes could be tested on the FNAB 
and the main tumor. In 39 out of 40 FNABs, the FISH of both chromosomes 3 and 8 
could be analyzed. In one case (EOM138) the FNAB was of low quality and as a result 
only chromosome regions 1 p36 and 3q24 could be anal)'"Led. 
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Fig. 4.1 Results of the FISH studies carried out on 40 rme needle aspiration biopsies of uveal 
melanoma and the corresponding tumor. 
In 11/249 hybridizations discrepancies between the FISH results of the FNAB and those 
of the corresponding tumor were detected (summarized in Table 4.2). In three instances 
(regions 8pll/8q22 (EOM151), 8q22 (EOM157) this variation was due to the 
classification (three versus four copies of chromosome 8) and did not represent real 
differences. In one tumor (EOMI71), FISH results of the FKAB suggested an additional 
chromosome 8 (gain of all chromosome 8 probes), whereas the tumor suggested the 
formation of an isochromosome 8q (normal chromosome 8pll, gain of centromere 8 
and gain of two copies of chromosome 8q22). Thus, in both cases, gain of chromosome 
8q was observed. In 6/249 hybridizations FISH showed normal copy numbers in the 
FNAB but abnormal numbers in the tumor samples. In 5 of these 6 hybridizations 
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(EOM148 (centromere 8), 150 (6q23), 151 (3q24) and 178 (8pll/8q22)) this concerned 
small abnormal subclones (12-17% of nuclei) that were detected in the main tumor, 
whereas they remained undetected in the FNAB. In EOM138 a subclone of 32% of 
nuclei showing gain of chromosome region I p36 in the main tumor was not found 
when analyzing the FNAB. To investigate the agreement between the FISH results of the 
FNAB and those of the direct tumor preparation, we calculated the weighted kappa of 
all probes separately and an overall weighted kappa. The overall weighted kappa was 
0.95 (range for the probes separately 0.90-1.00), indicating a very good agreement 
between the FlSH results obtained from FNABs and those obtained from the main 
tumor. 
TABEL 4,2 FISH RESULTS OF CASES wrrn DISCREPANCIES BETWEEN FNAB AND TUMORA 
Tt.'MOR Locus MA1TIUAI," COpy NUMBER DETECTED BY FISH (% IN FNAB/ TL'MOR)c 
2 3 4 >4 
EO:M138 lp36 FiT VO 88/61 1 (6 8/32 111 
EOM148 cen 8 FIr 012 90/83 2/12 8(3 0(0 
EOMl50 6q23 FIr <1- /17 91/77 3(8 2(0 0(0 
EOM151 3q24 FIr 5/16 79/83 10/l 6(0 0(0 
8pll FIr 0/0 22/8 41/15 36/77 1/0 
8q22 FiT 010 23/6 35/10 29/65 13/19 
£0:\(157 Sq"" .. FiT 0(0 59/60 15/25 26( 15 0(0 
EO::.1:171 8pll FiT 0/0 8/9S 91/3 111 0(0 
8q22 FIr 0(0 7/2 89/13 4/84 011 
EOM178 8pll FIr 2/0 98! 87 0/12 011 0(0 
8922 FIr 0/0 96/83 4/15 0/2 0(0 
a only cases in which differences in chromosome copy numbers were observed between ~AB and 
corresponding tumor are indicated in this table. 
b F. FNAB; T. tumor 
C percentage of cells in FKAB / tumor shovving 1. 2, 3, 4 or >4 FISH signals, respectively. for the 
investigated chromosome locus 
FISH results versus cytogenetic analysis of main tumor, 
Cytogenetic analysis of the melanomas could be performed in 26/40 cases. We found 
variation between the FISH findings of the FKABs and main tumors and those expected 
from the C}1:ogenetic analysis. In most instances (EOM 130,147,159,165,177,178 and 
182) the variation was due to the presence of partially defined or complex cytogenetic 
abnormalities and could be resolved by applying metaphase FISH using whole 
chromosome paints, or spectral karyotyping (Kaus et aI., 2001). In other cases 
(EOM123, EOM157 and EOM158) normal karyotypes were found after culturing, 
whereas FISH revealed abnormalities. In two cases (EOM174 and EOM187) only one 
metaphase could be analyzed due to poor tumor grovvth in vitro, and in 5 other cases 
(EOM148, EOM150, EOM151, EOM152 and EOM160) minor variations were fonnd 
between the cytogenetic and FISH results. In EOMl25 the FISH analyses revealed 2 
copies for the chromosome Ip36 and centromere 3 probes. However, cytogenetic studies 
showed a triploid karyotype with only two copies of chromosome region I p36 and 
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disomy for chromosome 3. This indicates a relative loss of these chromosome regions in 
this tumor, although the FISH had shown no abnormalities. 
DISCUSSION 
In this study we describe the application of fluorescence in situ hybridization for 
determining of the presence of genetic abnormalities in fine needle aspiration biopsies 
of uveal melanoma. The results of our study indicate that the tumor cells obtained by 
the FKAB are representative of the main tumor and that the chromosomal aberrations 
detected by FISH in these FNAB specimens are concordant with the rna jor clonal 
genetic changes observed by conventional cytogenetics or FISH analysis of the main 
tumor. 
In 249 out of 293 hybridizations we investigated both FNAB and the matched tumor 
and statistically we found a very good agreement between the FISH results of the FKAB 
and those of the main tumor. Variation between these results was observed for 
individual probes in 11 hybridizations, a total of seven cases. However, because more 
than one probe had been used for the identification of each chromosome, in six of 
these tumors (EOM148, 150, 151 (chromosome 8), 157,171 and 178) the presence of 
prognostically significant genetic variation could still be established. The results of only 
in 2 out of 249 hybridizations (0.8%) would have led to the misclassification of the 
tumor. In EOMI38 we only observed a gain of chromosome region Ip36 in 32% of the 
main tumor cells and not in the FNAB. Gain of chromosome I is a very rare finding in 
uveal melanoma and the prognostic relevance of this abnormality is unknown. In 
EOMI5I only the main tumor showed a subclone with loss of chromosome region 3q24, 
whilst the centromeric probe for chromosome 3 showed normal copy numbers in both 
tumor and FK.A.B samples. In one case, EOMI25, the relative loss of chromosome Ip36 
and chromosome 3 could not be demonstrated by FlSH alone (both in tumor and 
FNAB) and cytogenetic analysis was necessary to reveal the hypertriploid karyotype. 
The identification of such cases could be improved by the use of a reference probe for 
DNA ploidy, for example centromeric probes for chromosomes 2, 12, or 13, 
chromosomes, which are rarely involved in numerical abnormalities in uveal 
melanoma. 
The differences between FlSH and cytogenetic analysis can be explained by culture 
artifacts since the overgrowth of normal cells is not rare when culturing tumor cells. 
Additionally, FISH has an increased level of resolution for the detection of genetic 
abnormalities that may not be visible by conventional chromosome studies. 
Sisley recently demonstrated, using cytogenetic techniques, that all major clonal 
alterations were detectable in both FKAB and the main tumor (Sisley et aI., 1998). They 
showed that with short time cultures of FNABs, conventional cytogenetic analysis was 
possible in 60% of the cases. The advantage of FISH for identifying genetic variation, 
as we have demonstrated in the present study, is that it is easier to perform and the risk 
of selecting particular cell populations during culture is avoided. 
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Folberg et a!. (Folberg et a!., 1985) found onl)' a modest correlation (r=0,57) between 
the standard deviation of the nucleolar area measured in FNABs and that measured in 
the matched enucleation sample and concluded that the FNABs were unsuitable for 
determining prognosis using these parameters. However, the djfferences in sample size 
between tumor (200 cells per sample) and FKAB (50 cells per sample) in their study 
could explain their results. 
Fig. 4.2 Examples of cytogenetic and FISH analysis in uveal melanoma and FNAB. A) 
Representative karyot}pe of patient EOM121; 47 XY,del(l)(pSlp36),-3.der(4)t(1;4) (q12;q21), +8.+21. B) 
Kuclei isolated from short-term culture of the tumor specimen hybridized -with chromosome 3q24 
(green) and Ip36 (red) probes. C) Nuclei isolated from FNAB hybridized with probes for centromere 3 
(green) and centromere 8 (red). 
One must keep in mind that these FNAB were performed ex vivo under ideal 
circumstances and we were able to use up to 8 probes to compare the FISH results of the 
FNAB with those of the matched tumor. VVhen these biopsies are taken under less 
favorable i.e. in vivo conditions, FISH analysis using probes for chromosome 3 and 8 
will be sufficient to predict the outcome of the patient since it is generally accepted that 
variation of these chromosomes are of high prognostic significance. 
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Up until now, no specific regions or genes on chromosome 3 and 8 involved in the 
tumorigenesis of uveal melanoma have been identified. However, from our 
comparative genomic hybridization and spectral karyotyping study, we do have 
indications that region 8q21.1-21.2/8q23-24 and 3q13-q21 may be involved (~aus et 
aI., 2001). Should these regions prove to be the target regions, more specific FISH 
probes can be designed in order to improve the predictive outcome of this technique. 
Our results clearly demonstrate that FISH analysis of FKAB specimens can be used to 
examine for the presence of specific chromosomal abnormalities in the tumor cells of 
uveal melanoma patients. This method is particularly suitable in cases where no tumor 
tissue has been resected and/or when patients are treated with eye~retaining treatment 
protocols such as irradiation or radioactive plaque therapy. Detection of these 
abnormalities provides important additional information for predicting the outcome 
of these patients and will help to recognize those individuals particular at risk of 
developing metastatic disease. The earlier detection of metastases and, if available, the 
introduction of appropriate adjuvant therapies during primary treatment could 
contribute to a better survival rate of uveal melanoma patients. 
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ABSTRACT 
Objective To investigate whether chromosomal abnormalities can be detected by 
fluorescent in situ hybridization (FISH) on fine needle aspirate biopsies (FNAB) of 
suspect small pigmented uveal lesions in order to differentiate between choroidal nevus 
and melanoma. 
Methods Transvitreal FNAB of three suspect small melanocytic uveal lesions with 
presence of clinical high-risk factors and no documented growth, were analyzed by 
fluorescent in situ hybridization (FISH). In addition, diagnostic cytology was 
performed. 
Results FISH revealed extra copies of chromosome 8 in the biopsy sample of one 
patient who was subsequently treated by enucleation. Histopathology confirmed the 
diagnosis of malignant melanoma in a pre-existing nevus. Cytology could not 
differentiate between nevus and melanoma in all cases. In two other biopsies no 
chromosomal abnormalities were detected by FISH. These patients were followed for 
two years -without any sign of tumor growth. 
Conclusion FISH analysis of FNAB should be considered in cases of small meIanocytic 
choroidal lesions to differentiate between nevus and melanoma and to guide the 
ophthalmologist in the management of small melanocytic uveal lesions. 
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INTRODUCTION 
Management of small melanocytic choroidal lesions has been a matter of controversy 
for a long time. In the recent past, observation of small melanocy1:ic lesions was advised 
until tumor growth was documented. At present, early treatment is advised (Shields and 
Shields, 1993). Shields found in a large series of small melanocytic choroidal lesions 
that tumor thickness greater than 2 mm, posterior margin touching the disc, visual 
symptoms, orange pigment and sub retinal fluid, predict an increased risk for tumor 
growth up to 56% if all risk factors are found (Shields et aI., 1995; Shields et aI., 2000). 
Risk factors for distant metastases are tumor thickness, documented growth, distance to 
the optic disc, and ocular symptoms (Shields et aI., 1995). These observations can guide 
the ophthalmologist in deciding whether to treat the patient or not (Shields et aI., 1995; 
Shields et aI., 2000). The overall risk of developing metastatic disease from a small 
melanocytic choroidal lesion is 3% within 5 years. However, patients with a tumor 
carrying all high-risk factors do have 19% risk of developing distant metastases (Shields 
et aI., 1995). In a meta-analysis of small melanomas a mortality rate of 16% was found 
after five years (Diener-West et al., 1992). Despite the definition of these risk factors, the 
distinction between a benign nevus and a malignant melanoma remains difficult. 
Cytogenetic studies on enucleated eyes of patients ",ith a uveal melanoma have revealed 
that specific chromosomal abnormalities, i.e. loss of chromosome 3 and gain of 
chromosome 8q, are associated with poor prognosis (Prescher et aI., 1996; Sisley et aI., 
1997; White et aI., 1998). In most of the studies, classic cytogenetic analysis has been 
used to investigate the chromosomal abnormalities which is informative in only 60 to 
70% of the cases. Fluorescent in situ hybridization (FISH) can be used to study the 
presence of chromosomal variation in interphase nuclei. We recently demonstrated that 
FISH is suitable for the detection of chromosomal abnormalities in paraffin-embedded 
tissue and fine needle aspiration biopsies of uveal melanoma. FISH is informative in 
100% and chromosomal abnormalities are detected in 81% of the cases (Naus, 
submitted). 
In the present study, three patients with a small melanocytic choroidal lesion are 
described, who presented with clinical risk factors for tumor growth and metastasis but 
without documented tumor growth over a prolonged period of time. Because of these 
discrepancies, we performed transvitreal fine needle aspiration biopsies (FNAB) to 
investigate the nature of these lesions by cytology. Since only a small sample of material 
is needed for FISH, FISH analysis was performed on the FNAB before therapeutic 
interventions were considered. 
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PATIENTS AND ME1HODS 
In three patients, referred to our clinic between 1992 and 1994, a suspected melanocytic 
lesion was found and at that time, observation was advised. After re-.evaluation of these 
patients between October 1997 and March 1998, we decided to perform transvitreal 
FNAB in order to differentiate between a benign choroidal nevus or a small uveal 
melanoma and to assess chromosomal abnormalities in order to predict the risk of 
metastases. Prior to FN.A • .B an oncologic examination was performed in all patients 
including indirect ophthalmoscopy, fluorescent angiography (FAG) and an A- and B-
scan ultrasonography (USG). To exclude distant metastases or other primary tumors, 
the patients were examined by the oncologist, including X-thorax, liver 
ultrasonography and blood tests . .AlI patients gave informed consent. 
Transvitreal FNAB procedure 
A pars plana vitrectomy was performed under general anesthesia with the use of a three 
port vitrectomy system . .All vitreous in front of the tumor was removed. For the biopsy, 
a special 25 gauge biopsy needle connected to a 20-ml s}Tinge via a silicon tubing was 
used (Medical Workshop, Groningen, The Netherlands) (Figure 5.1). After perforating 
the retina the needle was inserted into the tumor and careful suction was applied. 
Under high magnification of the operating microscope, the needle was axially rotated 
with great care to release tumor cells from the tumor, suction was then released and the 
needle was withdrawn from the eye. The FNAB material was collected in culture 
medium (RPM! 1640/HEPES supplemented with 10% fetal calf serum and 1% 
penicillin/streptomycin) to prevent lysis of the cells, and processed for cytology and 
TISH analysis. 
Cytology and FISH analysis 
A single cells suspension was prepared from the FNAB material. For the cytology study 
of the specimens, drops of the single cells suspension were placed on a slide, air dried, 
fixed in methanol) and stained mth Giemsa. The rest of the single cells suspension was 
treated -with a hypotonic solution (O.075M KCl), fixed three times with methanol/acetic 
acid (3:1), and dropped onto clean glass slides which were air-dried overnight. Dual 
color FISH was performed using specific DNA centromeric and/or cosmide probes for 
chromosomes 3 and 8 and, when sufficient material was available, also for 
chromosomes 1 and 6, using standard procedures (Hagemeijer et aI., 1998). The 
centromeric probes Pa3.5 (Waye and Willard, 1989) for chromosome 3 and D8Z2 
(Donlon et aI., 1987) for chromosome 8 were used at concentration of 5 ng per slide. 
The cosmid probes Pl.I64 (8q22) (Sacchi et a!., 1995), cos52 (6q23) (Prof. Y. Nakamura, 
Tokyo, Japan) and pl.79 (lp36) (Buroker et a!., 1987) were used at higher 
concentrations of 50 to 75 ng per slide. After hybridization and washing, the slides 
were counterstained mth DAP! and mounted in anti-fade (Dabco-Vectashield 1:1). 
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Monosomy was defined when >15% of the cells showed loss of one signal; polysomy 
when >10% of the cells showed gain of a copy. 
REpORT OF CASES 
Case 1 
A 47-year-old woman complained of an irritating right eye at consultation in October 
1994. At that time the visual acuity was finger counting in the right eye and 20/20 in 
the left eye. A melanocytic lesion with a tumor diameter of 7.5 mm was found in the 
macula region, 1.5 mm from the optic disc. The melanocytic lesion showed drusen and 
subretinal fluid, but no orange pigment (Figure 5.2a). The liSG showed a tumor 
thickness of 3.8 mm with a low internal reflectivity and a choroidal excavation. The 
tumor was clinically diagnosed as a lesion suspect for a small choroidal melanoma, but 
no treatment was applied. The subretinal fluid was treated by low dose radiotherapy (15 
Gy in five fractions). During 3 years of follow-up, progression of the lesion could not 
demonstrate by serial FAG and USG. In October 1997 the patient was re-evaluated and 
it was decided to perform a transvitreal biopsy because of high risk of metastatic disease 
(tumor thickness> 3 mm, ocular symptoms and distance to the optic disc < 3 mm). 
Furthermore, local subretinal fluid did not respond to low dose radiotherapy. 
Fig 5.1 A 25 gauge biopsy needle connected to a 20-ml syTinge via a silicon tubing 
Case 2 
A 6&.year-old woman presented in 1992 with a 9 mm melanocytic lesion in the inferior-
temporal quadrant, 1.5 mm from the fovea of her left eye. The tumor showed some 
drusen and subretinal fluid but no orange pigment (Figure 5.2b). Her visual acuity was 
20/20 in both eyes. The tumor showed a tumor thickness of 3.S mm with low-reflectivity 
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and choroidal excavation as measured by USG. Although treatment was considered, the 
tumor showed no progression on examination by serial FAG and lJSG; therefore 
observation was continued. In March 1998 the patient was re-evaluated and was 
considered as having increased risk of growth (based on tumor thickness and distance 
to the fovea). However, tumor growth could not be demonstrated and the patient had 
no visual complaints. At that time it was decided to perform a FKA.B to verify the 
malignant nature of this tumor. 
Fig 5.2 Fundus photographs of case 1, 2 and 3. A) Case 1. Right fundus October 1994: B) Case 2. 
Fundus photograph of the left eye C) Case 3. Fundus photograph of the left eye; D) Case 3. Choroidal 
nevus 1 day after FNAB: notice limited pre-retinal blood 
Case 3 
A 48-year-old woman was referred to our department in 1992 with a melanocytic lesion 
in the posterior pole of the left eye. The tumor had tumor diameter of 7.5 mm, showed 
subretinal fluid and was located 2 mm from the optic disc (Figure 5.2c). The tumor 
thickness was 2.8 mm as measured by USG. Her visual acuity was 20/20 in the right eye 
and 20/60 in the left eye. Tumor gro'Wth could not be demonstrated and observation 
was advised. At the time of re-evaluation in January 1998, a transvitreal biopsy was 
advised because of the tumor size, the subretinal fluid, visual symptoms, and distance to 
the optic disc and fovea. One-day postoperatively, some pre-retinal blood was found, 
but this subsided after I week (Figure 5.2d). 
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RESULTS 
Casel 
The cy'tology specimen showed partly cohesive cells and single cells. All cells showed a 
polygonal appearance with round to oval nuclei and abundant cytoplasm. Melanocytic 
granules were scattered within the cells. Prominent nucleoli could not be demonstrated 
(Figure 3a). Three spots of the centromeric region of chromosome 8 were found in 26 
of 100 nuclei (Figure 3b), with no loss of chromosome 3 (Table 5.1). Gain of 
chromosome 8 is suspect for malignant transformation and therefore prompt treatment 
was advised. The tumor-containing eye was enucleated and histopathologic examination 
confirmed the diagnosis choroidal melanoma. The Ulmor contained spindle cells as 
well as epithelioid cells in a pre-existing nevus (Figure 3c). FISH analysis on the tumor 
specimen confirmed the FISH findings of the FNAB. After 36 months of follow-up the 
patient showed no local recurrences or distant metastases. 
TABLE 5.1 COpy NUMBERS CHROMOSOMAL REGIONS DETECTED BY FISH 
FNAB 
PROBE No. COPY 
CELLS NUMBER % 
2 87 
cen 3 100 
3 2 
4 10 
2 62 
con 8 100 3 26 
4 2 
>4 9 
6023 
CAsE 1 CAsE 2 
TUMOR 
No. COpy 
C£LLS N"L~ER % 
so 
50 
100 
6 
2 92 
3 o 
4 2 
o 
2 64 
3 34 
4 
>4 
2 92 
3 6 
4 0 
PROBE 
1p36 
ccn3 
cen 8 
FNAB 
No. COPY 
CELLS N-U'MBER % 
142 
121 
121 
2 
3 
4 
2 
3 
4 
2 
3 
4 
2 
4 
96 
o 
o 
3 
95 
4 
94 
o 
2 
o 
10 
CAsE 3 
FNAB 
PROBE NO. COPY 
1p36 
ccn3 
con 8 
CELLS NUMBER % 
38 
37 
37 
8 
2 89 
3 o 
4 3 
3 
2 94 
3 0 
4 3 
5 
2 92 
3 0 
4 3 
3 
2 94 
8q22 142 o 6q23 38 
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Case 2 
On cytological examination, the major part of the cells was disrupted and therefore cell 
shape could not be determined. The background showed melanocy'"tic granules. The 
nuclei were round to oval without prominent nucleoli. Malignant transformation of 
this tumor could not be demonstrated by cytology. BSH analysis (Table 1) showed no 
chromosomal abnormalities for chromosome 1, 3, and 8. Thus no chromosomal 
abnormalities indicating a high risk for metastases were detected. Nrer 32 months of 
observation there are no signs of tumor growth or distant metastases. 
Case 3 
Cytology showed abundant melanocytic granules with normal appearing nuclei. FISH 
analysis on only 37-38 nuclei revealed no chromosomal abnormalities for chromosome 
1, 3, 6, and 8 (Table 5.1). Treatment was not applied. Thirty-five months after the 
procedure tumor growth or distant metastases could not be demonstrated. 
Fig 5.3 Case 1 A) Cytology ofFNAB specimen: B) FISH analysis: 3 green spots for chromosome 8 and 
2 red spots for chromosome 3: C) Enucleation specimen: epithelioid melanoma cells in a pre-existing 
nevus. 
COMMENT 
The distinction between choroidal melanoma and choroidal nevus can be very difficult 
based on the clinical parameters alone. Clinical risk factors predicting romor growth 
and metastasis in small uveal melanoma, can help the clinician in the management of 
these lesions (Shields et aI., 1995; Shields et aI., 2000). Due to improvement in the 
knowledge about defining patients at risk and the increased experience in specialized 
oncology units, the rate of misdiagnoses has been decreased to less than 0.5%. In our 
patients clinical differentiation between choroidal nevus and small melanoma could 
not be made. At the time of presentation, observation was advised unless documented 
growth could be demonstrated. Mter three, five and six years, respectively of follow-up 
tumor growth could not be demonstrated. The present clinical practice, however, 
advocates treatment of small melanocytic tumors based on the ocular symptoms, tumor 
thickness, subretinal fluid, orange pigment, and distance to the optic disc and fovea. 
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The discrepancy between the presence of clinical risk factors for growth and metastases 
on one hand and the absence of growth over a three to six year period on the other 
hand, caused a therapeutic dilemma in our patients. Therefore, we decided to perform 
a transvitreal fine needle aspiration biopsy (FN.AB) in these patients for cytological 
examination and to investigate the presence of chromosomal abnormalities by flSH 
analysis. 
Cytological examination was not conclusive in all three patients which is in accordance 
with the relative contraindication for FN.A.B of a suspected intraocular tumor to 
differentiate between a large nevus and a small melanoma (Shields and Shields, 1993; 
Char and Miller, 1995; Char et al., 1996). However, FISH analysis was helpful in all 
cases: In first patient flSH analysis showed extra copies of chromosome 8q in the FNAB. 
Since in 81 % of uveal melanomas chromosomal abnormalities can be found and extra 
copies of chromosome 8q are associated with high risk for metastatic death in uveal 
melanoma, prompt treatment was applied. Although radiotherapy was advised the 
patient preferred to have an enucleation. The FISH analysis of the paraffin-embedded 
tumor confirmed the findings of the FISH on the FNA..B. In patient 2 and 3 the FISH 
analysis did not reveal chromosomal abnormalities. This does not imply that these 
lesions are benign tumors, since in some cases of large uveal melanoma no 
chromosomal abnormalities have been detected. We therefore cannot exclude a 
malignant melanoma based on our FISH findings. However, since no chromosomal 
aberrations were found, we classified these patients as low~risk for metastatic disease 
and further observation was advised until tumor growth is documented. Although the 
follow-up time after the procedure is relatively short (32 and 35 months respectively) no 
tumor growth or distant metastases have been found in these patients. 
Fine needle aspiration biopsy (FNA..B) is a safe method of obtaining tumor material 
from patients with a suspect melanoC}~ic choroidal lesion (Char et al., 1989; O'Hara et 
aL 1993). Performing FK.ABs on malignant tumors always raises the question whether 
there is an increased risk of spreading melanoma cells in the vitreous and at the 
vitrectomy ports. From previous reports we know that the relative risk for vitreous 
seeding and recurrences is very rare (Shields et al., 1993: Char and :Miller, 1995). In one 
study, however, the authors did find tumor cells in the fine needle tract in 8 out 15 
biopsies (Glasgow et al., 1988). This study was performed on enucleated eyes, without 
proper visual control under the operating microscope and no vitrectomy was 
performed prior to biopsy. The risk for serious complications is relatively 10w(Shields et 
al., 1993; Char and 1vliller, 1995). In a larger series no retinal detachments were 
documented. Subretinal and vitreous hemorrhages are described, but are of no 
significance after one week postoperatively. Only in case 3 we did experience some pre-
retinal blood, which subsided after one week. 
FISH analysis is a reliable method for detecting the abnormalities in chromosome 3 
and 8 in FNA..Bs. At our institute, ex vivo FNABs (after enucleation or local resection) in 
a series of 40 patients were informative in 100% of the cases and the FISH analysis of 
the FN.AB were concordant with the FISH analysis in the whole tumor (Naus, 
submitted). In a recent study, Sisley and coworkers, found also chromosomal 
abnormalities in FNA..B with a cytogenetic analysis with short time culture (Sisley et al., 
1998). FISH has been used in one other study of McNamara for the detection of loss of 
chromosome 3 in fresh uveal melanoma specimens (McNamara et al., 1997). 
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These three cases illustrate that FISH analysis on FNAE can be helpful in the 
management of patients "With a small melanocytic choroidal lesion resulting in reduced 
morbidity. Furthermore, FISH analysis on FNAB samples from classified uveal 
melanoma could be used to improve the prognostic accuracy prior to treatment. Char 
et ai, in a study of cytopathologic analysis of FNABs before radiotherapy, found a 
correlation between the detection of epithelioid cells in the FNAB and survival of the 
patients (Char et aI., 1996). By defining the risk of metastases in FNABs, treatment of 
uveal melanoma might be optimized and adjusted for an individual patient. Whether 
the detection of these chromosomal abnormalities will eventually lead to a change in 
the management of uveal melanoma, requires future investigations. 
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ABSTRACT 
vVe report on the establishment and characterization of two primary (EOM-3, EOM-29) 
and three metastatic uveal melanoma cell lines (OM::M-I, O:\w-2, OMM-3), and further 
cytogenetic characterization of a previously described primary uveal melanoma cell line 
(OCM-I). Only a few long-term growing primary uveal melanoma cell lines have as yet 
been established, while of metastatic uveal melanoma cell lines we have found no 
descriptions. The morphology of the in vitro cultured cells varied from spindle to 
epithelioid. The cell lines were characterized by immunocytochemistry, electron 
microscopy and cytogenetical analysis. The relative grovvth rate was determined by 
bromodeox}uridine (BrdU) incorporation. The melanocytic origin of the cell lines was 
determined by the positive staining 'With antibodies identifying melanoma associated 
antigens. Melanosomes and pre-melanosomes were indeed observed by electron 
microscopy in all cell lines. The stem cell karyotype was found to be normal in three 
cell lines (EOM-29, 0:111\1-2, OMM-3) and abnormal in three others (EOM-3, OC\i-l, 
01vL\1-1) showing a net loss of chromosome 6. The OCM-l and the OMM-l cell lines 
even demonstrated a large amount of structural chromosomal aberrations, the former 
being near tetraploid and the latter triploid. The EOM-29 cell line, cultured from an 
ciliary body melanoma, did not show the previously described chromosome 3 and 8 
abnormalities. 
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INTRODUCTION 
Uveal melanoma is the most common primary intraocular tumour in adults (Egan et 
al., 1988). These tumours spread haematogeneously and preferentially to the liver. A 50 
% overall incidence of metastasis occurs within 15 years after initial treatment by 
enucleation or radiotherapy of the tumour--containing eye (Kath et aI., 1993). After 
clinical diagnosis of hepatic metastases, median survival is extremely poor: between two 
and seven months (Kath et aI., 1993). The biological and molecular properties of the 
successive steps involved in uveal melanoma progression and metastasis could be studied 
in detail once established uveal melanoma cell lines were available. A limited number 
of cell lines obtained from primary uveal melanoma have indeed been described (Kan-
Yfitchell et aI., 1989; Aubert et a!., 1993; C\1assarelli et aI., 1994; De Waard-Siebinga et 
al., 1995), but not from metastatic uveal melanoma. 
In this study, we report on the successful establishment of two primary (EOM-3, EOM-
29) and three metastatic uveal melanoma cell lines (ONIM-I, O:MM:-2, O:MM-3) in our 
institute. These cell lines were characterized by immunocytochemistry, light and 
electron microscopy, and cytogenetic analyses. The relative growth rate was determined 
by bromodeoxjuridin (BrdU) incorporation. In addition, a previously described 
primary uveal melanoma cell line, OQvf-l (Kan-Mitchell et aI., 1989), was further 
characterized by extended karyotypic analysis. 
MATERIAL AND METHODS 
Tumour material 
After enucleation of the uveal melanoma containing eye, part of the ocular tumour was 
taken for cell culture. The eye was further histologically examined to confirm the 
diagnosis. When, during follow-up of the patient, metastatic disease was suspected, a 
biopsy was taken for diagnosis and for cell culture . .All patients had given full informed 
consent. Between January 1992 and May 1993, cells of the primary tumours of 16 
patients and of the metastatic tumours of four patients were processed for culture. The 
patients with primary uveal melanoma ranged in age from 22 to 87 (mean: 56.8); nine 
were female and seven were male; eight patients had a choroidal and eight patients had 
a ciliary body melanoma; three patients had a spindle-cell tumour, nine had a mixed-
cell tumour and four had an epithelioid-cell tumour; tumour diameter ranged from 3 
to 22 mm (mean: 11.6 mm). The patients were followed until May 1995; two patients 
died of metastatic disease and one is alive, 6 months after detection of a metastatic 
lesion in the subcutis. From all four patients with metastatic disease tumour material 
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was obtained from sub-cutaneous lesions. From one patient the primary as well as the 
metastatic tumour were available. 
Culturing methods 
The tumour material was processed and cultured within one to three hours after 
dissection as described by Luyten et al (Luyten et aI., 1993). In brief, the tumour-
containing eye or the metastatic lesion was dissected under sterile conditions. A full 
thickness biopsy was taken and transported in Dulbecco's-modified-Eagle's medium 
supplemented with 10% fetal calf serum, and 1 % penicillin/streptomycin (full DMEM). 
The tumour material was suspended with a small pair of scissors and strained through a 
linen cloth by continuous irrigation vvith full D).f£M. The resulting suspension of single 
cells and to a lesser extent of small clumps of tumour cells, was then washed two or 
three times with full DJ\1EM. This washing was repeated depending on the amount of 
pigment. The cells were seeded in a culture flask (Falcon plastic T-30) with 5 ml full 
DMEM at 5% CO2 (37°C). After one week the medium was renewed while the non-
attached cells were discarded. Subsequently, the culture medium was changed twice a 
week. At reaching confluence, the cells were detached with 0.05% trypsin and 0.5 mM 
Na2·EDTA and subsequently subcultured. Depending on the growth rate the cultures 
were passaged at 1:2 to 1:10 dilutions. 
BrdU incorporation 
To measure the logarithmic growth rate of the cells in culture, the cells were incubated 
in culture flasks for SLX hours with 1 mM BrdU (Boehringer Mannheim, .Almere, The 
Netherlands). After being washed and detached, the cells were centrifuged onto object 
glasses, fixed in 2 M HCL at 37°C for 30 minutes and then incubated in 0.1 M borate 
buffer pH 8.5 at room temperature for five minutes. The cells were subsequently washed 
twice with PBS and incubated for 30 minutes with a peroxidase-conjugated 
immunoglobulin of a mouse monoclonal antibody specific for BrdU (Boehringer 
Mannheim; dilution 1:33) in 1 % BSA/PBS. After washing with PBS again, the 
incorporated BrdU was visualized with 3'3 diaminobenzidine and ureum hydroxide 
(Sigma, St. Louis, MO). The percentage of BrdU incorporated cells could then be 
counted in one low power field (lOX) using an eye piece grid. 
Immunocytochemistry 
The cells were cultured on a coverslip, washed twice with PBS at 37"C and subsequently 
fixed in cold acetone at _20°C for 10 minutes. Endogenous peroxidase was inhibited by 
incubation in 0.3% hydrogen peroxide/methanol for 15 minutes. Subsequently the 
coverslip was incubated in 2% fetal calf serum/pBS for five minutes. The primary 
antibodies, S100 (Dako, Glostrnp, Denmark), NKI-C3 (Dako), HMB-45 (Biogenex, San 
Ramou, CA) and HNK-l (Becton Dickinson, San Jose, CA.) were incubated at dilutions 
of 1:600, 1:20, 1:50, 1:10, respectively for 1 hour. For S100, swine anti-rabbit 
peroxidase-conjugated immunoglobulin was used as a second step antibody (Dako; 
dilution 1:100). For the other three antibodies rabbit anti-mouse peroxidase-conjugated 
immunoglobulin (Dako; dilution of 1:100) was used. Both secondary antibodies were 
incubated for one hour. The activity of the peroxidase was then visualized using tablets 
of 3,3' diaminobenzidine HCL and hydrogen urea peroxide (Sigma). Finally, the cells 
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were counterstained "With haematoxylin for 10 seconds. Between each of the incubation 
steps the coverslip was rinsed with 0.1 % Tween-20/pBS. 
Antibodies 
The S100 antibody recognizes an acidic intracellular Cai-t" binding protein and is a 
sensitive but non-specific marker for melanoma cells (Moore, 1965). Monoclonal 
antibody KKI-C3 and HMB-45 binds both a cytoplasmic antigen produced by fetal 
melanocytes and melanoma cells of adults (Vennegoor et aI., 1985: Gown et aI., 1986). 
The monoclonal antibody HKK-I recognizes a family of cell adhesion molecules (CD 
57), migrating neural crest cells and a series of neural crest derivatives including 
tumours of neural crest origin (Abo and Balch, 1981). 
Fig 6.1 Light microscopy (scale bar 50 pm). A) The OCM-l cell line has small and large rounded 
cells, with one or more nuclei, growing upon a stellate and elongated cell layer with dendritic 
e.xtensions: B) The EO:M~3 cell line shows a monolayer of plumb polyhedral anaplastic, epithelioid cells 
with abundant cytoplasm, large nuclei and prominent nucleoli: C) The EOM~29 cell line forms spindle-
like patterns with large round nuclei; D) The OM:M:~l cell line: cluster of large round cells (mono- and 
multinucleated), irregularly shaped stellate and elongated cells, very large cells with abundant 
cytoplasm and cytoplasmic inclusions were observed: E) The 011M~2 cell line showed a monolayer 
characterised by predominantly elongated cells 'With large nuclei. abundant cytoplasm and long 
dendritic extensions, forming a bundle-like, spindle-cell pattern; F) The OlvIM·3 cell line has spindle-cell 
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appearance with dendritic extensions; the nuclei are large with abundant cytoplasn and prominent 
nucleoli. 
MHC class I expression 
Sub-confluent cell cultures were detached "With trypsin/EDTA, after which 
cytocentrifuge slides could be prepared. The major histocompatibility complex (MEC) 
class I expression was determined using the standard Nffi micro-<:ytocytoxity test with 
locally obtained reagents. 
Electron microscopy 
Mter detachment by use of trypsin/EDTA, the cultured cells were centrifuged and fixed 
in 3% glutaraldehyde at room temperature for 30 minutes. Then they were post-
osmificated for 30 minutes in 1% Os04, and subsequently embedded in Epon. 
Ultrathin sections were prepared and counterstained with uranyl acetate and lead 
citrate. 
Cytogenetic analysis 
In order to obtain metaphases, cultured cells in the logarithmic phase of proliferation 
were treated with colcemid for one to three hours. Mter trypsinization, the cells were 
subjected to a hypotonic (0.075 M KCL) solution. Finally the cells were gradually fixed 
with cold methanol/acetic acid (3:1 v/v) . ..A...ir-dried slides were banded by the reverse 
method. 
To identify the marker chromosomes, fluorescence in situ hybridization (FISH) was 
used. Slides were then hybridized with chromosome-specific libraries (pinkel et aI., 
1988), kindly provided by Dr. J. Gray. The results presented conform to the 
recommendations of the International System for Human Cy1.ogenetic Nomenclature 
(ISCN) (Mittelman, 1985). 
RESULTS 
Primary and metastatic uveal melanoma cell lines 
Out of the 16 cultures of the primary uveal melanomas, two cell lines could be 
established successfully. The remaining cell cultures stopped growing after being 
passaged two to five times. Of the cultures of the metastatic uveal melanomas, three out 
of four resulted in a stable growing cell line. The cell cultures from one patient, from 
whom both the primary and corresponding metastatic Ulmour were available, were not 
successful. The patient data and tumour data from the established cell lines are 
summarized in Table 6.1. 
The primary uveal melanoma cell line OCl\f-1, described by Kan-Mitchell and associates 
(Kan-Mitchell et aI., 1989), has been growing for more than seven years without 
morphological changes (Figure 6.la). The EOM-3 cell line was established from a mixed 
cell type primary uveal melanoma. During the first six passages, the cultured cells had a 
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spindle cell type appearance. However, a small clone of epithelioid cells started to grow 
and subsequently overgrew the rest of the tumour cells. The epithelioid-cell culture 
underwent no further morphological changes and has been growing now for two years 
(Figure 6.1 b). EOM-29 was established from a large extra-ocular extension of a ciliary 
body melanoma (epithelioid cell type) and could be passaged once a week. Gradually 
the passage time increased with a decreasing proliferation rate. Mter passage ten, the 
cells had a spindle like appearance in culture (Figure 6.1c) and continued to grow 
without demonstrating changes in their morphology. 
TABLE 6.1 PATIENT AND TUMOUR DATA OF SUCCESSFUL ESTABLISHED UVEAL MELANOMA CEIL 
UNES 
CELL PATIENT SL"'RVIVAL TuMoUR HISTOLOGY CELLUNE PASSAGE 
UNE GENDER/ LOCATIO'S MORPHOLOGY 
AGE (IM) 
OCM1 F/nr nc Posterior Spindle B Mixed >50 
EOM3 M/62 29 POsterior Mi..: ... ed Epithelioid 20 
E01129 M/S7 14 Ciliary body Epithelioid Spindle 15 
OMMI M/74 3431 Subcutis metastasis Mixed :Mi.xed 42 
OMM2 M/72 40' Subcutis metastasis Epithelioid Spindle 23 
OMM3 M/72 41' Subcutis metastases .Mi..xed Spindle 19 
1 Tumour related death 
nr, not reported 
A subcutaneous metastatic lesion (mixed cell type) was excised from a uveal melanoma 
patient (O:MM-I), who had undergone an enucleation of his primary tumour 29 years 
earlier. The primary culture of this metastatic lesion and the first ten passages consisted 
of adherent and non-adherent cells. Gradually more cells became adherent, showing a 
heterogeneous morphology of spindle and epithelioid cells. This morphological 
heterogeneous spectrum remained the same over 2.5 years (passage 42) (Figure 6.1d). 
The primary culture (O:MJvf-2) of a sub-cutaneous metastatic lesion (epithelioid cell type) 
had a spindle cell pattern in cell culture, and did not show morphological changes for 
2 years. The cells have been growing slowly but continuously, with a passage time of 
one month (Figure 6.1e). Tbe most recently established metastatic cell line (OMM-3) was 
cultured from a large, partly amelanotic sub-cutaneous metastatic lesion (mixed cell 
type) with a spindle cell appearance in cell culture. This cell line has now been growing 
for more than 1 year and no morphological changes have been observed (passage 19) 
(Figure 6.1£) 
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Fig 6.2 Electron microscopy. A) OCM-l: part of an uveal melanoma cell. The cytoplasm contains a 
few melanosomes (M) and pre-.melanosomes type 1 (PY!) and sporadic type 11 (scale bar, 0.350 )lm); B) 
EOYf-3: very primitiw. immarure cell v·lith a largt: nucleus and 2 prominent nucleoli. Only a few pre-
melanosomes t)-pt: 1 (P.M) are present (scale bar, 1 )lm); C) EOM-29: heavily pigmented cells with 
abundant cytoplasm in which there are many me1anosomes 1).1) and pre-melanosomes type III (P:M) and 
lysosomal structures (L) (scale bar. 1 ,Urn); D) O).{M-l: 2 melanoma cells contain in the cytoplasm a large 
amount of osmiophylic (dense) me1anosomes (M) and pre-melanosomes type III and IV, and only a few 
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type 11 (PM). Note the presence of lysosomes (L) (scale bar, 0.583 ~): E) 0:M:\1-2: melanoma cell with 
an aberrant cytoplasm in which dense fusiform melanosomes (M) and pre-melanosomes (type 11, III and 
IV) (PM) are observed (scale bar. 1 j.lm): F) O:MM-3: spindle rnelanocytic cells. The cytoplasm contains 
large amounts of rough endoplasmatic reticulum and pre-melanosomes types 11 and III (PM): a few 
lysosomes (L) are also present (scale bar, 1 ~). 
Electron microscopy, immunocytochemistry 
Electron microscopical morphology of the six cell lines is shown in Figure 6.2a-f. All 
figures are representative for the cultured cells examined and contained me1anosomes 
and pre-melanosomes (Table 6.2), The immunocytochemical staining of the five cell 
lines with )JKI-C3, :HM:s-45, S100, HNK-I and Brdu incorporation is summarized in 
Table 6.2. The KKI-C3 stained all five cell lines; expression of the other three markers 
appeared to be facultative. The cell lines EOM-3 and 0MJ\1-1 showed a relatively high 
BrdU incorporation, thus showing a high frequency of cell division. The more slowly 
growing cell lines EOM-29, OMM-2 and OMM-3 had indeed a lower BrdU 
incorporation. The primary cell lines OCM-l and EOM-29 were found to express :MHC-
class-I molecules, whereas in the EOM-3 cell line, no detectable J\.ffiC-class-I expression 
was observed. All three metastatic cell lines were found to express :MHC-class-I antigens. 
TABLE 6.3 CYTOGENETIC DATA OF UVEAL MELANOMA CELL UNES 
CEll. PASSAGE NO OF MODAL KARyOTYPE 
Llli'E METAPHA.SES CHROMOSOMES 
ANALYSED 
OC11-l >50 14 90-97 94,<4>,)(."(,-X,-X.dd(l )(p21 )[40% 1.der(2)t( 1 ;2)(p31 ;q3 7). 
add(3)(q12). +dd(3)(q13q23).dd(4) (q12)[60%).-4[40%]. 
add(5)(pll) [40%).add(5)(ql3).-6[60%].add(7)(q3S). 
dd(7)(q33).-7 .add(8)(q24)x2.-9.-11 ,inv(II)(plSq24),dd(12) 
(p12)x3.-12,add(13)(q31).-13 or t(I3q:14q)[60%],-lS. 
add(16)(p13k16[40%],-18[60%],-19[60%].add(20)(q13)x2 or 
x3,-20.add(21)( q21) ,·21 .-21 ,dd(22)( q 11 )x2.iso(22q)x2, +6-12 
markers 
E0.:'.1-3 10 22 46 46,X,-Y,.,.S,-6,+IS 
E011-29 5 10 46 46,XY 
OMM-l 8-10 22 60-68 64,<3>.X. -X.-Y .der( 1 )t( I ;3)(p31 :p 13) ,der(2)t(2:5) 
(q32:q 14?)x2 ,t(2: 1 0)( q32;q25), + 3[50% J ,-4,del(S )( q 13q 24), 
+7 ,add(8)(p 11),-9,-11 ,+ 12.inv(13)(q 12q34),-15,add(16)(p12). 
-17 ,del(l9)(p12),+20,add(21 )(pI3).-2l.+ 1-3 markers 
OMM-2 11-14 19 46 46.Xy[11]/44-45. with random loss of 1 or 2 chromosomes, 
[8 of which 2x -6] 
0M11-3 1-4 21 46 46,XY 
Cytogenetic analysis 
The karyotypes of the six cell lines are described in Table 6.3. The karyotypes were 
obtained from 10 to 25 metaphases from each cell line at different passages. Cells from 
cell line EO:M-29 and OMM-3 displayed a normal karyotype. The stemline karyotype of 
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OCM-l v."aS found to be tetraploid and to have many structural chromosomal 
aberrations (Figure 6.3a). These, among other changes, have resulted in a net loss of 3q 
and of the distal part of chromosome 8 (Sq24qter); monosomy 6 was observed in 60% 
of the meta phases of OCM-l. The stemline karyotype of EOM-3 was found to be 
pseudodiploid with numerical changes: a loss of Y, monosomy 6, trisomy 5 and 18 
(Figure 6.3b). The stemline karyotype of cell line OJ\.1:M-I was near triploid with many 
structural and numerical changes, a net gain of chromosome 3, 7, 12 and 20, and loss 
of 4, 8p, 9, 11, IS, 17, 21, among others (Fignre 6,3c). Cell line OMM-2 showed no 
clonal aberrations, but some non-clonal rearrangement, such as a monosomy 6 in 2 
cells and an unbalanced translocation (14;22) in one cell. 
Fig 6.3 Karytypes of the cell lines. A) OCM-l: B) EOM·3 and C) 0:t\n.1-1 
DISCUSSION 
Culturing of human uveal melanoma cells was first attempted in 1929 by Kirby (Kirby, 
1929), but until the present date only a few cell lines from primary melanomas (Albert 
et a!., 1984; Kan-Mitchell et a!., 1989; Aubert et a!., 1993; Massarelli et a!., 1994; De 
Waard~Siebinga et aI., 1995), and no cell lines from metastatic uveal melanomas have 
been described. The relative paucity of established uveal melanoma cell lines can be 
explained partly by the low incidence (l:lOO.OOO) of uveal melanoma and by difficulties 
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in the culturing of primary uveal melanoma tissue (Egan et aI., 1988). Lack of 
therapeutic modalities for patients with hepatic metastases has led to a high mortality 
among them within a very short survival time, and hence provides a problem with 
respect to the availability of fresh metastatic tissue as well. In this study we were able to 
establish twO primary uveal melanoma cell lines and three metastatic uveal melanoma 
cell lines. Although a limited overall number of tumours could be cultured at our 
institute, the success rate in the establishment of long-term growing cell lines was 
relatively high for metastatic uveal melanomas (3/4) as compared with primary uveal 
melanoma (2/16). Metastatic lesions originate from selected cells that have proved to be 
capable of growing in secondary organs. This could be the reason for the high success 
rate in culturing metastatic cell lines. The present availability of primary and metastatic 
uveal melanoma cell lines make it possible to study the differences between primary 
and metastatic uveal melanoma in vitro. 
To ascertain the melanocytic ongm of the cultured cells, the cells were 
immunocytochemically studied by the use of melanoma-associated antibodies. SlOO, 
NKI/C3 and HJ\tIB-45 are known to be powerful markers for differentiating tumours of 
melanocytic lineage from other anaplastic tumours. In addition, electron-microscope 
studies revealed melanosomes and pre-melanosomes in all the cell lines described. The 
cell lines showed a considerable variation in passage time as measured by BrdU 
incorporation. The cell lines EOM-3 and O:MM-l had relatively high BrdU 
incorporation and were shown to have high gro-wth rates with short passage times in 
culture. The cell lines EOM-29. OMM-2 and OMM-3 had low levels of BrdU 
incorporation and were also more difficult to maintain in culture. However, the cell 
lines 0111\1-2 and 0:MM-3 were stable over a long period of culture without showing any 
morphological changes. The cell line EOM-29 has been in culture for a relatively short 
period, showing no morphological changes, but immortality is not yet established. K 0 
difference in growth rate between primary and metastatic cell lines could be 
demonstrated by the BrdG incorporation. 
Although epithelioid cells have often been regarded as the most malignant cell type, 
three out of six cell lines in our study, were of the spindle cell type (EOM-29, 0:Mlv1-2, 
0111\1-3). This in contrast to the histological cell type of the original tumour of the 
patient. This can probably be explained by the selective outgrowth of certain tumour 
cells in a favourable culture medium such that used by us. In case of the cell line EOM-
3, the spindle cells of the fresh tumour culture were gradually overgrown by 
undifferentiated, anaplastic cells at passage five. After that time the uniform 
morphological cell type of EOM-3 remained unaltered. Whether the phenotypical 
change of the cell line EOM-3 is accompanied by genetical instabilities, reflecting one 
or more steps in tumour progression, or by simple selection is not known. Both cell 
lines 0C.\1-1 and O~-l consist of a heterogeneous population of cells with a high 
gro-wth rate, showing signs of selection of one of the morphological cell types present 
in the original tumour. 
The normal expression of ::vIHC class I molecules in five of the six cell lines indicates a 
possibility of a :MHC class I restricted T-cell response in metastatic uveal melanoma 
patients. In the EOM-3 cell line, :MHC-class-I expression is down-regulated and, as a 
result of this, increased susceptibility to natural-killer-cell activity has been 
demonstrated (Ma et aI., 1995). These data indicate that enhancement of the T-cell 
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response by the use of allogenic irradiated cell lines might be one of the most 
promising ways to treat patients with metastatic disease. 
In cytogenetical analyses of primary uveal melanoma, the most frequently described 
chromosomal abnormalities found are: monosomy of chromosome 3, net loss of genetic 
material of chromosome 6q and Sp, and gain of 6p and 8q (Horsman and White, 1993; 
Singh et aI., 1994). It has been suggested that monosomy 3 and the isochromosome 8q 
are associated with ciliary-body melanoma and poor prognosis (Sisley et aI., 1990). 
Cytogenetic analysis of our cell lines. showed a normal karyot)pe in three cell lines and 
karyotypic abnormalities in the other three, with partial loss of chromosome 6 among 
multiple other aberrations. OCM:-I and 0MJ.\1-1 were near~tetraploid and triploid, 
respectively. In these cell lines, partial loss of 3q and 8p were seen, as a consequence of 
structural changes. In contrast to other results on cytogenetical abnormalities in ciliary~ 
body melanoma, our cell line EOM-29, which was derived from a massive extrascleral 
growth of a ciliary-body melanoma, did not demonstrate the chromosome-3 and -8 
abnormalities. We have found however no systematic differences in the karyotypes of 
the cultured cells of primary versus metastatic tumours. The karyotyping was assessed 
after establishment of the cell lines and thus. some chromosomal abnormalities could 
be the consequence of in vitro clonal selection and progression, instead of a 
representation of the situation of the tumour in vivo. In future studies, cytogenetic 
analysis of primary uveal melanoma cell cultures will hopefully provide more 
information on the karyotype of the tumour cells. Furthermore, complementary studies 
using molecular cytogenetic approaches and comparative genomic hybridization could 
give more detailed information on chromosomal abnormalities in fresh tumour and 
cell lines in culture (Speicher et a!., 1994). 
86 
METHYLATION IS THE MAJOR CAUSE OF 
P16 INK4A INACTIVATION 
IN UVEAL MELANOMA CELL LINES 
Nicole C. Naus,1.2 Anette C.A. Verhoeven, I,;; Manja].::v.r. Muijtjens,2 Riena Aliredjo,2 
Gregorius P. M. Luyten,l Annelies de Klein,s 
From the Departments of lOphthalmology, 2Cell Biology & Genetics. 3 Clinical Genetics 
Erasmus Gniversity Rotterdam, The )Jetherlands. 
Submitted for publication 
CHAPTER 7 
ABSTRACT 
Purpose Uveal melanoma is the most common primary malignant intraocular tumor 
in the Western world. In cutaneous melanoma deletions or mutation of the 
p16f}.lK4a/p14ARF' gene are frequently found. In our effort to unravel the mechanisms of 
uveal melanoma tumorigenesis, we determined the possible involvement of these genes 
in uveal melanoma cell lines. 
Methods Nine uveal melanoma cell lines were investigated for deletions, mutations, 
methylation and expression of the p16JNK4a gene. In addition, the expression of its 
alternatively spliced gene product, p14ARF, was determined. 
Results In contrast to what is known from cutaneous melanoma, no homozygous 
deletions were detected in these nine cell lines. LOR was observed in 3 out of nine cell 
lines. Two of these cell lines also had a mutation the p16ll'lK4a gene. Furthermore, four 
out of nine uveal melanoma cell lines showed methylation of the promotor region 
resulting in the absence of plrJNK4a mRNA. 
Conclusions In total, six out of nine cell lines showed aberrant p16ll'lK4a mRNA or 
absence of expression. Our finding suggest that methylation, instead of homozygous 
deletion is the major cause of p16ll'lK4ainactivation in uveal melanoma cell lines. 
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INTRODUCTION 
Uveal melanoma is the most common primary malignant intraocular tumor in adults 
in the western world and research has been concentrating on the identification of 
(cyto)genetic changes in order to unravel the molecular pathogenesis. Cytogenetic and 
fluorescent in situ hybridization (FISH) analyses have shown that non-random 
abnormalities (e.g. monosomy 3, gain of chromosome 8q and abnormalities of 
chromosome 6) do occur in uveal melanoma (Prescher et aI., 1996; Sisley et aI., 1997; 
White et aI., 1998), but genes involved in the tumorigenesis are yet to be identified. In 
cutaneous melanoma, the p16INK4a gene (also known as CDKN2A, pi6 or MTS]), located 
on chromosome 9p21, plays an important role in tumorigenesis and is involved in both 
familial and sporadic tumors (Piepkorn, 2000). P16flolK-la evokes a Gl cell cycle arrest by 
inhibiting the cyclin-dependent kinases 4 and 6 (cdk4/cdk6) and can be inactivated by 
mutations, homozygous deletions or by methylation of the promotor region (reviewed 
by Piepkorn et al. (Piepkorn. 2000)). In cutaneous melanoma cell lines homozygous 
deletions or intragenic mutations of the p16DlK4a gene are found in about 50% and 20% 
of the cell lines, respectively (Walker et aI.. 1998). Furthermore germline mutations are 
found in approximately 20% of the familial cutaneous melanoma (Greene, 1999). The 
p16JNK4a locus harbors also a related gene, p14ARF which uses an alternative exon 1 (l~) 
and a different reading frame of exon 2 and 3 of p16I.VK4a, generating a structurally 
different protein. P14ARF binds and inhibits rvIDM2, thereby preventing p53 
degradation. In contrast to p16JNK4a , to our knowledge, no p14.'1RF mutations have been 
detected in familial or sporadic cutaneous melanoma. Since both cutaneous and uveal 
melanomas originate from neural crest derived melanocytes this prompted us to 
investigate the role of the p16JNK4a gene and the expression of p14ARF in uveal 
melanoma cell lines. In the present study we searched for deletions, mutations and 
methylation of the p16JNK4a gene and determined the expression of both genes in 9 
uveal melanoma cell lines. 
MErnODS 
Cell lines 
Kine uveal melanoma cell lines were used in the present study. EOM3, EO::vf29, OCiVIl, 
Me1202, 92.1 and Mel270 are cell lines established from primary uveal melanomas (De 
Waard-Siebinga et a!., 1995; Luy~en et a!., 1996; Verbik et a!., 1997). OMM1, OMM2 
and OMM3 are metastatic uveal melanoma cell lines derived from metastases of 3 
different uveal melanoma patients (Luyten et aI.. 1996). OMM2.2, OMM2.3 and OMM2.6 
are metastatic cell lines derived from separate tumor nodules in the liver of the same 
patient as Mel270 (Verbik et aI.. 1997). All cell lines were grown in RPMIl640 (with 
89 
CHAPTER 7 
HEPES and glutamate) supplemented with 10% fetal calf serum, 1% penicillin and 1% 
streptomycin and passaged depending on growth. 
Fluorescence in situ hybridization 
We examined the copy number of the p16D.'K:la /P1401RF IOOlS on interphase nuclei using 
the biotin-labeled PI probes 1062 and 1063 and cosmid c5 (Kamb et al.. 1994) as 
described before (Hagemeijer et aI., 1998). Per slide 75 ng probe was used. After 
hybridization and immunodetection, slides were counterstained with DA.PI and 
mounted in anti-fade (Dabco- Vectashield 1:1) and 300 nuclei per probe were scored 
according to the criteria of Hopman et al (Hopman et aI., 1988). The cut-off values used, 
were those described by van Dekken (van Dekken et al., 1990). Polysomy was defined as 
more than 2 hybridization signals in more than 10% of nuclei, and monosamy as a 
single signal in more than 15% of the nuclei. 
Chromosome 9 marker analysis 
Eight microsatellite repeats, selected from The Genome Database and depicted in Figure 
7.1 were synthesized by !sogen Bioscience (Maarsen, The Netherlands) and used as 
described previously (van der Riet et aI., 1994). Markers D9S171, D9S156 flank the 
p16fNK4a /P14ARF locus and marker CT29 is located -within this locus. 
pi fJNK"" mutation analysis 
Genomic DNA of the 9 cell lines was used for the mutation analyses. Analysis of exon 2 
was performed by Single Strand Conformation Polymorphism (SSCP) analysis as 
described previously (Gruis et aI., 1995). Analyses of exon 1 and 3 of the p16fNK4a gene 
was performed using Restriction Endonuclease Fingerprinting (REF) (Liu and Sommer, 
1995). Exon 1 was amplified using primers ElF: AGGTATTAGCITAGGATGTGTGGC, 
and E1R: CTACCTGATTCCAATTCCCCTG, resulting in a fragment of 1431 bp: exon 3 
was amplified with primers E3F: TCGCGCTITCTCTGCCCTCC, and E3R: 
GAAAACTACGAAAGCGGGGTGGG, resulting in a fragment of 392 bp. Polymerase 
chain reaction (PCR) products were purified using the Qiagen PCR purification system 
(Qiagen Inc, Santa Clarita. USA) and digested with Xbal, Ddel/Xmal. and Msel/Mscl 
(exon 1) or Rsal/Pstl, Rsa1/Sau3A, Xcml/Pstl (exon 3). After digestion and heat-
inactivation and fragments were end-labeled -with 6 ~Ci [y_32p] dATP. Products were 
loaded on a non-denaturing YlDE gel G.T. Baker Inc, Philipsburg, USA) containing 0% 
or 5% glycerol (exons 1 and 3) or 10% glycerol (exon 2). The gels were run at 6W for 
14 hours at RT or 4°C. After electrophoresis, the gels were transferred to blotting paper, 
dried and exposed to a Kodak X-Omat AR film for 24 hours. NI aberrant bands were 
sequenced (Base Clear, Leiden, The ~etherlands). 
Methylation specific PCR 
Bisulfite modification and methylation specific PCR (:\1SP) was carried out on all cell 
lines as described previously (Herman et al.. 1996). Cell line T47D (methylated) and Hela 
(unmethylated), were used as positive and negative control respectively. Furthermore, 
the methylation status was investigated in 5 primary retinal pigment epithelium (RPE) 
cultures, in 3 primary strains derived from uveal melanocytes and in lymphocytes of 5 
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uveal melanoma patients. PCR products were loaded onto 2.5% agarose gels, stained 
"With ethidium bromide, and directly visualized using UV illumination. 
Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) of pl6INK""and 
pl.f'RF 
RNA was isolated using GTC-lysates. RNA extraction was performed using the RNeasy 
kit (Qiagen Inc, Santa Clarita, USA). eDNA was synthesized from 1-3 [ig of total RKA 
using 2 [il of a random primer (0.5 [ig/ [il) and 10 U super RT (HT Biotechnology 
LTD, Cambridge, England). For p16fNK4', primers 57F GGAGCAGCATGGAGCCTI and 
E3R GAAAACTACGAAAGCGGGGTGGG generating a product of 566 bp, were used. For 
p14ARF primers (OL27 and OL28, generating a product of 291 bp) and running 
conditions were those described by Gardie et al. (Gardie et aI., 1998). Amplification 
products were separated on a 1 % agarose gel. 
RESULTS 
Cytogenetic and FISH analyses 
Cytogenetic and FISH analysis, using locus specific probes was performed to detect 
structural and/or numerical chromosomal abnormalities, which could disrupt 
chromosome 9p21. All cell lines, have been maintained in vitro for many years and are 
characterized by cytogenetically heterogeneous clonal cell populations (De Waard-
Siebinga et aI., 1995: Luyten et aI., 1996: Kaus et aI., 2001). Chromosome 9 
abnormalities were found in three cell lines (Table 7.1). In OCM1 and O::w:M1 a relative 
loss of chromosome 9 was found. In more than 70% of the metaphases of Mel270 this 
loss was also observed. In other metaphases of this cell line derivatives of chromosome 
9p were found. Loss of 9p21 was also observed in the three metastatic cell lines of 
Mel270 (01vfM2.2, 2.3 and 2.6) using FISH analysis. Nevertheless, we searched for 
deletions in 26 non-cultured sporadic uveal melanoma and detected loss of one copy of 
chromosome 9p21 in only one case: a uveal melanoma patient with a nevus of Ota 
(Naus et aI., unpublished results). 
Neither in the cell lines nor in the primary uveal melanoma homozygous deletions were 
observed. 
Chromosome 9 marker 
To investigate the possibility of smaller deletions or the presence of isodisomy of 
chromosome 9, we performed microsatellite analysis Volith markers distributed on 
chromosome 9 and around the p16J!v"K4-a. locus in particular (Figure 7.1). Homozygosity 
was found in :Mel270 and its metastases, in O:M\i1 and Mel202. The observed LOR in 
these latter two indicated the formation of an isodisomy of chromosome 9(p) (fable 
7.1). In these three cases all 9(p) markers showed evidence for one type of allele, 
suggesting loss of the other chromosome 9(p). In all other cases heterozygosity of 
marker CT29 was observed although homozygosity for some other markers did occur. 
Since no normal D)JA is available from these cell lines, a possible deletion of these loci 
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can not be excluded. Again, no homozygous deletions of the p16fl'.1K4a locus could be 
detected in any of the cell lines. 
DDDDDDD 
D~ ~~D~~~~~~ 
~~D~~D~~~~D~ 
D~D~DD~~~~DD 
D~D~DD~~~~DD 
~~~~ ~D 
DDD~DDDDDDDD 
D ~ DDDDDD 
Fig 7.1 chromosome 9 marker analysis in 12 uveal melanoma cell lines. All markers are listed 
from telomere to centromere with the approximate map location indicated to the left. Grey boxes. the 
retention of heterozygosity; black~gray boxes, homozygosity of the marker. 
Mutation analyses 
To search for gene inactivating events other than homozygous deletions, mutation 
analysis of the p16fNK4a gene was performed. Results of this mutation analysis are 
summarized in Table 7.1. In 4 uveal melanoma cell lines (OCM1, Me1202, Mel270 and 
OMM3) aberrant SSCP patterns of plt5"K4" were found (Figure 7.2). In the Me1270-
related metastatic cell lines (OMM2.2, OMM2.3 and OMM2.6) the same SSCP pattern 
was found as in the parental cell line. Sequence analysis of Mel270 and its metastatic 
derivatives revealed a C~G substitution in the 3' untranslated region (position 540, 
eDNA; GenBank Identification number 558656). Also in OMM3 a single basepair 
substitution (G-7A at position 580, cDNA) was found in the 3' untranslated region. 
Both substitutions were found to be relative common polymorphisms in cutaneous 
melanoma and are, in these tumors, associated with a shorter progression time to 
metastatic (Sauroja et al.. 2000). Furthermore, a 8 bp deletion in exon 2 of Mel202 
(position 232-240, cDNA) and a 28 bp deletion, starting at position 496 (cDNA) 
extending in intron 2 thus including the intron 2 splice-donor site of OCMl were 
found. These mutations were not described previously (http://vvww.uwcm.ac.uk/uwcm/ 
mg/search/335362.html). To evaluate the mutation frequency in uncultured primary 
uveal melanoma, we analyzed 30 primary uveal melanoma with SSCP analysis for 
mutation in exon 2 of the p16/NK4a gene but no mutations or (homozygous) deletions 
were found. 
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Fig 7.2 Examples of aberrant SSCP patterns of pl6lNK .. in uveal melauoma cell lines. (A) 
Mutation of Mel202 and (B) of OCM:l in exon 2 of p16D.'KoIa. (C) Polymorphisms in O:MM3, Mel270 and 
O::vnvf2.2 in exon 3. Kote the homozygous aberration of Mel202, Me1270 and OTvrM2.2. In OMM3 and 
OCMl heterozygous aberrations are observed. 
Methylation specific PCR 
Elimination of the p16INK4a function can also be achieved by methylation of the 
promotor region. To determine the methylation status of these uveal melanoma cell 
lines, we performed a methylation specific peR. In four out of 8 cases a product was 
amplified using methylation-specific primers, whereas no product was amplified in 
these cases with primers specific for unmethylated DNA (Figure 7.3). This indicates the 
detection of methylated p161NK4" alleles in these cell lines. Four cases were only positive 
with primers for unmethylated DKA In one case (EOM29) no PCR products could be 
amplified with either of the primers. In non-tumor samples (RPE cell lines, melanocyte 
cell lines and lymphocytes of uveal melanoma patients) the methylation specific PCR 
indicated that the p16I:->K.1a promotor was unmethylated (data not shown). 
RT-PCR 
To investigate the expression of the gene in the uveal melanoma cell lines, we 
performed a RT-PCR using primers for p16Jl1lK4a and p14ARF respectively. P 16f11'K-Ia 
expression was found in all cell lines with non-methylated promotor regions and in 
E0M29. In OeM] a 28 bp deletion including the intron 2 spice-donor site was detected 
and the use of a cryptic splice-donor site in exon 2 resulted in a frame-shift and a 
assumed protein with a substitution of the last 28 amino acids by HPRLKEPERL. As is 
shown in Figure 7.3, we detected both the wild type and truncated mRNA in OCMl. In 
Mel202 the deletion of 8 basepairs resulted in a frame-shift of the p16f1-.lK4a gene causing 
in a stop codon at position 388 and an assumed protein of hybrid p16fl'lK4a/p14ARF 
protein of 115 aminoacids. The deletion was to small to be visible using 
gelelectrophoresis. In cases where methylation was detected, no expression of the gene 
was found. In all cell lines normal p141iRF expression was detected (Figure 7.3). 
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TABLE 7.1 SUMMARY OF TIlE MARKER ANALYSIS, MUTATION ANALYSES, METIlYLATION 
SPECIFIC PCR ANDRT·PCR FOR TIlEP1SINK4A 
CEll. COPY PLOIDY, LOH ABERRANT SSCP METHYl..A TIOJ\ E..'G"RESSION 
LINE NUM:&EROF CHROMOSOME 9 plffNK4A PATrERN plffNK4A pl£fNK4A. 
9p21 LOCUS2 AB:-<ORMALITIES3 LOCUS (RT·PCR) 
EOM3 2,3 pseudodiploid + 
£OM29 2 pseudodiploid n; 
OG.\11 2,3 hypertetraploid. -9 cxon 2: 28 bp 
deletion 
92.1 2,4 hyperdiploid/ 
hypertetraploid 
Me1202 2,3 hyperdiploid cxon 2: 8 bp + 
dek>tion 
).1el270 1.2 hypodiploid. (:9 exon 3: + 
[5J, add(9)(p) [2J I polymorphism 
hyporetnploid [2] C540G 
01IM2.21 1.2 nd exon 3: + 
polymorphism 
C540G 
0:\11\12.31 1,2 nd + exon 3: + 
polymorphism 
C540G 
OX1:M:2.61 1,2 nd + cxon 3: + 
pol}TIlorphism 
CS40G 
0:\111.11 2,3 hypertriploid, -9 + 
Q).{M2 2,3 pseudodiploid + 
011M3 2,3,4 pseudodiploid exon 3: + 
pol}TIlorphism 
G.580A 
Abbreviations: nd. not done: nr, no result. 
, 
Metastatic cell lines derived from Mel270. ~ Detected by 
FISH. Only significant cell populations (loss in >15% or gain in >10% of the cells) are indicated. The 
main cell population is indicated in bold. ~ Ploidy and chromosome 9 abnormalities as observed by 
cytogenetic analysis 
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Fig 7.3 Methylation Specific PCR and RT -PCR of 12 uveal melanoma cell lines. The upper two 
panels represent the methylation specific PCR. M methylated; U: unmethylated. The lower twO panels 
show the results of the RT-PCR of p16IN1Z4:. and p14'\RF in 12 uveal melanoma cell lines. In Oc..\11 both 
the wild-type (566 bp) and mutated products (492 bp) are visible. In Mel202 the deletion of 8 bp is to 
small to discriminate on agarose gel. 
DISCUSSION 
Inactivation of tumor suppressor genes, by homozygous deletions, mutations or 
methylation of promotor regions is a common event in human cancers. In contrast to 
many tumors, such as cutaneous melanoma, in which mutations in specific genes are 
found, the molecular pathogenesis in uveal melanoma is largely unknown. In our 
search for genes involved in the tumorigenesis of uveal melanoma we studied nine 
uveal melanoma cell lines for deletions, mutations, methylation and expression of the 
p16/},'K411 gene. 
Gsing cytogenetic and FISH analysis no homozygous deletions were found in the uveal 
melanoma cell lines and primary tumors. However, in only three out of nine cell lines 
(E0M29, OMM2 and OMM3) we found an apparent normal expression of p16/},'K411. 
Thus in the other 6 cell lines alternative mechanisms are involved in the inactivation of 
this gene. Four out of nine cell lines (EOM3, 92.1, :Mel270 and O:MMl) showed 
methylation of the promotor region resulting in a total absence of the p16mK4a 
transcript. In OMMI and Mel270 we, additionally, observed LOH of the locus. Aberrant 
p16f!-,'K4a expression was also found in Mel202 where LOH and a 8 bp deletion in exon 2 
were detected resulting in an assumed protein of hybrid pI6I::-1K4a/pI4ARF protein of 115 
aminoacids, thereby disrupting not only p16INK4a but also p14ARF. Whether this affects 
the ability of the p14ARF protein to cause cell cycle arrest is unclear since others have 
shown that sequences encoded by exon 1~ alone are sufficient for ARF function (Quelle 
et aI., 1997). In OCMl a 28 bp deletion including the intron 2 spice-donor site was 
detected and the use of a cryptic splice-donor site in exon 2 resulted in a frame-shift 
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and a assumed protein of 138 bp. In all cell lines normal expression of exon l~ 
(pI4ARF) was detected using RT-PCR. 
Homozygous deletions of the p16fNK4a gene are the most common cause of gene 
inactivation in cutaneous melanoma cell lines (Foulkes et aI., 1997) and also in primary 
cutaneous loss of chromosome region 9p21 is frequently observed. However, the 
incidence of homozygous deletions in uncultured sporadic cutaneous melanoma is 
lower compared to the rate in melanoma cell lines. This is also seen in other tumor 
types and has led to the suggestion that these abnormalities were the result of in vitro 
selection (Cairns et aI., 1994). However, this controversy was laid to rest by the discovery 
of microdeletions that encompassed p16 and because of the presence of normal cells 
within primary tumor specimens hampering the detection of deletions (Cairns et aI., 
1995). In contrast to cutaneous melanoma, our results indicate that homozygous 
deletions are rare or absent in uveal melanoma cell lines as well as in primary uveal 
melanoma. Although, mutations were detected in two uveal melanoma cell lines, in 30 
primary uveal melanoma we did not detect any mutations in exon 2. This low 
frequency of mutations in primary uveal melanoma are concordant to those published 
by others (Ohta et al.. 1994; Singh et al.. 1996a; Merbs and Sidransky. 1999). A recent 
publication of Merbs et aI. (Merbs and Sidransky, 1999) suggested that homozygous 
deletions or methylation were found in sporadic uveal melanoma in 12% and 6% 
respectively. Our series on uveal melanoma cell lines showed that methylation was the 
most common mechanism for p16!NK4a inactivation i.e. four out of nine cell lines. This 
is also likely to occur in primary uveal melanoma since others have shown that 
methylation status is not influenced by cell culture (Gonzalgo et aI., 1997). Furthermore, 
we found no methylation in cultures derived from retinal pigment epithelium and 
uveal melanocy"tes. In cutaneous melanoma, methylation of the p161NK4a promotor is 
infrequent and whether uveal melanoma are more prone to methylation of p16f}.iK4a 
than to homozygous deletions, compared to cutaneous melanoma, has to evaluated in a 
larger study. 
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SUMMARY 
The PTEN gene at chromosome region lOq23 has been shown to be mutated in 
cutaneous melanoma cell lines and primary tumours. However, its role in the 
development of uveal melanoma is not known. In this study we investigated 9 uveal 
melanoma cell lines for genetic changes in this gene. Using cytogenetic studies, two cell 
lines were found to have a translocation involving chromosome lOq. Fluorescent in situ 
hybridisation (FISH) using a PAC probe containing the entire coding sequence of the 
PTEIV locus revealed no abnormalities except for a hemizygous deletion in a subclone 
of one cell line. In all cases normal expression was detected by reversed transcriptase-
PCR (RT-peR) and no mutations in the coding region of the gene were found using 
single stranded conformation polymorphism analyses (SSCP). We therefore conclude 
that, in contrast to cutaneous melanoma, the PTE.!Y~ gene does not appear to playa role 
in the pathogenesis of uveal melanoma. 
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INTRODUCTION 
The molecular pathogenesis of uveal melanoma is largely unknown. Cytogenetic studies 
have shown that recurrent abnormalities do occur, including deletions of chromosome 
1 p, loss of chromosome 3, gain of chromosome 8q and alterations of chromosome 6 
(Prescher et aI., 1996; White et aI., 1996; Sisley et aI., 1997). However, specific 
chromosomal regions or genes involved in tumorigenesis have yet to be identified. 
In 40% of the cutaneous malignant melanoma cell lines, sporadic mutations are found 
in the PTE..rvT gene (Guldberg et aI., 1997), although reports on the incidence of sporadic 
mutations in primary cutaneous melanoma seem to be conflicting (Boni et aI., 1998; 
Tsao et aI., 1998). The findings on the PTEN gene in cutaneous melanoma cell lines 
prompted us to investigate the role of the .?TEN gene in uveal melanoma cell lines since 
both cutaneous and uveal melanoma arise from neural crest derived melanocytes. PTEV' 
is a known tumour suppressor gene and sporadic mutations of the PTEN gene or 
deletions of the PTEN locus at chromosome 10q23 have also been found in 
glioblastomas (Wang et aI., 1997), prostate (Cairns et aI., 1997), breast (Li et aI., 1997) 
and endometrial carcinomas (Risinger et aI., 1997). Germline mutations of PTEN are 
responsible for Cowden disease and the Bannayan-Zonana syndrome (Marsh et aI., 
1998). The PTE.V protein encodes a dual-specific phosphatase and plays a major role in 
the inhibition of cell migration and the formation of focal adhesions (Tamura et aI., 
1998). In the present study, we examined 9 uveal melanoma cell lines using cytogenetic 
analysis supplemented with FISH to search for deletions or translocations affecting the 
PTEN gene region at 10q23. The expression of the gene was investigated by RT-PCR, 
and SSCP analysis of all 9 coding regions was carried out to screen for the presence of 
small mutations. 
MATERIALS AND METHODS 
Uveal melanoma cell lines 
Nine uveal melanoma cell lines isolated from primary or metastatic uveal melanoma 
were used in the present study. EOM3 and EOM29 (Luyten et aI., 1996), OCM1 (Kan-
Mitchell et aI., 1989), 92.1 (De Waard-Siebinga et aI., 1995), Mel202 and Mel270 (Chen 
et aI., 1997) were all established from primary tumours. OMM1, OMM2 and OMM3 
(Luyten et aI., 1996) were derived from metastases of 3 different uveal melanoma 
patients. All cell lines were cultured in RPMl1640/ HEPES supplemented with 10% fetal 
calf serum, 1% penicillin and 1% streptomycin and passaged depending on growth. 
C}~ogenetic data of cell line EOM3, EOM29, 0C.\11, OMMI, 0MM2 and OMM3 have 
been published previously (De Waard-Siebinga et aI., 1995; Luyten et aI., 1996). The 
karyot)pe of 92.1 was reevaluated. Cytogenetic studies on Mel202 and Mel270 were 
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carried out in our laboratory using standard cytogenetic techniques.The karyotypes of 
all cell lines described according to the standard nomenclature (ISeN, 1995) are given 
in Table S.1. 
Fluorescent in situ hybridisation 
A PAC probe, 190D6, containing the entire coding sequence of the PTEN locus was 
isolated from a PAC library and was used for FISH analysis of the cell lines. Single 
colour FISH using biotin-labeled PAC190D6 was performed on chromosome 
preparations as described before (Hagemeijer et aI., 1998). Per slide 75 ng of PAC 
190D6 was used and the probe was prehyhridised with COTl DNA for 30 min. After 
hybridisation and immunostaining, slides were counterstained vrith D.API and mounted 
in anti-fade (Dabco-Vectashield 1:1) and 300 interphase nuclei were scored in each case. 
A cut-off value for deletions was calculated from hybridisation on cultured uveal 
melanoma cells known to have apparently normal chromosomes 10. The cut-off value 
was determined at 10% (mean of aberrant signals + 3 sd). 
Single-strand conformation polymorphism (SSCP) analysis 
The 9 exons of the PTR!V gene were amplified using 11 pairs of primers (Vlietstra et aI., 
1998). Fifty ng of genomic tumour DNA was amplified as follows: Hot start of 4' 95"C 
followed by 30 cycles of I' at 95"C, 90" at 55"C (exons 1-6) or 50"C (exons 7-9), 2' at 
72"C. PCR was performed using 0.1 U Taq polymerase (HT Biotechnology LTD, 
Cambridge, England), 20 pmol of each primer, 0.05 mM dATP, 0.2 mM dGTP, dTrP, 
dCTP and IJlCi [a}2P]dATP per reaction. PCR products were loaded on a denaturing 
MDE gel (J.T. Baker Inc, Philipsburg, USA). The gels were run at 6W for 15 hours. After 
electrophoresis, the gels were dried and exposed to a Kodak X-Omat AR film for 24 
hours. 
RT-PCR 
RNA was isolated using GTC-Iysates. RNA extraction was performed using the RNeasy 
kit (Qiagen Inc, Santa Clarita, USA). eDNA was synthesised from 1- 3 ).1g of total RNA 
using 2 J.l.l of a random primer (0.5 Ilg/ J.l.l) and 10 (; super RT (RT Biotechnology 
LTD, Cambridge, England). Two partially overlapping primer pairs were used to 
amplify the PTEZ, eDNA. Pair I: 977F CCACCAGCAGCTTCTGCC ATCTCT and 1736R 
CCAATrCAGGACCCAC ACGACGG. Pair 2: 1649F GTrCAGTGGCGGAACTTGCA 
ATCCTCA and 2423R CCCTATACATCCACAGGGTTTTGACACTTG. The PCRs contained 
0.2 mY! di'<-rP, 20 pmol of each primer, and 0.1 U Taq polymerase (HT Biotechnology 
LTD, Cambridge, England). Amplification was performed as follows: 1 cycle of 4' 95°C, 
30 cycles of l' 95°C, 2' 65°C, 2' 72°C followed by a final extension of 10' 72°C. 
Amplification products were separated on an 1 % agarose gel. 
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RESULTS 
The cytogenetic and FISH results are summarised in Table 8.1. Only one cell line 
(Mel270) had underrepresentation of chromosome 10 and this was present in a 
subclone. Two cell lines (Mel270 and OMJ\1I) had structural abnormalities involving the 
long arm of chromosome 10. FISH studies using PAC probe 190D6 for the region IOq23 
showed agreement between the numbers of signals seen and the reported cytogenetic 
findings in 6 cell lines. In 3 cell lines (OJ\.fMI, Olv1lVI2 and :Me1270) variation in the 
number of FISH signals was observed. In 0:M:..\11 and OMlvI2 a small population of 
interphase nuclei was unexpectedly found to have 4 signals for the PAC probe 190D6. 
Examination of 7 metaphases from O:M:M:l showed the expected three FISH signals. 
Interphase FISH studies on line Mel270 revealed 12% of the nuclei to have only one 
signal for I90D6. This is above the established cut-off level of 10%. Monosomy for 
chromosome 10 was found in a subclone (3/7 metaphases) of this line on cytogenetic 
analysis. 
Mutation analysis on genomic DNA was performed using exon-specific SSCP. All 9 
exons and flanking sequences were amplified using 11 primer pairs. In all cases two 
single stranded bands were visible. We did not detect any abnormal banding patterns 
indicative for a mutation in the PTELV gene. Examples of exon 3 and 5 amplifications 
are shown in figure 8.1. 
~ "" '" '" "" c ~ ~ '" ON ~ C '" ;; ;; G "" N 
"" "" "" 
~ 0 oi -;:; -;:; 0 0 0 ~ 0 ::l ::l ~ 
"' '" 
~ 
Exon 3 
Exon 5 
Fig 8.1 Exon-specific SSCP for exon 3 and 5 of the PTEN gene in uveal melanoma cell lines. 
The two single stranded bands are clearly visible (arrowheads). 
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Although in none of the cell lines mutations could be detected in the coding region, 
mutations in the 5' UfR could not be excluded. Therefore we investigated the 
expression of the PTEN gene using RT-PCR. Two partially overlapping primers were 
used. In all cell lines both PCR products of 759 and 774 bp were amplified (figure 8.2). 
No abnormal sized bands were found. 
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977F-1736R 
... -------
1649F- 2423R ... -.-----
Fig 8.2 PTEN mRNA expression in uveal melanoma ce1llines. Agarose gel analysis of RT-PCR 
amplified fragments. Two partially overlapping primers were used which amplified products of 759 
(977F/1736R) and 774 bp (1649F/2423R). 
DISCUSSION 
Recent investigations showed that 40% of the cutaneous malignant melanoma cell lines 
harbour mutations of the tumour suppressor gene PTEV' at chromosome region IOq23. 
This prompted us to investigate the presence of loss or mutations of the PTE1v gene in 9 
uveal melanoma cell lines using cytogenetic and molecular genetic techniques. 
Cytogenetic analysis revealed 2 cell lines 'with structural abnormalities in the long arm 
of chromosome 10. In both cases FISH analysis showed that the breakpoint was not 
located within the PTEN gene. One of these cell lines had also a subclone of cells with 
loss of chromosome 10 and interphase FISH studies on this line revealed this 
subpopulation with one signal for chromosome 10q23. The discrepancy between the 
FISH findings of 12% monosomy for this chromosome and the cytogenetic results (43% 
monosomy) may be due to the fact that this particular subclone is actively proliferating. 
Lines OMMI and OlMM2 had small populations of interphase nuclei with 4 FISH signals 
for the PTRN" gene. In both instances these subclones were not detected by chromosome 
analysis. This can be explained by the fact that the clones may not have been actively 
proliferating, or they may have later arisen in vitro since the FISH studies were carried 
out at a later passage than the original cytogenetic analyses. 
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TABLE 8,1 KARYOTYPFS AND RESULTS OF TIlE FISH ANALYSES OF_ THE PTE GENE IN 9 UVEAL MEL\NOMA CELL LINES 
CELL TUMOUR 
I.INE TYPE 
EO:"13 primal')' 
EO:"I29 primary 
OC\1l primary 
92.1 primar}' 
MEI.202 primary 
:"1EL270 prilll,try 
0:"11'111 metastasis 
O:"L\12 metastasis 
O:"IM3 metastasis 
KARYOTYPE (ISCN,1995) 
46,X"Y,l5,-6,t IB[20f 
'16,XY[20]3 
94 ,XX" X,-X,dd(l )(p21) ,del (2)t(l ; 2)(p31 jq3 7 ),add{3){ q 12), +deJ(3)( q 13q 23kl ,de I{ <I){ q 12) ,add{S )(p I I ),;Hld( 5){ (113),-6, 
-7,add(7)(q35), del(7)(q33),add(l:!)(q2<1)x2,-9,-1 J ,iIlY( II }(p 15q24),-12,del( 12)(p 12)x3,-13,;Hld( 13){q31),-15,-
16,add( 16){p 13) ,-18,-19,-20,add(20)( q 13)x2, add(20)( '113 ),-21 ,-21 ,add(21)( '121) ,del(22)(q II )x2, i(2 2q)x2, t6-12m a rf c p 1.1]:1 
47 ,add(X){q2ro ),t-B,t-8,del (II )t{ I; Il)(q22jq23~24),add( 17)(q2,1-25)[,1]/-17 ,idelll,add( 12){p 11)[4 }!94,idclllx2,;tdd( 12)(p II) 
x2[3J/97,idemx2, 1-7 ,t-7 ,add(9)(p22)x2,tmarfcp5 J1 
50-53,XX[3],-X[13},t-dic( I ;9)(p II;p II ),t5[3 ],add(6)(q?15),t-add(6)(q?15),t-7 ,t8,t8,t8,del(9)('12?1)[2],del{9)(q3?2)[2], 
i(9)(1' I 0)[3], add{ 11 )(q22),;Hld{ J8)(q21 ),der(20)I{S;20){q 12;q13),add{22)(p 11)[cpI6] 
43~48,XY,add(2)(p2?4)[4],?.ldd(3)('12)[5],psu i dic(6)(q II ),dcr(7)dcl(7){q22q22)add(7){q32)x2,?del (8)(p)[3 J,-9[5], 
?add(9)(p)[ -I], add(9)(p )[2] ,tder(9)add{9)(p )dcJ(9)( q)[21, -10[31 ,add( I 0)(q2?)[3 ],add( 12)(p II )[2],~ 13[ 6] ,add{ 13 )(p II), 
mld{ I 6)(q II ),add( 17)(1'2(3)[ 6],-19,add(21 )(p I )[2], 1-1~3mar[cp7]/81-87 ,psu i dic(6){q II)x2,der(7)del(7)(q22q22) 
;tlld( 7){ q 32)x 2 ,add{ 1 0 )(q 2?) ,add{ 17 )(p2?3), +marx2[ c p2] 
60--68,X,-X,-Y ,der( I )I{ I ; 3 )(p3I; p 13) ,der(2)t(2j5 )( q 3 2jq 14?)x 2, t(2; I 0)( q 32;( 125), t3[ 31..-4 ,dele 5)( q 13'124), f 7 ,add(S)(p II ),-9, 
-11 ,t 12, iJlv( 13)(q 12q34),-15,ildd( 16)(p 12),-17 ,del( 19)(1)12), t 20,-21 ,atltl(21)(p 13), + 1-3 mar{cp7]3 
38-46,XY,-Y,-20[cp 1 6]3 
46,XY[20]3 
lExpected cop)' number of chromosomes 10 based on cytogenetic findings 
2 Actual copy number of the PTEN gene detected b)' FISH (perc{'ntage of cells; only significant leyels are giyen) 
3PreYiously described by Luyten et al,1996 
~Kar)'otype was reevaluated and described according to the ISCN1995 
No, No. Pl'EN SIGNAI.s 
COPIESO}O' DhiECTED Wfil 
CHR.lOt FISI-I2 
2 2 (94%) 
2 2 (S7%) 
4 4 (80%) 
2 2 (45%) 
4 4 (43%) 
2 2 (91%) 
1(12%) 
2 2 (72%) 
., 
,I (11%) 
3 3 (80%) 
,I (12%) 
2 2 (83%) 
4 (12%) 
2 2 (93%) 
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Except for a small proportion of cells of Mel270, no significant variation in the 
PTEN gene could be detected by FISH or cytogenetic analysis in these 9 uveal 
melanoma cell lines. In addition, SSCP analysis revealed no aberrant bands shO'wing 
that mutations in the PTEN gene were not present. This is in accordance with the 
observations of the RT-PCR where we found expression of the PTEN gene in all cell 
lines and no abnormal sized RNA These results are in contrast to cutaneous malignant 
melanoma cell lines. 
The question remains, however, whether we can extrapolate our findings on uveal 
melanoma cell lines to fresh tumour material. The cytogenetic findings in primary 
uveal melanoma show, in general, a simple karyotype with only a few recurrent 
abnormalities as loss of chromosome 1 p and chromosome 3, gain of chromosome 8q 
and stIucrural abnormalities of chromosome 6 (Prescher et aI., 1996; White et aI., 1996; 
Sisley et aI., 1997). Some of the uveal melanoma cell lines in our study had these 
genetic changes but these were accompanied by more complex chromosome variation. 
Whether these complex abnormalities are the result of prolonged cell culture, or due to 
the fact that tumours with more complex karyotype are more likely to grow in vitro is 
unclear. However, the fact that in our study no PTE1V mutations were found in these 
uveal melanoma cell lines and that cytogenetic abnormalities involving chromosome 
10q23 were not observed, and are also not common in primary uveal melanoma, 
suggests that PTEV mutations or deletions probably do not playa role in the aetiology 
of uveal melanoma. This is in contrast to primary cutaneous melanoma where 
chromosome lOq23 abnormalities have been observed, indicating the involvement of 
the PTE.V gene. Other genetic differences between cutaneous and uveal melanoma have 
been reported. Whereas in 100% of the cutaneous melanoma involvement of the CDK2 
gene or its downstream target genes has been postulated (Walker et aI., 1998), CDKN"2 
mutations or loss is rarely observed in uveal melanoma cell lines and primary tumours 
(Singh et aI., 1996a; Singh et aI., 1996b). Also cytogenetically, there is a clear difference 
between uveal and cutaneous melanoma. The typical abnormalities found in uveal 
melanoma, such as loss of chromosome 3 or gain of 8q, are rarely observed in 
cutaneous melanoma. However, chromosome 1 and 6 abnormalities have also been 
reported in the latter. 
Biological differences also exist between these two tumours. The integrin expression, 
which is important for the growth and metastatic capacity of melanoma cells, as well as 
the expression of melanoma associated antigens differ markedly between uveal and 
cutaneous (Mooy and De Jong, 1996; Marshall et al., 1998). All these data suggest that, 
despite the common embryonic origin, these tumours follow a different path towards 
tumorigenesis and have a different biological behaviour. 
In summary, our results indicate that the PTEN gene is probably not involved in the 
pathogenesis of uveal melanoma and that the tumorigenesis of uveal melanoma 
involves a different set of genes to these involved in cutaneous melanoma. 
104 
GENERAL CONSIDERATIONS AND FUTURE 
PROSPECTS 
CHAPTER 9 
9.1 GENERAL CONSIDERATIONS 
The detection of chromosomal abnormalities in solid tumours not only provides 
information on the outcome of cancer patients, but may also point to chromosome loci 
involved in tumorigenesis. As is described in chapter 1 and 2 of this thesis, predicting 
the survival outcome of uveal melanoma patients based on classical prognostic markers 
such as tumour diameter or cell type remains difficult. Cytogenetic analyses have shown 
that specific chromosomal changes, especially loss of chromosome 3, are strongly 
associated with patient survival (Prescher et aI., 1996; Sisley et aI., 1997: White et aI., 
1998). We have analysed 80 uveal melanoma for chromosomal changes in 
chromosomes 1, 3, 6 and 8 using both cytogenetic and FISH analyses and found that, 
after correcting for several other co-variables, survival was not correlated with the 
solitary loss of chromosome 3, but with a mutual loss of chromosome 1 p36 and 3 
(Chapter 2). It is most likely that the patients described in literature who succumb to 
metastatic disease and have tumours with loss of chromosome 3, also actually have lost 
the chromosome 1 p36 region. In contrast to these studies, in which conventional 
cytogenetics and/or CGH was used, we performed FISH analysis with a probe specific 
for chromosome Ip36 allowing a more sensitive analysis of this chromosome band. We 
selected this probe based on the cytogenetic finding that loss of chromosome 1 p36 was 
commonly found in our series of uveal melanoma. The prognostic significance of 
mutual loss of chromosomes Ip36 and 3, enables us to select patients with a high risk of 
metastatic disease more accurately and may lead to an adjustment of the treatment 
protocols for this specific group of patients. New treatment protocols for metastatic 
uveal melanoma are under investigation, but the preliminary results are, in general, 
disappointing. However, these trials are being applied to patients diagnosed of 
metastatic disease. We theorise that when these or other adjuvant therapies can be 
applied to high risk patients without (clinical detectable) metastases, the results may be 
promising. 
Chromosome analysis can only be performed when tumour material is available. 
However, more and more patients are being treated with radiotherapy, restricting 
prognostic evaluation. In these cases and in patients where the diagnosis of uveal 
melanoma is uncertain, chromosome analysis using FISH can be applied to fine needle 
aspiration biopsies (chapters 4 and 5). Through our large uveal melanoma sample. we 
were able to show that the FISH technique was feasible to detect the genetic changes 
and that these biopsies were representative for the main tumour. Although these results 
are very promising, clinicians are stille resistant to taking a biopsy from a tumour. The 
potential risk of seeding tumour cells in the biopsy tract, although unlikely to cause 
recurrent disease. results in a wait and see attitude. Therefore, this method should also 
be studied on in vivo biopsies followed by careful patient and tumour follow-up. Only 
then will we be able to prove this matter beyond a doubt. 
The finding that mutual loss of chromosome 1 p and 3 correlates strongly with survival, 
not only provides information guiding ophthalmologists in the treatment of uveal 
melanoma patients, it also suggests that genes located on chromosome 1 p and 3 interact 
with each other, thereby causing a more aggressive phenotype. This may help to further 
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delineate the chromosomal region of interest. Also, chromosome data obtained with 
modern cytogenetic techniques such as SKY and CGH, enable us to narrow down this 
region. These data point to the involvement of regions which remained undetected 
using conventional cytogenetics or FISH only. We found a small deletion on 
chromosome 3ql3-21 and two regions on chromosome 8 (8q21.1-21.2 and 8q23 ..... 24). 
Furthermore, in these complex cases, gain of chromosome 6p and 8 occurred more 
frequently than can be detected by conventional analysis (chapter 3). We observed 
small parts of chromosome 8 being translocated to other chromosomes. Additional 
FISH analyses using (sub)telomeric probes should be carried out to investigate if a 
particular chromosome 8 region is commonly involved in these translocations or 
whether this is a more random phenomenon. 
Monosomy 3 is suggested to be is an early event in tumorigenesis. White and coworkers 
found an isodisomy 3 in a non-pigmented part of a tumour wherease the pigmented 
part showed monosomy 3. They hypothesised that this abnomormality of chromosome 
3 plays a central role in the molecular pathogenesis of uveal melanoma (White et aI., 
1996). This hypothesis is supported by data of Presher et aI, who described a uveal 
melanoma with two subclones, both containing monosomy 3. In one subclone there was 
a trisomy S and in the other sucblone as isochromosome Sq. The authors suggested that 
a stemline contained loss of chromosome 3 only and that the subclones developed 
independently from each other. (Prescher et aI., 1994) These data furthermore suggest 
that gain of chromosome Sq is a subsequent event. Additionally, our ovm data (chapter 
2) and those of Aalto et al (Aalto et al., 2001) suggest that loss of chromosome 1 p plays 
an important role in the transition of primary uveal melanoma to metastatic disease. 
The role of chromosome 6 remains uncertain. Based on all these results, we can propose 
the following uveal melanoma progression model (Figure 9.1): 
normal 
melanocyte 
? 
-------
primary 
melanoma 
-
metastatic 
melanoma 
! t t 
monosomy3 
chromosome 6? 
Fig 9.1 Tumour progression model for uveal melanoma melanoma. 
loss of chromosome Ip 
gain of chromosome 8q 
Although chromosome 1 p36 is deleted in many tumour types, as of yet, no convincing 
tumour suppressor gene has been identified. One of the most interesting candidate 
genes is p73, a p53 homologue. This gene is further discussed in paragraph 10.2, Future 
Prospects. 
Furthermore, CMM1, a melanoma gene, was linked to this region on chromosome band 
1p36 (Bale et al., 1989). These data, could not be confirmed by other researchers, 
however, despite intensive efforts. 
Although several tumour suppressor genes have been mapped to chromosome 3p, such 
as VHL (Von Rippel-Lindau syndrome), TGFBR2 (transforming grov.w factor beta 
receptor 2 in colorectal cancer), DLECl (deleted in lung and oesophageal cancer 1), as 
107 
CHAPTER 9 
of yet, no known tumour suppressor genes have been mapped to chromosome 3q13-24. 
Interestingly, however, this region harbours a relativaly high amount of genes involved 
in ocular pathology, such as BFSP2 (beaded filament structural protein 2 involved in 
congenital cataract), BPES (blepharophimosis, epicanthus inversus and ptosis type I), 
GLCIC (glaucoma 1C) and RHO (rhodopsin, involved in retinitis pigmentosa type 4) 
(http://nciarray.ncLnih.gov/cgi-bin/cards/). Although these syndromes give rise to 
clearly distinct phenotypes, it may suggest that this region may be eye specific. In order 
to demarcate this chromosome 3 region found by CGH, we are currently performing 
LOB analysis using polymorphic markers. 
C-myc, located on chromosome 8q24.1, has been suggested to be a candidate oncogene 
because of the frequent accumulation of chromosomes 8q in uveal melanoma. 
Surprisingly, expression of c-myc was found to be correlated v.rith an improved 
prognosis, in contrast to what is known from cutaneous melanoma where it was shown 
to be correlated v.rith decreased survival (Chana et aI., 1999). Furthermore, the RCAl 
gene (renal carcinoma, familial, associated 1), involved in renal cell carcinoma, is 
known to map to chromosome 8q24.1. However, our CGH results show that the critical 
region on chromosome 8 is probably more proximal to these genes. Unfortunately, 
until now, no known tumour-related genes are mapped to this regions. 
In the second part of the thesis, we hypothesised that tumour suppressor genes that are 
known to be involved in cutaneous melanoma could also be involved in uveal 
melanoma tumorigenesis. We established and characterised primary and metastatic 
uveal melanoma cell lines to facilitate mutation analyses and expression studies of these 
genes (chapter 6). "Vhen using cell lines, one should remember that it is a artificial 
system. It is generally agreed that using cell lines has disadvantages, the main question 
being whether the individual cell lines are representative of the original tumour 
(Masters, 2000). As we have shown in chapter 6, the uveal melanoma cell lines still 
express the melanoma-associated antigens and (pre-)melanosomes are also present, 
indicating their melanocytic origin. However, this does not imply that the uveal 
melanoma cell lines are representative for primary uveal melanoma in general. We 
observed that the specific chromosomal changes found in primary uveal melanoma, 
such as loss of chromosome 1 p36, monosomy 3 and gain of chromosome 8. were not 
present in our uveal melanoma cell lines. It might be that only those tumours v.rith 
specific genetic aberrations are amenable for cell cultures, thereby causing selection. In 
addition, an accumulation of genetic abnormalities may be necessary for unlimited 
growth. In contrast, the main advantage and reason why cancer cell lines are so Volidely 
used is that they provide an almost unlimited supply of cells with similar genotypes and 
phenotypes. :Moreover, cell lines can be used to compare lines derived from different 
tissues such as cutaneous melanoma and uveal melanoma. We used cell lines to analyse 
genes like p16/NK'la, pl4ARF and PTEV. In contrast to cutaneous melanoma cell lines, we 
found no PTR7"l alterations in primary and metastatic uveal melanoma lines (chapter 
8). Furthermore, no homozygous deletions of the p16/NK4a locus were found, although 
this is known to be the major cause of gene inactivation in cutaneous melanoma cell 
lines. In 26 uncultured primary uveal melanoma, we detected a deletion of 
chromosome 9p21 in only one case. This patient had also a nevus of Ota, a condition 
which is known to associate with uveal melanoma. Uveal melanoma cell lines were 
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however shown to inactivate p16FNK4a by promotor region methylation. Ko alterations 
in p14ltRF were found (chapter 7). These and other data, such as a different 
chromosomal constitutions and expression of melanoma-associated antigens, suggest 
that cutaneous and uveal melanoma follow a different molecular path toward tumour 
initiation and to metastatic disease (Cree, 2000). These findings may indicate that not 
the origin of these melanomas, but the environment (skin versus eye), is decisive for 
which path a tumour cell follows to eventually result in a generalised metastatic disease. 
9.2 FUTURE PROSPECTS 
We have shown that FISH analysis for chromosomes Ip36 and 3 enables us to identify 
uveal melanoma patients vvith a high risk of metastatic disease. Monosomy 3 is already 
used by some clinicians as a marker for poor prognosis. However, we have shovm that 
both chromosomes 1 p36 and 3 should be tested for prognostic purposes. 
Furthermore, this thesis provides a backbone for research into delineating the critical 
regions and identifying genes involved in uveal melanoma development and metastatic 
disease progression. We found evidence that both chromosome 1 p and 3 loss contribute 
to a more aggressive phenot)pe of uveal melanoma. Furthermore, our studies point to a 
small deletion on chromosome 3ql3-24 and two specific regions on chromosome Sq 
(Sq21.1 .... 21.2 and Sq23--24). To confirm these aberrations and to narrow dovm the 
regions on these chromosomes, allelic imbalance studies using polymorphic markers, 
have to be performed. These studies should be performed in the few cases which 
showed normal copies of chromosome 1 p and 3 in the tumour but still developed 
metastatic disease. It is tempting to consider that, in these cases, homozygosity is present 
due isodisomy formation. Furthermore, LOH studies should be carried out in cases with 
partial losses of chromosomes 1 p36 and 3. 
Furthermore, SKY and CGH will be usefull to delineate the region of interest on 
chromosome 1, 3 and S. Especially those patients whose tumours had partial losses or 
gains on these, should be further characterised using these techniques. CGH can even be 
applied in cases where no fresh tumour material is available. It would be interesting to 
apply CGH on paraffin embedded material from liver biopsies in cases with metastatic 
disease. This method can also be used to survey the numerical chromosomal changes in 
familial cases of uveal melanoma. Additionally, an array of BAC clones can be used for 
CGH analysis. This offers a better sensitivity and resolution than metaphase 
chromosomes, the traditional target for CGH and thereby allows a further refinement 
of the target regions found by conventional cytogenetics or CGH (pinkel et aI., 1998). 
Other strategies to identify genes involved in uveal melanoma include the testing of 
putative candidate genes and the screening of micro arrays. Potential tumour 
suppressor genes include the p63 and p73 genes (Yang and McKeon, 2000). The 
involvement of p53 in uveal melanoma is uncertain but the location of the p63 and 
p73 on chromosome 3q27-29 and 1p36 respectively, makes them interesting candidates. 
Recently, it was shown that the TA-p73 and TA-p63 isotypes are capable of inducing 
apoptosis or, possibly, tumor suppression (Yang et aI., 1998). Furthermore, it was found 
that primary lung cancers, squamous cell cancers and epithelial neoplastic cells 
predominantly express the LlNp63 isotypes. (Nylander et a!., 2000). The LlN isoforms of 
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p63 are known to have dominant negative effects on both the TA-isoforms of p63 and 
on p53 (Yang et aI., 1998). All these data suggest a complex cross-talk between the 
members of the p53 gene family. 
Lastly, DNA chip technology can be used to analyse differences in expression patterns 
on large number of genes in two samples. These samples can be tumour versus normal 
samples or, for example, tumours with and without chromosome Ip and 3 loss. Also, 
genes from one particular chromosome or chromosome arm can be tested. The data 
obtained with this technique could provide information on tumor progression 
pathways, on genes involved in tumorigenesis and may allow the identification of 
tumour subsets with highly malignant phenot)pes (Bittner et aI., 2000) . .Although the 
purpose of this method seems unlimited, it will only yield useful information if the 
starting material is well characterised, as is the case in our samples. 
In the last 6 years, we have collected well characterised tumour material and these 
samples provide an excellent starting point for these novel types of analyses. 
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In this thesis we describe cytogenetic and molecular genetic analyses of uveal 
melanoma. Uveal melanoma is the most common intraocular tumour in adults in the 
Western world, Volith an annual incidence of 7 per million people. About half of the 
patients die VI--1.thin fifteen years after time of diagnosis of metastatic disease, which is 
preferentiall y located in the liver. Several prognostic markers have been demonstrated 
to associate with (disease free) survival, however, the selection of patients at risk of 
metastatic disease remains difficult. In an attempt to more carefully predict the patients 
outcome, we analysed eighty uveal melanoma from patients treated with enucleation 
for chromosomal changes using cy"togenetic and FISH techniques (chapter 2). We found 
a strong correlation between a concurrent loss of chromosomes 1 p and 3 and a 
decreased disease free survival of the patients. Using these parameters patients at risk 
for metastatic disease can be selected which may justify adjuvant therapies in these 
cases. Furthermore, these data provide information about chromosome regions 
involved in uveal melanoma progression. Genes such as p73, mapped to chromosome 
Ip36, and p63 on chromosome 3q27, will be tested for their involvement in uveal 
melanoma tumorigenesis. 
Most uveal melanoma show simple karyotypes and cytogenetic and/or FISH analysis 
will be sufficient to characterise these genetic changes. However, in some cases, complex 
karyotypes or discrepancies between cytogenetic and FISH analyses are found. In 
chapter 3, we describe the analysis of the complex chromosomal abnormalities in five 
primary uveal melanoma and two uveal melanoma cell lines using conventional 
cytogenetic, FISH, SKY and CGH analyses. We demonstrated that, using cytogenetics or 
FISH only, chromosome 6 and 8 abnormalities are clearly underestimated. Furthermore 
we found a small deletion on chromosome 3q 13-21 which may narrow down the 
chromosome region on chromosome 3 involved in uveal melanoma tumorigenesis. 
These chromosome analyses are only applicable to patients treated with enucleation, 
since only then tumour material is available. However, more and more patients are 
treated with radiotherapy, restricting genetic prognostic evaluation. We investigated 
whether FISH analysis on fine needle aspiration biopsies of uveal melanoma could 
provide a tool for genetic studies in patients treated with eye conserving protocols 
(chapter 4). We found that FISH analysis is suitable for the detection of chromosomal 
changes in these ex vivo biopsies, and that the biopsies were representative for the 
original tumour. These data, indeed, suggest that this method can be used to obtain 
information about the chromosomal composition of these melanomas, which enables us 
to predict the patients outcome. 
Chromosome analysis can also be applied to biopsies of lesion suspected to be uveal 
melanoma (chapter 5). In that study, we performed FISH analysis to three of such 
lesions and found gain of chromosome 8, in one case, suggesting malignant 
transformation. In the remaining cases no chromosomal changes were detected. In the 
first case we decided to enucleate the patient and found a small melanoma derived 
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from a pre.existent naevus. In the other two cases, no action was undertaken and 
appoximately 3 year after the procedure, no tumour progression was observed. 
The second part of this thesis describes the establishment of uveal melanoma cell lines 
(chapter 6) and mutation analyses of potential tumour suppressor genes on these cell 
lines. In cutaneous melanoma cell lines, deletions or mutations in the P16JNK4a and 
PTEN gene are frequently described. In chapter 7 we describe the mutation analysis of 
the p16f!\'K4a and p14ARF gene in uveal melanoma. In contrast to what is known from 
cutaneous melanoma, we found that methylation is the major cause of p16fSK4a 
inactivation in uveal melanoma cell lines. In the PTEN gene, no mutations were found 
in uveal melanoma cell lines (chapter 8), These data suggest that, despite a common 
origin, uveal and cutaneous melanoma follow a different route towards tumorigenesis. 
The general conclusions, which can be drawn from the studies described in this thesis, 
are discussed in chapter 9. Furthermore, in this chapter, recommendations for future 
research are made. 
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In dit proefschrift worden de cytogenetische en moleculair genetische analyse van 
oogmelanomen beschreven. Het oogmelanoom is de meest voorkomende primaire 
maligne tumor van het oog met een jaarlijkse incidentie van 7 per miljoen mensen. De 
helft van deze patienten overlijdt uiteindelijk aan de gevolgen van uitzaaiingen, 
waarbij vooral de lever is aangedaan. Het onderzoek naar oogmelanomen heeft zich 
vooral geconcentreerd op het vinden van parameters die correleren met de overleving 
van de patient. Het voorspellen van de prognose van een individuele patient bleef 
echter tot nu toe moeizaam. 
In het eerste deel van dit proefschrift, wordt de nadruk. gelegd op de 
cytogenetische afwijkingen in oogmelanomen. 
In een serie van 80 tumoren hebben "Wi j onderzocht of patienten met een hoog 
risico op uitzaaiingen kunnen worden onderscheiden van patienten met een lager 
risico, op basis van chromosoom af"Wijkingen in de tumor. Wij hebben hierbij gebruik 
gemaakt van cytogenetica en FlSH technieken (hoofdstuk 2). Er werd een sterke 
correlatie gevonden russen verlies van zowel chromosoom regio I p36 en chromosoom 3 
en de ziektevrije overleving van de patient. Deze prognostische marker stelt ons in staat 
hoog-risico patienten te selecteren. Bij deze patienten kunnen we overwegen 
aanvullende therapie te geven. 
Buiten deze klinische relevantie van onze bevindingen geven deze resultaten 
inzicht in welke chromosoomregiol's betrokken kunnen zijn bij het ontstaan of de 
uitbreiding van oogmelanomen. Genen zoals p73 (op chromosoom Ip36) en p63 (op 
chromosoom 3q27), dienen te worden onderzocht op hun betrokkenheid in 
oogmelanomen. 
Meestal vinden we in oogmelanomen eenvoudige chromosomale af"Wi jkingen en 
volstaan cytogenetica en FISH voor de analyse van deze tumoren. In sommige tumoren 
worden echter complexe af"Wijkingen gevonden. In hoofdstuk 3 beschrijven "Wij het 
gebruik van SKY en CGH als aanvullende technieken in vijf van deze gevallen en in 
twee oogmelanoom cellijnen. Chromosoom 6 en 8 af"Wijkingen werden vaker gevonden 
dan verwacht op basis van cytogenetica en FISH analyse. Bovendien hebben we een 
kleine deletie op chromosoom 3ql3-24 opgespoord, hetgeen het gebied op chromosoom 
3, dat mogelijk een rol speelt bij het ontstaan of de uitbreiding van oogmelanomen, 
verder verkleint. 
De hierboven beschreven chromosoomanalyse kan aIleen worden gedaan op 
tumormateriaal. Tegenwoordig worden veel patienten echter behandeld met bestraling 
van het aangedane oog waardoor er geen materiaal beschikbaar is voor analyse. Wij 
onderzochten of in dergelijke gevallen biopten van de melanomen genomen konden 
worden voor chromosoom onderzoek (hoofdstuk 4). Van veertig oogmelanomen 
hebben we, na enucleatie, een biopt genomen. Deze biopten hebben we, samen met een 
stukje van de oorspronkelijke tumor, geanalyseerd met FlSH. Het bleek dat deze 
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biopten goed te gebruiken waren voor FISH analyse en dat ze representatief 
waren voor de tumor waaruit het biopt genomen was. Hoewel deze biopten genomen 
waren van geenucleeerde ogen, wijzen de resultaten erop dat we bij patienten die 
behandeld worden met oogsparende therapieen, ook chromosoomanalyse kunnen 
verrichten ter evaluatie van de prognose van de betreffende patient. 
Biopten kunnen ook genomen worden in gevallen waarbij de diagnose 
oogmelanoom niet geheel zeker is. Wij hebben in drie van zuIke gevallen biopten 
genomen en chromosoomanalyse verricht met behulp van flSH analyse (hoofdstuk 5). 
In een van deze drie biopten vonden we een extra chromosoom 8, hetgeen suggereert 
dat er kwaadaardige cellen aanwezig zijn. Bij deze patient werd behandeling 
geadviseerd waarbij de patient de voorkeur gaf aan enucleatie. In de andere twee 
biopten werden geen afwi jkingen gevonden en werden de patienten gevolgd zonder 
verdere behandeling. Bij deze patienten werd in de drie jaar na het nemen van de 
biopten geen tumorgroei waargenomen. 
Het tweede deel van dit proefschrift beschrijft de moleculair genetische analyse 
van oogmelanomen. In hoofdstuk 6 beschrijven wi j het ontwikkelen en karakteriseren 
van twee primaire en drie metastatische oogmelanoom cellijnen. Deze cellijnen stellen 
ons in staat genen te onderzoeken die mogelijk betrokken zijn bij oogmelanomen. 
Genen waarvan we weten dat zij betrokken zijn bij huidmelanomen zijn het 
p16/NK4alp14ARF gen en het PTEN gen. In tegenstelling tot huidmelanomen, waar 
mutaties en verlies van het p16INK4a gen frequent gevonden worden, vonden wij dat in 
oogmelanomen dit gen meestal (in 4 van de 9 cellijnen) uitgeschakeld was door middel 
van methylering (hoofdstuk 7). Ook werden in deze oogmelanoom cellijnen geen 
mutaties in het PTEN gen gevonden (hoofdstuk 8). 
De conclusies die getrokken worden uit het onderzoek beschreven in dit 
proefschrift worden uiteengezet in hoofdstuk 9. Bovendien bevat dit hoofdstuk 
aanbevelingen voor verder onderzoek. 
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Ook de studenten Wieke, Nazik, Riena en Anneke, die aan dit onderzoek hebben 
meegewerkt, dank ik v~~r hun inzet. Ik vond het erg leuk met jullie te werken. 
Emine, ik ben blij dat ik een voorzet heb kunnen geven voor jouw project. Maak er iets 
moois vanl 
Een andere afdeling waar ik heel wat uren heb doorgebracht is de klinische genetica, 
lab 816. 
Dr. R. Slater, beste Ros, dank voor het minutieus nakijken van de vreselijke tab ellen met 
karyotyperingen en voor de taalkundige correcties. Hierdoor is dit boekje een goed 
leesbaar geheel geworden. Dank je dat je als expert zitting wilde nemen in de 
commissie. Heel vee! geIuk aan de andere kant van de oceaan. 
Prof. dr. A. Hagemeijer, u stond aan de wieg van de cytogenetisch analyse van de 
oogmelanomen. Dank hiervoor. Ik hoop dat wij in de toekomst onze samenwerking 
kunnen uitbreiden. 
Berna, je staat niet aIleen op afdeling, maar ook daarbuiten altijd klaar voor moral 
support. Dank voor je gezelligheid en heel veel succes in je nieuwe functie. 
Ellen en Marjan, dank voor het karyotyperen van het tumormateriaal. 
Ook aIle andere dames van de 8'1<', dank voor jullie interesse en de kop jes thee. 
Ik zou geen resultaten kunnen hebben verzameld zonder tumormateriaal. Dat had ik 
vooral aan Dr. eM. Moo)', Neeltje, te danken. Wij hebben samen in heel wat ogen 
geprikt en gesneden. Je deur stond altijd open voor vragen of om even wat coupes te 
bekijken. De resultaten mogen er zijn. Dank je voor aIle hulp. 
Liesbeth, Nel en Mike Kliffen, stonden altijd klaar als er weer eens onverwacht "een oog 
binnenkwam". Bedanktl 
Dr. D. Paridaens, beste Dion, jou bedank ik voor het insturen van aIle oogmelanomen 
en voor het bijwonen van en de inbreng op de werkbesprekingen. 
Janneke Alers dank ik voor haar bijdrage aan de CGH experimenten. Ik heb veel van je 
geleerd en wens je veel succes bi j je verdere carriere. 
De kamer waar ik, zeker het laatste half jaar, veel tijd heb doorgebracht is kamer 
EeI610,oogheelkunde. 
Antoinette, ruim vier jaar lang zijn v.>ij elkaars kamergenoot geweest. Bedankt voor je 
gezelligheid, de kopjes koffie en de kilo's snoep die we naar binnen werkten, vooral 
ti jdens jouw zwangere maanden. Ik hoop je snel aIs collega AGIO te kunnen begroeten. 
Succes bij de laatste loodjes. 
Ingrid en Jan-Roelof, ik vond de dagen dat jullie ook op de 16" zaten altijd erg gezeIlig. 
Dank daarvoor. 
Ook alle andere medewerkers van de afdeling oogheelkunde bedank ik voor hun 
interesse. Kees, Corrie en Monique bedank ik voor het prikken van aIle bloed jes van de 
oogmelanoom patienten. Hierbij gaat mijn dank natuurlijk ook uit naar de patienten 
zelf, die bereid waren bi j elke controle vijf buizen bloed in te leveren. 
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Mijn nieuwe collega AGIO's Marjolein, Roger, Jaqueline, Raan (sorry Raan, weddenschap 
verloren) en Caroline, bedankt voor de vrijheid die jullie mij in de afgelopen maand 
hebben gegeven en voor de belangstelling voor de vorderingen. Caroline, bedankt voor 
aIle vruchtbare discussies over correlaties, confounders en hogere statistiek. 
"Boi Nicole met Nicole" van Basten, jouw regelvaardigheid en organisatorisch talent 
bewonder ik zeer (de gratificatie is bijna binnen). Dank voor al je tijd. 
Dr. Karen Sisley and Prof. Ian Rennie, thanks for giving me the opportunity to work at 
your lab in Sheffield for two months. I enjoyed our time in Jerusalem and Philadelphia 
very much and I hope to see you soon in Amsterdam. Karen and Chris, thanks for 
lending your house to me. 
Mijn paranimfen, Ernst en Bennie, i1. ben vereerd dat jullie mij ter zi jde willen staan. 
Ernst, dank je voor je vriendschap, je vertrouwen in een goede afloop van dit boek je 
en het gefilosofeer over opleidingen en onderzoek doen. Ik hoop dat we sne1 tijd 
vinden om, samen met Sjaanke en Michie1 weer eens een weekendje Hame1en te doen. 
Bennie, ik ben erg blij dat je onze oogme1anomen club bent komen versterken. Dank 
voor al je hulp bij de laatste loodjes. Ik weet zeker dat we een goed team zullen zijn. 
De Bergpolderstraat, ja dat is natuurlijk een verhaal apart. Martine, Aart, Jeroen en 
Renkse, jullie zijn echt gewe1dig! Altijd tijd voor een kopje koffie (thee mag ook), een 
wijntje of pannenkoeken. Als ik weer eens veel te lang gewerkt had, was er altijd we1 
iemand die Guus al binnen had gelaten of eten had gegeven. Dank voor deze sociale 
controle. 
Saskia en Renske, al jaren vormen vn j een drie-eenheid. JIllie vriendschap en 
vertrouwen in mij, betekenen heel veel voor me. Nu dit boe1.je af is, heb ik einde1ijk 
weer eens tijd voor de hammam of een avond beppen. Ik zal jullie hulp nooit vergeten. 
Natuurlijk bedank ik ook aIle andere vrienden en (schoon)jamilie voor hun 
belangstelling. 
Pa en ma, door jullie ben ik zoals ik ben. Jullie hebben mij geleerd door te zetten, ook 
als het even niet gaat zoals je wilt. Jullie betrokkenheid en nimmer aflatend 
vertrouwen, raakt mij diep. Dit boekje is voor jullie. 
Mijn allerliefste Michiel, dank je voor aIle steun, suggesties, hulp, betrokkenheid en nog 
veel meer. Eigenlijk wil ik maar een ding tegen je zeggen en dat is: ja, ik wil. 
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